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ABSTRACT 
Rectal route of drug administration is particularly useful when patients cannot tolerate 
orally yet are unable to receive parenteral injections. Furthermore, studies have shown 
that it may be possible to circumvent first pass metabolism if absorption was localised 
in lower rectum. This is theoretically achievable if suppositories were bioadhesive.  
 
The aim of this thesis was to evaluate two types of commercial hydrogenated palm 
kernel stearin (HPKS) namely ChocExa (CE) and Supersocolate SpecialTM (SS) as 
base candidates for bioadhesive suppositories in comparison to cocoa butter (CB). 
Robustness of these bases during suppository manufacturing was compared using both 
DSC-simulated and extemporaneous methods. Diclofenac sodium (DcNa) which 
undergoes extensive first pass metabolism was selected as model drug. Suppositories 
containing 50 mg DcNa and 1-5 %w/w bioadhesive polymers manufactured using CB, 
CE and SS as base were evaluated in terms of physical properties, drug release, 
bioadhesive properties as well as stability under different storage conditions. The 
bioadhesive polymers used were Carbopol
®
 974P NF (CBP), hydroxypropyl 
methylcellulose 2910 (HPMC), poly(vinylpyrrolidone) K30 (PVP) and carboxymethyl 
chitosan (CMCTS). Two self-fabricated methods using the texture analyser (tensile 
and shear stress) were developed to study bioadhesion of suppositories against porcine 
colon mucosa under simulated rectal conditions. 
 
Physical characterisation found that CE and SS were comparable to CB in terms of 
thermal profile, solid fat content (SFC), pH, viscosity and displacement values (DV) 
but with added advantages of reduced polymorphism and less stringent manufacturing 
parameters. Solidification of CB melt into suppositories was highly dependent on the 
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maximum heating temperature (Tmax) and cooling rate (Crate). HPKS on the other hand 
were more robust, as long as it is completely molten HPKS would solidify into stable 
β’ polymorph; while cooling rates did not affect crystallisation. All the bioadhesive 
suppositories melt between 32.5-35.5 °C. Addition of CBP decreased rate and extent 
of DcNa release in a concentration dependent manner, resulting in bi-exponential first-
order kinetics release pattern. The other bioadhesive polymers had minimal impact on 
DcNa release. The tensile method to study bioadhesion found that bioadhesive 
properties decreased in the order of PVP > CBP > CMCTS > HPMC while the shear 
method PVP > CMCTS > CBP = HPMC. In both instances, HPMC showed poor 
bioadhesion with limited benefit in development of bioadhesive suppositories. 
Formulations containing 5 %w/w PVP and CMCTS were selected for subsequent 
stability assessment based on considerations of complete DcNa release and good 
bioadhesive properties. These suppositories required refrigeration as suppositories 
stored for 200 days at room temperature (24.5 ± 2.5 °C; RH 58 ± 5 %) showed 
graininess and loss of surface glossiness, increased melting point, possible 
triacylglycerol (TAG) separation, higher SFC at 37 °C, prolonged softening times and 
decreased amount of DcNa release. These changes were unfavourable for 
suppositories and may lead to ineffective treatment. Generally, SS suppositories 
subjected to accelerated ageing released DcNa more efficiently than CE.   
 
Although both HPKS were suitable suppository base substitutes of CB, SS provided 
superior stability in terms of resistance to depression of DcNa release. PVP on the 
other hand conferred the best bioadhesive properties among all polymers evaluated. 
Thus, SS suppositories incorporated with 50 mg DNa and 5 %w/w PVP may be a 
potential candidate for further development.  
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 Introduction 1.1
Suppositories are solid dosage forms intended for administration to the human body 
via insertion into body orifices, mainly the rectum; where it softens, melts or dissolves 
to release the incorporated medication which then exerts its therapeutic effects locally 
or systemically. Suppositories can also be administered via the urethra or the vagina 
(pessaries) (Allen et al., 2008). 
 
Rectal suppositories are usually cylindrical with either one or two tapered ends, 
shaped like a bullet or a torpedo. Length can be up to 32 mm and it usually weighs 
about 1–2 g (Allen et al., 2005; Ansel, 1981). The various shapes and sizes of 
suppositories are shown in Figure 1.1. 
 
 
Figure 1.1: Shapes and sizes of rectal, vaginal and urethral suppositories (University 
of North Carolina Eshelman School of Pharmacy, 2015). 
 
Although less common nowadays, suppositories are a relatively old method of 
administering medications to the human body; dating back to as far as the ancient 
Egyptian civilization; as evidenced in the Ebers Papyrus scriptures from 1550 BC 
(Bryan and Smith, 1930).  
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These days, suppositories are mainly employed as locally-acting laxatives (Table 1.1) 
to promote defecation or to treat anorectal diseases such as haemorrhoids and 
ulcerative colitis (Cooper and Gunn, 1987). Nonetheless, there is also a substantial 
amount of commercial suppository formulations marketed for systemic delivery in 
Malaysia (Table 1.2). Drugs prescribed as a suppository for systemic treatment 
include analgesics, antibiotics, tranquilizers and antihistamines.  
 
Table 1.1: The list of commercial suppositories for local action registered with the 
Drug Control Authority in Malaysia. 
Product  Name Active Ingredient Strengths 
Pentasa 5- aminosalicylic acid, mesalazine 1 g 
Salofalk 5- aminosalicylic acid, mesalazine 250, 500 mg 
Xyloproct 
lignocaine, hydrocortisone acetate, zinc 
oxide, aluminium subacetate 
- 
Bisacodyl bisacodyl 5, 10 mg 
Pricolax bisacodyl 5, 10 mg 
Dulcolax bisacodyl 5, 10 mg 
Proctosedyl 
hydrocortisone, framycetin sulphate, 
aesculin, cinchocaine 
- 
Liproct hydrocortisone acetate, zinc oxide, lidocaine - 
Doproct 
zinc oxide, hydrocortisone acetate, 
benzocaine 
- 
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Table 1.2 : The list of commercial suppositories for systemic action registered with the 
Drug Control Authority in Malaysia. 
Product Name Active Ingredient Strengths 
Primperan metoclopramide hydrochloride 10, 20 mg 
Tramadol Stada tramadol hydrochloride 100 mg 
Remedol paracetamol 125, 250 mg 
Arfen paracetamol 125, 250 mg 
Tempol paracetamol 125, 250 mg 
Pritamol paracetamol 125, 250 mg 
Poro paracetamol 125, 250 mg 
Shoren diclofenac sodium 12.5, 25 mg 
Dicloren diclofenac sodium 12.5 mg 
Profenac diclofenac sodium 12.5 mg 
Voltaren diclofenac sodium 12.5, 25, 50 mg 
Almiral diclofenac sodium 100 mg 
Diclogesic diclofenac sodium 12.5, 100 mg 
Voren diclofenac sodium 12.5, 25, 50, 100 mg 
Pritaren diclofenac sodium 12.5 mg 
 
 Advantages of suppositories 1.1.1
Oral drug delivery remains the most common route of drug administration and has the 
highest rate of patient acceptance. However, the oral route of administering 
medications may not always be the best option. For example, drugs which undergo 
extensive first-pass metabolism or pre-systemic degradation such as lidocaine (De 
Leede et al., 1983), diclofenac sodium (DcNa) (Menasse et al., 1978; Willis et al., 
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1979) and salbutamol (Goldstein et al., 1987; Morgan et al., 1986). Conversely, drugs 
administered to the lower rectum would largely be absorbed into the systemic 
circulation, thus circumventing the hepatic first-pass metabolism to afford greater 
bioavailability (Allen et al., 2008; Kokate et al., 2006; Watanabe, 2007). For drugs 
with unpleasant taste and odour, such as cysteamine (a new treatment for nephropathic 
cystinosis), suppositories may be an alternative route for drug administration (Buchan, 
2011). 
 
Rectal administration of drugs is also particularly useful when the oral route is 
occluded or disrupted by nausea, vomiting or during acute convulsions (Allen et al., 
2005). Nausea and vomiting which limit oral intake of medications are common 
symptoms in patients undergoing chemotherapy or in palliative care. Hence, 
alternative routes such as rectal or transdermal drug delivery would be beneficial for 
these patients (Allen et al., 2005; Davis et al., 2002; Warren, 1996).  
 
Terminally ill and palliative care patients in the outpatient setting would often require 
frequent administration of multiple analgesics. For these patients, the intravenous (IV) 
and intramuscular (IM) routes are less practical as they may not always be under the 
immediate care of qualified health care practitioners.  
 
Clinically, there is also a great deal of unmet needs for alternative routes of 
administering medications for patients who underwent total gastractomy, ileal 
resectioning procedures, and patients inserted with nasogastric or nasojejunal tubes 
where modified release oral formulations are very often rendered less effective. Hence, 
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non-peroral or transmucosa formulations such as rectal suppositories would be of 
great value in the outpatient management of such patients.  
 
Furthermore, various recent studies showed that the use of preoperative rectal 
nonsteroidal anti-inflammatory drug (NSAID) have successfully delayed time before 
the first request for anaesthesia; reduced the use of supplemental opioids and scored 
lower on visual analogue scales in both major and minor surgeries in both adults and 
paediatrics (Bahar et al., 2010; Fayaz et al., 2004). 
 
 Patient acceptance and social stigma 1.1.2
A study found that only 18 % of patients favoured suppositories over IM 
postoperative analgesia (Carroll et al., 1996). Various studies showed that the main 
reason for rejection of suppository was mainly due to the misconception where 
patients regard its method of administration as a form of invasion or violation of 
dignity, leading to subsequent humiliation (Colbert et al., 1998). 
 
Conversely, Vyvyan and Hanafiah (1995) reported that 46 % of the middle aged 
patients surveyed were receptive towards rectal drug administration; however 98 % of 
these patients felt the need for discussion prior rectal administration. Meanwhile, 
Bonner et al. (1996) found that only 15 % of patients aged between 15-91 years old 
objected to suppository administration under anaesthesia, although 59 % of them 
preferred to be informed preoperatively. Another study by Dodd et al. (2004) also 
found high degree of acceptance towards suppositories in women for relief of 
postnatal pain. Among younger children, Hinton et al. (2007) found that there was 
considerable acceptance towards the use of suppositories as an alternative route to oral 
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dosage forms; and that there was also a 69.5 % caregiver acceptance of malarial 
treatment via rectal route. These were encouraging findings which indicates 
diminishing stigmatism towards the use of suppositories.  
 
 Suppository base 1.1.3
The type of suppository base used depends on the intended release profiles and nature 
of the active drug. Suppository bases can be classified according to their physical 
characteristics; fatty bases, water soluble bases and the emulsifying bases (Allen et al., 
2005; Cooper and Gunn, 1987). 
 
 Fatty bases  1.1.3.1
Suppositories made of fatty (oleaginous) bases must melt upon administration into the 
rectum before the drug partitions into rectal fluids for absorption across rectal 
membranes into the systemic circulation (Allen et al., 2008). This group of bases 
include cocoa butter (CB), palm oil, palm kernel oil (PKO) and cottonseed oil or fat-
based glycerine compounds containing high molecular weight (MW) fatty acids such 
as glyceryl monostearate (Allen et al., 2005). Fatty bases contain very little water and 
has low tendency of hygroscopicity. Commercialised bases nowadays are usually a 
combination of two or more fatty bases, for example Wecobee
®
 which is derived from 
fully hardened palm kernel and cottonseed oils (Stepan Specialty Product, 2014). 
 
 Cocoa butter (CB) 1.1.3.1.1
The traditional base, CB or theobroma oil is obtained from the roasted seeds of 
theobroma cacao and presents itself as a yellowish-white solid at room temperature 
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which melts at 30–36 °C (Allen et al., 2005). CB is desirable due to its melting range, 
non-irritant nature and miscibility with a wide range of medicaments. However, it 
exhibits both rancidity and polymorphism on storage. The fatty acid composition of 
CB is shown in Table 1.3.  
 
It is generally accepted that CB exist in 4 different polymorphs, namely α, β, β’ and γ 
forms although some literatures suggested up to a number of 6 distinct polymorphs 
(Loisel et al., 1998; Marangoni and McGauley, 2003; van Langevelde et al., 2001; 
Wille and Lutton, 1966). Each of the polymorphic forms exhibit different melting 
ranges with β form being most stable. The presence of metastable polymorphs with 
lower melting points are not conducive for suppositories, especially in warm tropical 
climates (Allen et al., 2008). Other disadvantages of CB include its inability to 
contract and detach from suppository moulds on cooling, thus necessitating the 
lubrication of moulds with liquid paraffin to aid suppository removal (Cooper and 
Gunn, 1987). There is also substantial batch to batch variation since CB is sourced 
naturally and the fatty acid content was found to be affected by geographical origin of 
the CB (Chaiseri and Dimick, 1989; Spangenberg and Dionisi, 2001). 
 
These disadvantages of CB suppository bases prompted the development of newer 
commercial bases with specific set of properties to overcome formulation difficulties.  
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Table 1.3 : The composition of the major fatty acids in CB and hydrogenated palm kernel stearin (HPKS). 
Fatty acid  
(carbon no : 
double bonds) 
Weight (%) 
CB HPKS 
Spangenberg and 
Dionisi (2001)
1
 
Lonchampt and 
Hartel (2004) 
Toro-Vazquez et 
al. (2004) 
Rossell (1975)
2
 Siew (2001) 
Peyronel and 
Marangoni 
(2014) 
Lauric (12:0)    49.6 56.6 43.3 
Myristic (14:0) 0.09  0.1 30.4 22.0 28.8 
Palmitic (16:0) 25.1 26.8 25.8 11.5 7.9 12.6 
Stearic (18:0) 37.4 35.6 34.5 2.8 8.6 14.2 
Oleic (18:1) 33.0 33.5 34.9 2.4  0.2 
Linoleic (18:2) 2.4 3.2 3.0    
Arachidic (20:0) 1.1 0.9 1.0   0.3 
 
               
                                                 
1
 Values quoted for sample CB-28, deodorized CB originated from Malaysia.  
2
 Values quoted for HPKS (Iodine value =1.8). 
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 Palm kernel oil (PKO) and hydrogenated palm kernel stearin (HPKS) 1.1.3.1.2
Oil palm (Elaeis guineensis) is one of the richest vegetable oil plants and is widely 
used in the food industry. PKO is produced as a by-product via extraction of the 
residual kernels (Akinoso and Raji, 2011; Pantzaris and Ahmad, 2002; Zhou et al., 
2010).  
 
PKO was found to contain 81.67 % of saturated fatty acids; mainly the short-chain 
fatty acids, such as lauric (C12) and myristic (C14) acid. It has a slip melting point of 
27–29 °C and iodine value of 16-20 (Goh, 1994). However, the slip melting point of 
the PKO can be altered via hydrogenation or blending with other palm oil products 
(Goh, 1994; Pantzaris and Ahmad, 2002). Further hydrogenation of PKO produces 
hydrogenated palm kernel stearin (HPKS) with a melting point of 32.5-34.5 °C (Siew 
and Ng, 2000; Siew, 2001). The common composition for HPKS is shown in Table 
1.3. 
 
Recently, Noordin and Chung (2007) developed two new suppository bases using 
combinations of locally sources hydrogenated PKO, HPKS and hydrogenated palm 
kernel olein with mixtures of stearic acid and glyceryl monostearate. The authors 
found that the bioavailability of aspirin administered rectally in these bases were 
superior to the equivalent dose administered orally.   
  
 Water soluble and water miscible bases 1.1.3.2
Unlike fatty bases, water soluble bases disintegrate and dissolve in rectal fluids upon 
insertion into the human rectum (Allen et al., 2008). Since the rectum has very small 
amount of fluid, complete vehicle dissolution can be difficult and water will be 
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attracted from rectal tissues towards the suppository via osmotic effect causing pain to 
the site of administration. Polyethylene glycol (PEG), poloxamer and glycerinated 
gelatin are among the common water soluble bases used to produce suppositories. 
 
PEG are polymers made up of ethylene oxide and water, produced in various chain 
lengths, MW and physical states. It is possible to formulate PEG bases with desired 
consistency and characteristics by combining different grades of PEGs via fusion 
process (Allen et al., 2008).  
 
Meanwhile, glycerinated gelatin base could be easily prepared by dissolving 20 % 
granular gelatin in 70 % of glycerine, added with 10 % of solution or suspension of 
the desired drug. The resulting base is hygroscopic in nature and could potentially 
irritate the rectal surface; thus requiring moistening by dipping into water prior to 
insertion into the rectum (Allen et al., 2008). 
 
Poloxamers on the other hand, are odourless, tasteless, water soluble, block co-
polymers which exhibit reverse-thermal gelation properties; they remain liquid at 
room temperature and undergo phase transition to gel at body temperature (Choi et al., 
1998; Keny and Lourenco, 2010). Various studies investigated formulations of 
thermogelling bioadhesive suppositories using poloxamer in attempts to eliminate 
discomfort caused by insertion of a conventional solid suppository into the rectum as 
well as to localise drug absorption within the lower rectum (Barakat, 2009; Choi et al., 
1998; Keny and Lourenco, 2010). 
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 Emulsifying bases 1.1.3.3
These include mixtures of oleaginous bases and water miscible materials, 
disintegrating agents, collagen and natural gums. When formulated as suppositories, it 
disperses in rectal fluid to form oil-in-water emulsions due to its surface active 
properties and spreads as a smooth layer over  mucous membranes (Allen et al., 2008). 
As an example, the Witepsol
®
 series composed of triacylglycerols (TAG) of saturated 
C12-18 fatty acids with varied portions of partial glycerides and fatty bases which 
contain the TAG from palm, palm kernel and coconut oils with self-emulsifying 
glyceryl monostearate and polyoxyl stearate (Cremer Oleo GmBH & Co. KG). 
 
 Ideal base characteristics 1.1.4
Allen et al. (2008) and Cooper and Gunn (1987) summarized that an ideal suppository 
base should have the following qualities: (1) melt at body temperature or dissolve in 
body fluids; (2) readily release medicaments; (3) physically and chemically stable; (4) 
nontoxic, non-irritating and non-sensitizing; (5) compatible with a large variety of 
drugs; (6) chemically and physiologically inert; (7) contract slightly on cooling; (8) 
easy to manufacture by fusion, compression and extrusion.  
 
 Manufacturing of suppositories  1.1.5
Suppositories can be manufactured via a number of methods, namely hand rolling and 
shaping, cold-compression and fusion moulding. The method of choice greatly 
depends on nature of incorporated drug and the scale of manufacturing process as it 
will not be practical to produce large quantities of suppositories via hand-rolling and 
shaping method (Allen et al., 2008).    
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 Hand rolling  1.1.5.1
Grated CB and all other required ingredients for the suppository are triturated 
manually in a mortar to form a plastic-like mass. The mass is then quickly formed into 
a ball using palms previously cooled in ice water and rolled into a cylinder using a 
broad bladed spatula over a pill tile. The formed cylindrical mass can then be cut into 
desired lengths and then shaped as desired by hand (Allen et al., 2008; Ansel, 1981). 
 
 Cold compression method 1.1.5.2
In this method, the active drug, suppository base and excipients are blended 
thoroughly and pulverised to form a uniform blend of mixture which then softens into 
a paste-like consistency due to the friction of the mixing process (Allen et al., 2008; 
Ansel, 1981). The paste is then extruded into a mould and compressed for shape 
setting, the resultant suppositories are then forced out of the mould orifice.  
 
A similar method produces suppositories with uniform circumference by extruding the 
paste through a perforated plate and cutting the extruded mass into the desired length 
(Ansel, 1981). This method is suitable for incorporation of thermolabile drugs as the 
process involves minimal heat exposure. It also enables the incorporation of large 
amount of drugs that are insoluble in the base as it is unlikely for the insoluble 
material to settle or separate from the suppository base. Such phenomenon is 
commonly observed in suppositories produced via fusion moulding method. 
 
 Fusion moulding method 1.1.5.3
Fusion moulding method is by far the most commonly employed method to 
manufacture suppositories as it is compatible with most conventional bases. The 
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process involves base melting and subsequent incorporation of drug and other 
excipients into the molten base and pouring the melt into moulds for solidification. 
The overfilled (excess) base is then scraped off using a warmed spatula to form a 
smooth flat surface. The nominal capacities of the common moulds are 1, 2, 4 and 8 g 
(Cooper and Gunn, 1987). This method would require prior calibration of moulds as 
the densities of bases and drug are different (Allen et al., 2008; Ansel, 1981). 
 
 Human rectum 1.2
 Anatomy  1.2.1
The human large intestine begins at the colon and extends to the rectum and anal canal 
at the terminal end (Kokate et al., 2006). The rectum is preceded by sigmoidal colon 
and ends at anal canal (Watanabe, 2007). The rectum is approximately 15-20 cm in 
length, with a comparatively small surface area of approximately 200–400 cm2; while 
the anal canal is the final 2.5-5 cm of the large intestines leading to the anal verge 
(Barleben and Mills, 2010).  
 
The rectal wall is made up of three layers; mucosa which composes of several layers 
of cylindrical epithelial cells; submucosa; tunica muscularis and the visceral 
peritoneum (Allen et al., 2008). There are three rectal valves in the rectal ampulla - 
superior, middle and inferior rectal valves. The rectum is usually non-motile and has 
no villi or microvilli (Allen et al., 2008). When a suppository is administered into the 
rectum, it either melts or dissolves in the rectal ampulla to release incorporated drug to 
allow diffusion across the rectal mucosa and subsequent absorption into systemic 
circulation (Watanabe, 2007). 
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 Rectal mucus  1.2.2
The human rectum contains only 2-3 mL of inert mucus when devoid of faecal matter 
(Allen et al., 2008). Mucus is a layer of viscous, gel-like secretion by goblet cells 
which lines all organs of the human body such as the oculo-rhino-otolaryngeal tracts, 
airways, gastrointestinal tract (GIT), and urogenital tract (Andrews et al., 2009; Bansil 
and Turner, 2006). It is made up of a mixture of mucin glycoproteins, water, 
electrolytes, enzymes, bacteria and sloughed epithelial cells (Irons and Robinson, 
2003). The bulk of mucus content is approximately 95 % water with 0.5-5 % mucin 
glycoproteins and lipids, while 0.5-1 % of the contents consist of mineral salts with 
another 1 % free proteins (Edsman and Hagerstrom, 2005).  
 
This mucus layer functions as a physical barrier to protect the internal environment 
from pathogens and noxious stimuli; ensures sufficient hydration of the epithelium 
surface; provides a permeable gel layer for exchange of excretion products, nutrients 
and gases, and lubricates the epithelium to allow passage of objects (Bansil and 
Turner, 2006; Irons and Robinson, 2003). Rectal mucus is therefore, the first barrier 
against diffusion of administered drugs before absorption across the mucosa 
membranes. 
 
 Rectal absorption  1.2.3
The absorptive capacity of human rectum is significantly lesser than upper GIT due to 
the limited surface area and absence of microvilli compared to small intestines. Drug 
absorption via rectal mucous membrane is a passive process where only lipophilic, 
unionised form of drug is absorbed across the membrane (Allen et al., 2008). 
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The upper rectum is drained by superior hemorrhoidal vein directly into hepatic portal 
system while the lower rectum is drained by inferior and middle haemorrhoidal veins 
into the systemic circulation; bypassing first pass metabolic pathways (Kokate et al., 
2006). However, the presence of extensive anastomoses may decrease the avoidance 
of first pass metabolism, although it is generally accepted that at least 50-70 % of 
active ingredients administered rectally circumvents the first pass effect (Allen et al., 
2008; Watanabe, 2007).  
 
 Factors affecting rectal absorption 1.2.3.1
Since rectum is not naturally an absorptive organ, the amount of drug absorbed is 
greatly influenced by various physiologic and physicochemical factors (Table 1.4). 
 
Table 1.4: Summary of factors affecting rectal absorption of drugs (Allen et al., 2008). 
Physiological factors Physicochemical factors Formulation factors 
colonic contents 
nature and form of active 
drug 
microsphere encapsulation of 
drug 
circulation route physical state of drug 
presence of permeation 
enhancers 
rectal fluid pH and 
buffering capacity  
nature of suppository base bioadhesive properties 
volume of rectal fluid presence of excipients 
 
motility of rectal wall   
 
 Physiological factors 1.2.3.1.1
There is greater contact between administered suppository and rectal wall for drug 
absorption to occur when the rectum is empty and devoid of faecal matter, enabling 
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greater absorption of drug than when it is distended with colonic contents. Likewise, 
absorption of rectally administered drugs can also be altered by medical conditions 
such as diarrhoea, colonic obstruction and tissue dehydration (Allen et al., 2005). 
 
Since both upper and lower rectum are drained by superior and inferior haemorrhoidal 
veins respectively, the position at which the suppository is retained within the rectum 
could affect systemic bioavailability as drugs absorbed via inferior haemorrhoidal 
veins avoid first-pass metabolism of the liver (De Leede et al., 1983). 
 
The pH of the rectal fluid is essentially 7.2–7.4, with negligible buffering capacity 
(Allen et al., 2008; Jantzen et al., 1989; McNeil et al., 1987). Hence, the form of drug 
incorporated into the suppository would greatly remain chemically unchanged once it 
is released from the dosage form.  
 
 Physicochemical factors 1.2.3.1.2
As with drug absorption across the gastric mucosa, only unionised, undissociated form 
of drug with sufficient lipophilicity would be able to travel across the bilayer lipid 
membrane structure of rectal mucosa due to the bilayer lipid membrane structure. 
However, the drug also has to be sufficiently soluble in rectal fluids to partition away 
from the lipophilic bases or dissolve from the hydrophilic bases prior to absorption. 
 
The size of drug particles suspended within the suppository base can influence its rate 
of dissolution in rectal fluids which then affects the rate of absorption. The smaller the 
size of drug particles, the greater the surface area available for dissolution; thus a 
faster absorption of drug can be expected (Cooper and Gunn, 1987). 
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Drugs which are highly soluble in the formulated suppository base tend to exhibit 
slower drug release than when they are formulated in bases in which they are less 
soluble (Allen et al., 2008; Ermiş and Tarimci, 1995; Ibrahim et al., 1990; Nair and 
Bhargava, 1999). This was clearly demonstrated by Nair and Bhargava (1999) where a 
lipophilic drug fluconazole (log P = 0.44), had highest release rates from the PEG 
compared to the more lipophilic bases like Suppocire
®
 AP, Witepsol W45 and CB. 
Therefore, a general rule to optimise drug release would be to formulate hydrophilic 
drugs in fatty oleaginous suppository bases and lipophilic drugs in hydrophilic bases 
(Allen et al., 2008, 2005). An alternative method employed to improve drug release is 
to incorporate surfactants or absorption enhancers into the suppository formulation 
(Shegokar and Singh, 2010). 
 
Conversely, when sustained release of drug from the suppository is desired, various 
excipients have been employed to retard drug release from the bases via formation of 
drug containing micellars using lecithin (Nishihata et al., 1985); solid-reverse-
micellar-solutions also using lecithin (Schneeweis and Müller-Goymann, 2000); 
incorporation of hydrophobic polymers such as hydroxypropyl methylcellulose 
phthalate HP-55 (Ohnishi et al., 1986) or waxy hydrophobic materials such as 
aluminium stearate and dioctyl sodium succinate (Ahmed et al., 2000).    
 
 Bioadhesion 1.3
Adhesion is the term used to describe the bond produced by interfacial forces when a 
pressure-sensitive adhesive, either a natural or synthetic polymer, comes into contact 
with a surface to allow prolonged attachment of the adhesive on the contact surface. 
Bioadhesion is therefore the interaction which results in the adhesion of the polymer 
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to a biological surface (Ahuja et al., 1997; Roy and Prabhakar, 2010). Various regions 
of the body, particularly the GIT is lined by mucosal epithelial which is covered by a 
layer of continuous mucus (Ahuja et al., 1997; Roy and Prabhakar, 2010).  
 
 Theories and mechanisms of bioadhesion 1.3.1
Although exact mechanisms of bioadhesion are not known, it is generally accepted 
that it involves initial wetting and swelling of the bioadhesive polymer. This is 
followed by interpenetration between polymer chains and mucosal surface, with 
subsequent formation of chemical bonds between entangled chains which constitutes 
the bioadhesion phenomenon. Various theories have been hypothesised to explain the 
phenomenon. 
 
a) Diffusion theory 
This theory postulated that polymer chains of bioadhesive material diffuse into the 
glycoprotein network and vice versa in a time-dependent manner until there is 
sufficient interpenetration to form mechanical interlocking and subsequent semi-
permanent adhesive bonds, producing a networked structure which results in adhesion 
(Ahuja et al., 1997; Andrews et al., 2009; Roy and Prabhakar, 2010). 
 
b) Adsorption theory 
Adhesion is a result of intermolecular forces acting between atoms in bioadhesive 
polymer and mucus (Ahuja et al., 1997). Both primary and secondary forces were 
thought to be involved although adhesion is mainly due to secondary forces such as 
electrostatic forces, van der Waals forces, hydrogen bonds and hydrophobic 
interactions (Ahuja et al., 1997; Andrews et al., 2009; Roy and Prabhakar, 2010). 
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c) Electronic theory 
This theory generally stems from the fact that adhesive polymers and mucus typically 
have different electronic characteristics (Lee et al., 2000). Electron transfer happens 
when adhesive polymer comes into close contact with the glycoprotein mucus 
network, forming an electrical double layer. The attractive forces across this double 
layer results in adhesion (Ahuja et al., 1997; Roy and Prabhakar, 2010). 
   
d) Wetting theory 
This theory is applicable for liquids or bioadhesive systems with low viscosity, where 
the adhesive component would penetrate surface irregularities, harden and anchor 
itself to the surface (Andrews et al., 2009). If the two adhering surfaces were brought 
to close contact in the presence of fluid, the fluid could act as an adhesive to attach 
both surfaces. 
   
e) Fracture theory 
The fracture theory evaluates bioadhesion based on difficulty (strain required) to 
separate two adhering surfaces, which represents strength of the adhesive bond (Ahuja 
et al., 1997; Andrews et al., 2009). 
 
 Factors affecting bioadhesion 1.3.2
The extent of bioadhesion between polymer and mucosa depends largely on polymer 
properties, environment for bioadhesion and various physiological variables (Table 
1.5). 
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Table 1.5: Factors affecting bioadhesion (Ahuja et al., 1997; Andrews et al., 2009). 
Polymer properties Physiological factors 
functional group mucin turnover 
degree of hydration disease states 
MW, chain length and degree of cross-linking pH 
polymer concentration 
 
pH and charge  
swelling   
 
Polymers containing carboxyl functional groups such as polycarbophils and 
polyacrylic acid polymers are known to show better bioadhesion at acidic 
environments whereby bioadhesion decreases with increasing pH. Park and Robinson  
(1985) found that cross-linked polyacrylic acid has limited bioadhesive properties 
above pH 6. This was attributed to the ionisation of the carboxyl groups which lead to 
repulsion between negatively charged carboxylate anions and also a reduction in the 
formation of hydrogen bonds (Andrews et al., 2009; Park and Robinson, 1985). 
 
Degree of hydration and swelling characteristics of the bioadhesive polymer is also 
important as swelling relaxes the polymer chains to facilitate interpenetration of the 
chains. However, excessive swelling has been shown to significantly reduce 
bioadhesion (Park and Robinson, 1985). 
 
Studies have shown that there is an optimal MW and critical polymer chain length in 
order to produce bioadhesive interactions (Tobyn et al., 1996, 1995). As polymer MW 
increases, internal cohesion of the polymer molecule increases, resulting in higher 
bioadhesion. However, the increase in MW also decreases aqueous dispersibility of 
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the polymer and hence fewer solubilised carboxylic groups are available for hydrogen 
bonding (Tobyn et al., 1996). Extensive crosslinking of the polymer also limits 
flexibility and mobility of the polymer chains, thus impeding penetration and 
entanglement of the polymer–mucus matrix, resulting in lower bioadhesive forces 
(Andrews et al., 2009). 
 
Physiologically, mucus turnover is expected to limit residence of bioadhesive dosage 
forms on the mucosal surface. The rectum has been known to possess relatively low 
mucus turnover rates as compared to other regions of the GIT and this might be less 
important in influencing rectal bioadhesion. However, diseased states like 
inflammatory bowel disease could increase mucus production, or in diarrhoea where 
there is significantly greater amount of water available (Allen et al., 2008).   
 
 Bioadhesive polymers 1.4
Although a large number of polymers exhibit bioadhesive properties, only a selected 
number of polymers are suitable for pharmaceutical use due to safety considerations. 
Some of the polymers adapted for pharmaceutical formulations are listed according to 
their solubility in water and ionic charges in Table 1.6.    
 
Anionic polymers are widely used as bioadhesive polymers due to their strong 
bioadhesive properties and low toxicity. These polymers are characterised by the 
presence of carboxyl, hydroxyl, amide or sulphate functional groups which dissociates 
into negatively charged groups at pH larger than their respective pKa. Polyacrylic acid 
polymer such as polycarbophil and carbopol are one of the most popular bioadhesive 
polymers in pharmaceuticals (Yahagi et al., 2000, 1999). 
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The most widely used cationic polymer is chitosan; which is derived by hydrolysing 
the aminoacetyl of chitin from crabs or shrimps. Various studies have reported on the 
bioadhesivity of chitosan for development of bioadhesive dosage forms, including 
rectal suppositories (Lehr and Bouwstra, 1992; Tarimci and Ermis, 1997) despite 
reports that chitosan lacks bioadhesion (Wong et al., 1999a). 
 
Table 1.6: Some of the bioadhesive polymers used in pharmaceutical dosage forms 
(Irons and Robinson, 2003; Lehr and Bouwstra, 1992). 
 Water soluble  Water insoluble 
Anionic Alginic Acid 
Carageenan 
Sodium carboxymethyl 
cellulose 
Carbopol 934P 
Polycarbophil 
Cross-linked polymethacrylic acid 
Cationic Aminodextran Gelatin 
Chitosan 
Amphiprotic Carboxymethyl chitosan  
Non-ionic Polyethylene Glycol 
Poly(vinylpyrrolidone) 
Hydroxypropyl cellulose 
Hydroxypropylmethyl cellulose 
Ethyl cellulose 
 
 Carbomers 1.4.1
Carbomers are high MW carboxyvinyl polymers which are crosslinked with acrylic 
acid using either allylsucrose or allyl pentaerythritol (Singla et al., 2000). A typical 
example of carbomer is Carbopol
®
 (CBP), its chemical structure shown in Figure 1.2a. 
These polymers are commercially available in various grades depending on MW and 
structure of the polymeric chain. 
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Figure 1.2 : The general chemical structure of bioadhesive polymers used, (a) 
Carbopol
®
(CBP); (b) poly(vinylpyrrolidone) (PVP); (c) N,O-carboxymethyl chitosan 
(CMCTS) and (d) hydroxypropyl methylcellulose (HPMC).  
 
These polymers have been used in the development of various bioadhesive dosage 
forms such as buccal tablets (Ikinci et al., 2004), transdermal gels (Shin et al., 2005), 
ophthalmic gels (Edsman et al., 1996), pellets (Gomez-Carracedo et al., 2007), 
suppositories (Ramadan, 2012; Yahagi et al., 2000, 1999) and more recently, as a 
bioadhesive conjugate on liposome surfaces (Makhlof et al., 2011; Werle et al., 2010). 
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CBP
 
is an anionic compound which appears as white, acidic, fluffy, hygroscopic 
powder. These polymers are insoluble in water and have a pKa of approximately 6.0 ± 
0.5. They are capable of swelling up to 1000 times their volume and 10 times their 
diameter to produce a gel with pH 4.0–6.0 (Lubrizol Advanced Materials, 2009). At 
pH above pKa, the carboxylate group on the polymer ionises causing repulsion 
between the negatively charged polymer backbones, leading to swelling (Lubrizol 
Advanced Materials, 2009; Singla et al., 2000).  
 
 Poly(vinylpyrrolidone)  1.4.2
Poly(vinylpyrrolidone) (PVP) is a synthetic, water soluble neutral polymer produced 
by free-radical polymerisation of vinylpyrrolidone in water or isopropanolol (Guo et 
al., 1998). Its general chemical structure is shown in Figure 1.2b. There is no general 
consensus on the bioadhesive properties of PVP as various studies have reported the 
absence or limited bioadhesion forces exerted by these polymers. Ivarsson and 
Wahlgren (2012) and Jones et al. (2004) reported poor or negligible bioadhesion for 
PVP while other researchers found that formulations containing PVP exhibited 
considerable bioadhesive strength in the form of coated alginate beads (Suknuntha et 
al., 2011), tablets (Hamzah et al., 2010), buccal patches (Wong et al., 1999b) and 
bioadhesive thermogelling rectal gel (Barakat, 2009). 
 
Apart from imparting bioadhesion, PVP was also reported to increase the rate of drug 
release and sometimes result in a burst of drug release due to its high solubility which 
promotes pore formation (Islam et al., 2012; Suknuntha et al., 2011).  
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 Chitosan and carboxymethyl chitosan (CMCTS)  1.4.3
Chitosan is derived via partial deacetylation of the natural polysaccharide chitin. 
Chitosan possesses both hydroxyl (-OH) and amine (-NH2) groups delivering many 
useful properties such as gel and film forming capacity and bioadhesion (Tungtong et 
al., 2012). However, the use of chitosan is hampered by its poor solubility at pH > 6.5. 
 
This leads to the incorporation of carboxyl (-COOH) groups to form amphiprotic 
carboxymethyl chitosan (CMCTS) which permits solubility even at neutral pH, yet 
retaining good film forming (Mourya et al., 2010) and bioadhesive properties (Shinde 
et al., 2013) of its parent chitosan. The structure of CMCTS is illustrated in Figure 
1.2c. To date, CMCTS has been incorporated into pH sensitive hydrogels (Chen et al., 
2004; Vaghani et al., 2012), nanoparticles (Shinde et al., 2013) and transdermal 
patches (Sarfaraz et al., 2012). However, CMCTS has yet to be formulated into 
suppositories. 
 
 Hydroxypropyl methylcellulose (HPMC) 1.4.4
Hydroxypropyl methylcellulose (HPMC) is a non-ionic alkyl-hydroxyalkyl cellulose 
ether derivative containing methoxyl and hydroxypropyl groups (Figure 1.2d). HPMC 
dissolves in water to form a solution with pH 5.0–8.0 at a concentration of 2 %w/w 
(Rowe et al., 2009). 
 
HPMC has been incorporated into various drug delivery systems due to its ability to 
gel on hydration and adhere to both mucin and mucosal surfaces. Due to its nonionic 
and water soluble nature, possibilities of interaction with other components of the 
formulation are greatly reduced. It has been incorporated into dosage forms to produce 
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buccal tablets (Akbari et al., 2010; Wong et al., 1999a), buccal patches (Vishnu et al., 
2007) oral bioadhesive tablets (Alladi et al., 2011), bioadhesive vaginal tablets (Bhat 
and Shivakumar, 2010), bioadhesive transdermal gels (Cho and Choi, 2011) and nasal 
insert (Bertram and Bodmeier, 2006). 
 
 Bioadhesive suppositories and its advantage 1.5
Retention of suppository within the lower rectum via incorporation of bioadhesive 
polymers enables absorption of the released drug into the lower haemorrhoidal vein 
which conveniently escapes first-pass degradation. This can be an excellent method to 
deliver drugs which undergo extensive first-pass metabolism.  
 
Furthermore, the rectum also has relatively low fluid content, thus dissolution of drugs 
released from suppositories would theoretically be the rate limiting step for drug 
absorption. Bioadhesive suppositories could potentially overcome this problem by 
prolonging contact time between molten base and rectal mucosa where absorption 
takes place. Securing dosage forms at the site of action also builds up a concentration 
gradient for passive diffusion of drugs across the mucosa (Lehr et al., 1992; Roy and 
Prabhakar, 2010). 
 
Yahagi et al. (1999) developed double-phased bioadhesive suppositories containing 
lidocaine using Carbopol 934P and beeswax in Witepsol H15. The group used 10 % 
carbopol and 20 % beeswax in an attempt to anchor the suppository within the lower 
rectum. As a result, increased systemic bioavailability of lidocaine from the double 
phased bioadhesive suppository was observed.  
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Even when the drug is not extensively degraded during first pass metabolism, 
suppositories containing bioadhesive polymers have been found to improve systemic 
bioavailability of ramosetron (an antiemetic) by 2.5 times compared to when the 
suppository was formulated without bioadhesive component (Yahagi et al., 2000).  
 
 Diclofenac sodium (DcNa) 1.6
As one of the more common NSAID, DcNa is prescribed for a myriad of conditions, 
ranging from long term treatment in patients with rheumatoid arthritis to short term 
treatment of muscular pains and aches. Recently, there has been great interest in using 
rectal DcNa for postoperative pain management that could successfully improve pain 
scores and reduce need for rescue analgesia (Dhawan et al., 2009). 
 
DcNa is scientifically known as sodium (O-((2,6-dichlorophenyl)-amino)-phenyl)-
acetate and is a weak acid with pKa of 4 and a partition coefficient (n-octanol/ aqueous 
buffer, pH 7.4) of 13.4. The ultraviolet (UV) absorbance of DcNa is detected at a 
wavelength of 270-276 nm (Palomo et al., 1999).   
 
It has a half-life of 2.3 hours after oral administration and is rapidly excreted from the 
body. DcNa also precipitates under acidic conditions. Although the drug is fully 
absorbed into the system, the absolute systemic bioavailability of active drug is only 
approximately 50 % due to the extensive first-pass metabolism (Willis et al., 1979). 
Therefore, dosage forms which could effectively avoid the hepatic first pass would 
technically allow administration of DcNa at lower doses without compromising the 
clinical responses (Palomo et al., 1999). 
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A study conducted in healthy volunteers revealed that peak serum levels of unchanged 
DcNa upon administration of suppository containing 50 mg DcNa occurred within 1 
hour, while peak serum levels were only attained after the 2 hours of administration in 
the subjects given enteric-coated tablets containing equal amount of drug (Reiss et al., 
1978). The therapeutic plasma concentration of diclofenac in human was reported to 
be 0.75–2.0 µg/mL (Winek et al., 2001) although other papers have reported that 
concentrations as low as 100 ng/mL of plasma diclofenac was effective in initiating 
analgesic effects (Radermacher et al., 1991). Meanwhile, trough concentrations of 
Voltaren
®
 SR were found to be 22-25 ng/mL, suggesting that the diclofenac minimum 
therapeutic concentration might be within the range of 20-50 ng/mL. 
 
To date, DcNa has been commercially marketed as enteric coated tablets, delayed 
release tablets for oral administration, gel and ointments for topical applications, 
suppositories for rectal administration and injectable solution for either IM or IV 
administration. The conventional dose for DcNa orally is 50 mg twice or thrice a day 
or 75 mg twice a day for adults. The latest addition to the market would be the 
Voltaren
®
-XR, an extended release formulation of DcNa for once daily dosing. 
 
 Aims and objectives 1.7
Despite being a traditional suppository base, CB has been known to exist in various 
polymorphic forms, therefore; an alternative base without the extensive polymorphism 
exhibited by CB is highly desirable. Furthermore, suppositories seem to be an 
excellent option for delivery of drugs which undergo extensive first pass metabolism 
because absorption from the lower rectum enters systemic circulation directly.  
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The aim of this project was therefore to evaluate and characterise bioadhesive DcNa 
suppositories produced using local HPKS.  
 
Specific aims of the studies in this thesis were:  
 to evaluate suitability of HPKS as an alternative to CB as suppository base. 
HPKS are widely available in Malaysia as a by-product of palm oil at a low 
cost 
 to optimise manufacturing methods for suppositories made with both HPKS 
and CB using differential scanning calorimetry(DSC)-simulated manufacturing 
as well as extemporaneous methods 
 to physically characterise DcNa suppositories containing bioadhesive 
polymers made using HPKS in comparison to those made using CB  
 to study release of DcNa from various suppository prototypes and the release 
kinetics involved 
 to fabricate and develop novel experimental prototypes for evaluation of 
bioadhesive properties of suppository prototypes incorporated with 
bioadhesive polymers (CBP, PVP, HPMC and CMCTS) 
 to investigate the feasibility of synthetic membranes as substitute for biological 
membranes in bioadhesion studies. Synthetic membranes are easily available, 
standardised and doesn’t require prior processing. 
 to evaluate physical stability of suppositories under different storage 
conditions and duration in terms of thermal profile (DSC method), hardness, 
softening time and drug release 
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CHAPTER 2   
PREFORMULATION STUDIES 
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 Introduction 2.1
The suitability of cocoa butter substitutes (CBS), namely ChocExa (CE) and 
Supersocolate Special
TM 
(SS) was assessed as part of the preformulation work for 
development of a fast-acting bioadhesive suppository. Both CE and SS are HPKS 
derived from kernel of oil palm fruits. CB, a traditional suppository base which was 
indicated to possess qualities of an ideal suppository base is used for comparison 
(Ansel, 1981; Kasture et al., 2007).  
 
Although a suppository base is chemically inert and functions only as a carrier for the 
active drug, properties of the base could affect physicochemical properties of resultant 
suppositories. Therefore, it is pertinent to characterise the various base properties, 
namely; 
 
(a) Thermal profile 
Two types of thermal analysis; thermogravimetric analysis (TGA) and DSC can be 
used to study the thermal profile. TGA detects and quantify base decomposition (CB, 
CE and SS) in terms of mass loss while the DSC shows phase changes encountered by 
the base upon exposure to temperature range encountered during manufacturing 
process (Giron, 1986; Schimdt, 2010).  
 
(b) Solid fat content  
Solid fat content (SFC) measures the solid-to-liquid ratio in fats over a temperature 
range. It has traditionally been determined using dilatometry (Walker and Bosin, 
1971) and more recently using pulsed nuclear magnetic resonance (p-NMR) (Leung et 
al., 1985) or ultrasonic velocimetry (Singh et al., 2004). An alternative method of SFC 
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determination is by continuous integration of the DSC thermogram of a sample 
subjected to heating across a desired temperature range (Menard and Sichina, 2000; 
Nassu and Gonçalves, 1999).  
 
(c) pH of molten base  
Since the rectum is relatively devoid of buffering capacity, pH of the suppository base 
would determine pH of rectal environment (Ahmad, 2001; Bottger et al., 1989). 
Certain bases alter pH of rectal environment and this could be potentially problematic 
if solubility of the drug is highly pH-dependent (Dash and Cudworth, 2001).  
 
(d) Partition coefficient of DcNa in molten base / distilled water 
Partition coefficient of DcNa between base and water determines how rapidly and 
completely it partitions out of suppository in the rectum (Allen et al., 2008). A small 
partition coefficient (favours aqueous phase) would permit rapid release of DcNa from 
the bases, supporting the aim of this study to develop fast-release suppositories. 
 
(e) Viscosity of molten base  
Viscosity of the molten base during manufacturing affects uniformity of incorporated 
drug within the dosage form (Allen et al., 2008; Coben and Lieberman, 1986). It is 
practical that molten base be sufficiently viscous to prevent sedimentation of additives 
but not too viscous that it makes manufacturing difficult or impedes drug release 
(Azechi et al., 2000). 
 
Both CE and SS have never been used in the pharmaceutical industry. Thus, proper 
characterisation of these bases would allow a systematic approach in subsequent 
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formulation work. This chapter aims to characterise physical properties of HPKS in 
comparison to CB as conventional suppository base and compares the robustness of 
the bases towards various manufacturing parameters for subsequent optimisation of 
CB and HPKS suppository manufacturing methods.   
 
 Materials 2.2
CB was purchased from JB Cocoa, Malaysia; while CE and SS were obtained as 
samples from Lam Soon, Malaysia and Cargill, Malaysia respectively. DcNa was 
purchased from Shreeji Pharma International, India. Product specifications are 
included in Appendices 1-3.  
 
 Methods 2.3
 Characterisation of suppository base 2.3.1
 Thermal profile 2.3.1.1
 Thermogravimetric analysis  2.3.1.1.1
TGA is conducted by placing 16.0 mg of unprocessed (raw) CB into a 40.0 μL 
standard aluminium crucibles (Mettler Toledo, USA) sealed with a lid previously 
pierced with a 50.0 μm hole to relieve vapour entrapment during the thermal cycle. 
Analysis was carried out using a thermogravimetric analyser connected to a GC10 gas 
controller system (Mettler Toledo, USA). Suppository bases were scanned at a speed 
of 1 °C/min across a range of 25 to 70 °C. The flow of nitrogen purge was fixed at 5 
mL/min. Experiment was repeated in triplicates.  
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 Differential scanning calorimetry  2.3.1.1.2
DSC was conducted using TA Q2000 (TA Instruments, Delaware, USA) connected to 
RCS 40 refrigeration system (TA Instruments, Delaware, USA) under nitrogen gas 
flow of 50 mL/min. Unmanipulated (raw) base samples (CB, CE, SS) of 4-6 mg were 
crimped into a hermetic Tzero aluminium pan and equilibrated to -10 °C before 
subjected to heating to 60 °C at a rate of 5 °C/min (first heating). The samples were 
then cooled to -10 °C at a rate of 5 °C/min before undergoing a second heating to 
60 °C. Samples were held isothermally at 60 and -10 °C for 1 minute before cooling 
and second heating phase respectively. Thermograms were analysed using TA 
Universal Analysis 2000 software. The melting point is defined as the endothermic 
peak. Samples were selectively replicated to ensure consistency. 
 
 Solid fat content (SFC) 2.3.1.2
Two methods were used to determine SFC in this study; namely the DSC method and 
p-NMR method. The DSC method was modified from Leung et al. (1985) and was 
conducted using instruments and methods mentioned in Section 2.3.1.1.2. SFC of the 
raw bases was obtained by continuous integration of the thermogram generated. 
Experiment was replicated using fresh samples. Determination of SFC using the p-
NMR was carried out by Malaysian Palm Oil Board (MPOB) using the MPOB 
p4.9:2004 method.  
 
 pH of molten base 2.3.1.3
The pH of molten base (without additives) was determined using methods modified 
from Dash (2001). 1.0 g of base was placed into a scintillation vial and added with 
10.0 mL of distilled water. The vial was then left to shake for 6 hours at 100 rpm in an 
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isothermic shaker (WiseCube
®
 WIS-20, Wisd Laboratory Instruments) kept at 37.0 ± 
0.5 °C. The solution was filtered using a 0.45 µm filter and pH reading of the solution 
was measured using a calibrated bench top pH meter (Eutech, USA) before and after 
shaking. Procedures were conducted in triplicates for each base. ANOVA test 
followed by post hoc Tukey’s HSD (Honestly Significant Difference) analysis (SPSS 
Inc., version 20, USA) was used to analyse the results.   
 
 Partition coefficient of DcNa in molten base/ distilled water 2.3.1.4
The partition coefficient of DcNa in the bases were determined using methods 
modified from studies by Ahmad (2001) and Nayak (2010). 3.0 g of base was weighed 
into scintillation vials and added with 3.0 mL of 5 %w/v of aqueous DcNa. The vials 
were sealed and left to shake for 24 hours at 100 rpm in an isothermic shaker 
(WiseCube
®
 WIS-20, Wisd Laboratory Instruments) kept at 37.0 ± 0.5 °C. The 
aqueous phase was filtered with 0.45 µm nylon filters and absorbance measured at 
276 nm. 3.0 g of base shaken with 3.0 mL of distilled water was used as control. 
Procedures were conducted in triplicates for each base. ANOVA test followed by post 
hoc Tukey’s HSD (Honestly Significant Difference) analysis (SPSS Inc., version 20, 
USA) was used to analyse the results.   
 
 Viscosity of molten base 2.3.1.5
Rheological properties of only molten bases (without additives) were measured using 
a LVDV-E rotational viscometer (Brookfield, USA) fitted with DAA cylindrical 
spindle s87. The small volume sample chamber used was fitted with a water jacket 
attached to a digital heating circulator unit (Protech, USA) maintained at 37.0 ± 0.5 °C. 
Molten samples (2 mL) were added into the sample chamber and allowed to 
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equilibrate to 37.0 °C for 5 minutes. The viscosity measurement in units of centipoise 
(cp) was obtained at various rotational speeds ranging from 20-100 rpm for torque 
measurements above 10.0 %. Procedures were conducted in triplicates for each base 
and expressed as mean ± SD. 
 
 Optimisation of manufacturing parameters 2.3.2
Due to similarities in thermal profiles between CE and SS (Section 2.4.1); SS was 
used as an example of HPKS base in DSC-simulated suppository manufacturing 
studies (Section 2.3.2.1) and extemporaneous manufacturing of suppositories at 
various Tmax (Section 2.3.2.2). The robustness and ease of manufacturing of SS 
suppositories were compared against conventional suppository base CB.  
 
 DSC–simulated suppository manufacturing 2.3.2.1
Simulation of the suppository manufacturing process was conducted using DSC 
system mentioned in Section 2.3.1.2.2. Unmanipulated (raw) base (CB or SS) of 4-6 
mg were subjected to a heat/cool/heat cycle across a predetermined temperature range. 
The manufacturing parameters which potentially affect polymorphic behaviour of CB 
and SS were investigated, namely; (a) maximum temperature the base was heated 
before solidification (Tmax); (b) heating rate during melting of the base (Hrate) and 
cooling rate for solidification of the molten base to suppositories (Crate). Samples were 
selectively replicated to ensure consistency. 
 
 Effects of Tmax on phase behaviour 2.3.2.1.1
The first heating prior to a cooling cycle was used to simulate melting of base 
followed by cooling and solidification in moulds. Independent, freshly prepared 
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samples were heated to various Tmax (CB = 34, 35, 36, 37, 38, 39 and 40 °C; SS = 36, 
38, 40, 42 and 50 °C) during the first heat cycle. Molten CB was then cooled and 
equilibrated at 4 °C before the second heating takes place. Second heating cycle was 
conducted from -10 to 60 °C upon completion of the first heat/cool cycle to identify 
the polymorphic behaviour of crystallised CB and SS after heating to various Tmax 
(during first heat/cool cycle). Heating was conducted at 5 °C/min and cooling at 
2 °C/min. Samples were held isothermally for 0.2 minutes in between each heat or 
cool cycle.  
 
 Effects of Hrate and Crate on phase behaviour 2.3.2.1.2
To study the effects of Hrate, CB samples were heated from -10 to 37 °C while SS 
samples were heated to 42 °C at various Hrate (1, 5 and 10 °C/min) during the first heat 
cycle and cooled to 4 °C at 2 °C/min. In the Crate studies,  CB and SS samples were at 
5 °C/min to 37 and 42 ºC respectively followed by cooling down to 4 °C at various 
rates (0.5, 2, 5 and 10 °C/min). The second heat cycle thermograms obtained by 
heating the samples from -10 to 60 °C at 5 °C/min were used to identify the 
polymorphic behaviour of crystallised CB and SS after being subjected to different 
Hrate and Crate in the first heat/cool cycle.  
 
 Extemporaneous manufacturing of suppositories at various Tmax 2.3.2.2
Two types of suppositories were produced in this section for evaluation, base-only 
suppositories (blank) and suppositories containing the model drug DcNa. The 
suppositories were prepared by fusion method. Base (CB or SS) was heated over a 
water bath (Julabo, Germany) to various Tmax temperatures (CB heated to 32, 34, 36, 
37 and 42 ± 0.5 °C; SS to 36, 40, 42 and 50 ± 0.5 °C).  
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In DcNa-containing suppositories, DcNa was added into the molten base with gradual 
stirring before pouring into the 1.0 g steel suppository mould cavities to cool at 
controlled room temperature of 22 ± 1.5 °C; relative humidity (RH) 63 ± 3 % until 
solidification of molten base. The produced suppositories each contained 50 mg DcNa. 
Blanks were moulded without DcNa into the molten. Suppositories were then placed 
into the refrigerator (3.5 ± 1.5 °C) for additional 10 minutes. The excess base 
overfilling the mould cavities were scrapped off using a warm spatula to produce 
suppositories with a smooth, flat end. The produced blank suppositories were scraped 
and 4-6 mg of sample was crimped into a hermetic aluminium pan and heated in the 
DSC from -10 to 60 °C at 5 °C/min. The ease of manufacturing suppositories at 
various molten temperatures as well as the quality of the manufactured suppositories 
was assessed. Quality of manufactured suppositories was evaluated based on the 
presence or absence of cracks, bubbles or discoloration and well as smoothness to 
touch. 
 
 Determination of displacement value (DV) 2.3.2.3
Blank suppositories (CB, CE and SS) were produced using calibrated six-cavity steel 
suppository moulds (each cavity 1.0 g) and the suppositories produced were weighed. 
The same moulds were used to manufacture suppositories containing 10 %w/w DcNa. 
The medicated suppositories were weighed.  
 
Displacement value (DV) determination was repeated in triplicates for each base and 
calculated using Equation 2.1 as stated  by Mollel (2006) and Vidras et al. (1982) :  
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Equation 2.1 𝑭 =
𝑿𝑩
𝟏𝟎𝟎 ( 𝑨 − 𝑩) − 𝑿𝑩 
 
Where,     
 F = displacement value 
 X = percentage of additive used (DcNa) 
 B = weight of suppositories containing X % additive 
 A = weight of blank suppositories made without any additives 
 
 Results and discussion 2.4
 Characterisation of suppository base 2.4.1
Based on the thermogravimetric data generated, the bases appear to be stable over the 
temperature range of 25 to 70 °C. Weight loss of the base was minimal and 
insignificant, thus it was concluded that decomposition did not occur across the range 
of temperature that they are exposed to during manufacturing process. 
 
Due to the large variability in naming of polymorphic forms in published literature, 
the polymorphic forms for CB and both HPKS (CE and SS) encountered in this thesis 
will be referred to as described in Tables 2.1-2.2 respectively. Designation of 
polymorphic forms was based on their respective melting points in comparison to 
previous published literature.     
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Table 2.1 : Reported polymorphic forms of CB and the variability in their nomenclature. Table includes nomenclature used to describe CB 
polymorphs in this thesis. 
Melting range 
(°C) 
Von Vaeck 
(1960) 
Wille and 
Lutton (1966) 
Lovegren et 
al. (1976) 
Van Malssen 
et al. (1999) 
Allen et al. 
(2008) 
Beckett 
(2008) 
Nomenclature in  thesis 
(CB) 
-5 to +5    γ   1 (Not observed) 
12 to 15   VI   I 
2 
16 to 20 γ I V α γ  
21 to 24 α II IV 
‡β’ 
α II  
25 to 27 
 §
III III  III 3A 
27 to 30 β’ IV II β’ IV 3B 
29 to 34 β V I β  V 4A 
34 to 36  VI   β VI 4B 
                                                 
‡ Van Malssen et al. (1999) suggested that β’ exist as a range rather than two distinct forms, recorded by Beckett (2008) and Wille and Lutton 
(1966) as forms III and IV; and forms II, III and IV by Lovegren et al. (1976). 
§ Form III was subsequently found to be a mixture of different proportions of forms II and IV, as confirmed in studies by Aronhime et al. (1988). 
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Table 2.2 : The reported polymorphic forms of lauric fats, PKO blends, HPKS and the variability in their nomenclature. Table includes 
nomenclature used to describe CE and SS polymorphs in this thesis.  
 Lauric fats PKO blend
**
 HPKS 
Melting range 
(°C) 
Anihouvi et al. 
(2013) 
Noordin and Chung 
(2009) 
Siew (2001) 
Peyronel and 
Marangoni (2014) 
Rossell 
(1975) 
Nomenclature in  
thesis (CE and SS)
 ††
 
-30 to -10 α     Not observed 
20 to 28  Form I    Not observed 
28 to 32 
β’ 
Form II    β’2 
33 to 34 Form III β’ β’  
‡‡β’ 
β’1 
35 to 37     β 
                                                                                                                                                                                                                  
                                                 
** Custom blend composed of HPKS: PKS: virgin PKO at ratio of 5:2:3. 
†† Iodine value of 0.4 in CE and 0.29 in SS. 
‡‡ Melting point quoted for β’ forms from HPKS are based on four different degrees of hydrogenation and iodine value (IV) of 8.3, 4.4, 2.5 and     
   0.4. 
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The first heating thermograms in Figure 2.1 (solid lines) depicted melting profiles of 
the unmanipulated (raw) bases; while the second melt thermogram (dash lines) 
obtained from reheating the bases after first heating and cooling showed tolerability of 
the bases to subsequent solidification after heating to high temperatures.   
 
At least three distinct polymorphs were observed in the unmanipulated CB based on 
the first heating thermogram (Figure 2.1a, solid line). They were form 2 (11.9 °C), 
form 3A (22.1 °C), form 3B (28.8 °C) and form 4B (34.7 °C). Form 1 was not 
observed throughout this study due to its metastable nature which resulted in its 
spontaneous crystallisation into form 2 polymorph (Dewettinck and Foubert, 2004). 
The CB stock used in this study has been stored for about 3 years at 3.5 ± 1.5 °C, 
stabilisation of the form 4A into form 4B polymorph over the storage duration 
resulted in the existence of form 4B as the major component in unmanipulated CB.  
 
Upon cooling after the first heating, CB existed mainly in form 2 which exhibits an 
endotherm peak at 20.3 °C (melting of form 2) and to a much lesser extent, form 3B 
which melted at 26.6 °C (Figure 2.1a, dashed line). The presence of these 
polymorphic forms is unfavourable, as the suppositories would theoretically remain in 
the liquid state at room temperatures, causing sedimentation and separation of the 
active drug or additives from the base.  
 
Previous studies by Siew (2001) suggested that HPKS predominantly crystallises into 
β’ polymorph which has a melting endotherm at 32.5 °C followed by a shoulder at 
35–38 °C. The author also observed an exothermic event at 22-25 °C suggestive of a 
transition from lower melting polymorphs to the more stable β’.  
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Both the HPKS used in this study were found to have lesser polymorphic forms 
compared to CB. In the first heating cycle, CE (Figure 2.1b, solid line) yielded three 
distinct melting endotherms; β’2 presented as a small peak at 27.0 °C, a larger 
endotherm at 34.1 °C by the β’1 form and a less visible shoulder around 37.1 °C 
attributed to the presence of β form. This was consistent with the HPKS melting points 
reported by Chapman et al. (1971). Upon cooling, molten CE crystallised into the β’2 
form which exhibited a single melting endotherm at 31.7 °C, as observed in the 
second heating thermogram (Figure 2.1b, dash line).  
 
Similarly, SS displayed three different forms; the β’2 form (27.9 °C), β’1 form 
(35.7 °C), and β form (present as a shoulder around 38.4 °C) (Figure 2.1c, solid line). 
Upon first heating and cooling, SS crystallised into β’2 which melts at 31.9 °C (Figure 
2.1, dash line). Both CE and SS existed in polymorphic forms with melting points at 
approximately 32 °C after the first heat/cool cycle, despite a slight shift in the 
endotherm peak to a lower temperature compared to the first heating. This reflected 
the robustness of HPKS over CB towards temperature manipulation.  
 
All three bases had melting points close to the human body temperature, which is an 
essential characteristic of a suppository base.  
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Figure 2.1: DSC thermograms showing the first and second heating profiles of 
unadulterated (raw) bases (a) CB; (b) CE and (c) SS. Solid lines and dash lines 
indicate the first and second heating respectively. Thermograms were offset for 
clarity. Enthalpy of fusion was included on far right of each thermogram. 
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Figure 2.2a shows the SFC of the three bases determined using the DSC method. The 
melting integral of a thermogram corresponds to the proportion of melted fat at a 
particular temperature (Marquez et al., 2013). The SFC curves (Figure 2.2a) of all 
three bases (CB, CE, SS) were similar and have very steep slopes between 32-38 °C.  
 
Comparatively, the SFC generated using the p-NMR (Figure 2.2b) showed that curves 
for both CE and SS were almost identical but were skewed to the right of the CB 
curve. This was due to the experimental methods where CB samples have been heated 
up to 80 °C to clear thermal memory before analysis, thus the SFC curve is likely to 
correspond to the less stable polymorphic form of CB. The DSC method allows 
continuous measurement of a single sample across the entire range of temperature and 
allows the measurement of unadulterated (raw) samples; hence preferred for studying 
the processing behaviour of the base during suppository manufacturing. In general, 
both the HPKS (CE and SS) remained solid until higher temperatures than CB before 
undergoing a similar sharp melting over a narrow range of temperature.  
 
The SFC of fats can be used as a prognostic indicator of essential properties; for 
example, the SFC below 25 °C provides an indication of hardness of the particular fat, 
while the SFC between 25-30 °C reflects its resistance to heating (Torbica et al., 
2005). Meanwhile, the steepness of the slope at 35 ± 2 °C is more relevant in 
suppositories as it reflects how rapidly the suppository melts at human body 
temperature. 
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Figure 2.2 : SFC (%) of unadulterated (raw) suppository bases (CB, CE and SS) 
determined using (a) DSC method and (b) p-NMR method (MPOB p4.9 : 2004).  
 
Meanwhile, none of the three bases significantly altered pH of distilled water upon 
melting (p> 0.05). The model drug DcNa have been reported to have a solubility of 
0.0036 mg/mL in pH 4.5 acetate buffer to 0.036 mg/mL at pH 5.3 where a modest 
increment of pH by 0.8 lead to a 10-fold increase in solubility of DcNa (Chuasuwan et 
al., 2009). Therefore, any changes in pH brought about by melting of bases could 
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potentially affect the solubility of DcNa and its release from the bases; considering the 
lack of buffering capacity in the rectal cavity.  
 
An important attribute of a suppository base is its ability to release the incorporated 
drug completely upon melting. The melting profile, viscosity, partition ratio and 
solubility of drug in surrounding aqueous environment impacts the ease of drug 
release. If a drug has higher solubility in the fatty base over the aqueous phase (rectum 
environment) then it may be incompletely released from the suppositories or released 
slowly (Allen et al., 2008). DcNa was found to preferentially partition into the 
aqueous phase over oily phase in all the three studied bases. This suggested that all the 
three bases release DcNa rapidly, although the partition ratio (base/water) of DcNa in 
CB (0.245 ± 0.007) was significantly higher (p< 0.05) than both CE (0.031 ± 0.003) 
and SS (0.037 ± 0.008).  
 
 
Figure 2.3 : The viscosity of the bases (CB, CE and SS) under different shear rates 
maintained at 37 ± 0.5 ºC. Mean ± SD, n=3. 
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Figure 2.3 showed that the viscosities of all three bases decrease with increasing shear 
rate. CE generally had similar viscosity to CB over shear rate of 20–100 rpm at 37 ºC 
while SS appeared less viscous than both CE and CB. CE and SS are mainly 
composed of shorter-chained lauric acid (C12) while the longer stearic acid (C18) 
predominates in CB (Allen et al., 1999; Gros and Feuge, 1952). A molten base with 
lower viscosity may offer better spreadability in the rectum upon melting, thus 
increasing surface area for drug release, but at the same time extremely low viscosities 
risk sedimentation of drug particles during manufacturing. The lower viscosities in CE 
and SS in this situation were compensated by a steep SFC profile (Figure 2.2), as 
rapid solidification reduces risk of drug sedimentation. 
 
 Optimisation of suppository manufacturing methods 2.4.2
The first heating in the heat/cool/heat cycle in the DSC-simulated manufacturing of 
suppositories was conducted to simulate heating up of the base; this is then followed 
by cooling of the molten to produce solid suppositories. Finally, the second heating 
was used to determine the melting profile of the suppositories produced. 
 
The small endothermic peak observed in the 10-20 °C regions (Figures 2.4a–d, inset) 
in CB samples was attributed to melting of metastable form 2. The entailing 
exothermic peak observed at the range of 15–25 °C corresponded to direct solid-solid 
transition of the metastable form 2 to form 3A (Dewettinck and Foubert, 2004), which 
intensity increases proportionally to increasing amounts of form 2 present. CB molten 
heated to a Tmax between 34-37 °C (Figures 2.4a–d) crystallised mainly into form 2 as 
well as a mixture of form 3A and 3B. Similar to previous studies, the experiments 
carried out in this study using DSC were unable to distinguish between the form 2 to 
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form 3 transitions and the direct crystallisation of form 3 from the melt (Toro-Vazquez 
et al., 2004). The presence of a small peak at approximately 36 °C (Figures 2.4a–c, 
asterisk) simply implied the incomplete melting of form 4B in the initial raw base 
before cooling down rather than as a result of the thermal manipulation imposed. The 
size of form 4B peak decreased as the Tmax was increased (Figures 2.4a–c) and 
completely diminished when Tmax was above 37 °C (Figures 2.4d–g).  
 
When CB was heated to Tmax > 37 °C, the main polymorphic form produced was form 
2 with small amounts of form 3A which was present as a shoulder at 25–28 °C 
(Figures 2.4e-g, solid arrow). Complete removal of crystal ‘memory’ followed by 
continuous cooling to 4 °C at 2 °C/min resulted in formation of unstable form 2 
polymorph. The small amounts of form 3A observed could be a result of the 
spontaneous transition from any form 2 polymorph produced (Dewettinck and Foubert, 
2004). This highlighted the narrow temperature derangement tolerated by CB during 
manufacturing before the base preferentially crystallises into form 2 polymorph. 
 
51 
 
 
Figure 2.4 : Thermograms of the second heating cycle of CB samples. CB was 
subjected to various Tmax (5 °C/min) before being cooled at 2 °C/min to 4 °C. Subtle 
peaks are enlarged in the respective figure inset. Arrow denotes small amounts of 
form 3A polymorph present as a shoulder. Asterisk denotes residual form 4B 
polymorph from first heating. 
 
Figures 2.5a–f showed that SS base heated to between 36 and 50 °C recrystallised into 
a single polymorphic form, the stable β’2 form (31-32 °C). This was consistent with 
previous studies which reported the preferential crystallisation of lauric fats into the 
β’2 polymorph (Anihouvi et al., 2013; Ehlers, 2012; Rossell, 1975; Timms, 1984). 
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Figure 2.5 : Thermograms of the second heating cycle of SS samples. SS was 
subjected to various Tmax heated at 5 °C/min before being cooled at 2 °C/min to 4 
°C. Asterisk denotes residual β polymorph from first heating. 
 
Presence of a small peak around 37-39 °C (Figures 2.5a–b, asterisk) was thought to be 
due to incomplete melting of β form in the base before the cooling cycle. SS has a 
wide range of Tmax tolerance of at least 10 °C (Figures 2.5c–f), a contrasting difference 
to CB. This simplifies manufacturing of suppositories using SS as it required less 
stringent temperature control. As long as SS is completely molten (>38 °C), it would 
solidify into a stable β’2 polymorph. This trend was observed for Tmax up to 50 °C. 
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On the contrary, there was a narrow range of Tmax between 34-38 °C which the CB 
base has to conform to during manufacturing. CB has to be heated up to the 
temperature at which it completely melts, yet ensuring that it does not overheat to 
produce form 1 (α form) or require excessively long time for solidification. Unlike CB, 
crystallisation of SS was not affected by Tmax during manufacturing using DSC-
simulated methods across the Tmax range of 40-50 °C.  
 
Figures 2.6a–c showed the crystallisation of molten CB previously heated to 37 °C 
upon cooling at 2, 0.5 and 0.2 °C/min. CB molten cooled at 2 °C/min has three 
distinct crystallisation exotherms at 21.9, 18.3 and 14.4 °C respectively (Figure 2.6a). 
At cooling rate of 0.5 °C/min, there were two crystallisation exotherms at 21.5 and 
10.5 °C (Figure 2.6b), while cooling rate of 0.2 °C/min resulted in a single 
crystallisation exotherm at 23.3 °C (Figure 2.6c). This was translated into the different 
polymorphic forms as characterised by distinct endothermic peaks observed upon 
reheating (Figures 2.6d-f). At the cooling rates investigated, CB crystallised mainly 
into form 4A (Figures 2.6d-f, open arrow). CB cooled at 2 °C/min contained 
considerable amounts of form 2 (Figures 2.6d-e, solid arrow) which diminished as 
Crate was lowered. Presence of form 2 is supported by the appearance of an exothermic 
peak around 18–20 °C (Figures 2.6a-b, asterisk) which corresponded to its transition 
to 3A polymorph. Melting of this 3A polymorph appeared as a faint shoulder around 
22–26 °C (Figures 2.6a-b; hash). This exothermic peak at 18–20 °C was absent when 
the Crate was reduced to 0.5 and 0.2 °C/min (Figure 2.6f).  
  
5
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Figure 2.6 : Thermograms of the cooling cycle of CB samples at (a) 2 °C/min, (b) 0.5 °C/min and (c) 0.2 °C/min after undergoing first heating to 
Tmax of 37 °C. Thermograms of the second heating cycle are shown in the corresponding thermograms (d–f). First heating was conducted at 
5 °C/min and subjected to solidification at various cooling rates. Subtle peaks are shown in figure insets. Solid arrows denote presence of form 2 
while open arrows denote form 4A. Asterisks denote exothermic event while hashes indicate presence of form 3A.      
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Even when CB was heated to 38 °C, it may still be possible for the molten to 
crystallise into form 3B polymorph (Figure 2.7d, asterisk) with a melting point at 
30.2 °C via slow cooling at 0.5 °C/min, albeit in mixture with substantial amounts of 
metastable form 2 (Figure 2.7d, solid arrow). However, the formation of 3B 
polymorph decreased when CB was heated to 39 °C (Figure 2.7e, asterisk) and 
completely diminished with Tmax of 40 °C (Figure 2.7f). In CB heated to 40 °C, slow 
cooling at 0.5 °C/min produced only form 2 polymorphs (Figure 2.7f, solid arrow). 
CB heated to 38-40 °C crystallised mainly into form 2 (Figures 2.7a-c, solid arrow) 
with small amounts of 3A polymorphs (Figures 2.7a-c, open arrow) upon cooling at 
2 °C/min. The difference in Crate greatly affects crystallisation and polymorphic form 
of molten CB. Rapid cooling resulted in an unstable diffuse crystalline phase made up 
of low energy polymorphs, while slow cooling allows more time for the TAG chains 
to pack into a lamellae to form a stable, 3-D structure (Metin and Hartel, 2005). 
 
In molten SS however, the Crate had less influence on the resultant polymorphic forms. 
SS consistently underwent a single step crystallisation process (Figures 2.8(i)a-d) into 
the stable β’ polymorph (mixture of β’1 and β’2) with a melting endotherm at 31-33 °C 
(Figures 2.8(ii)a-d, solid arrow); regardless of the Crate between 0.2-5 °C/min. This 
robustness observed in SS is favourable especially for the manufacturing of 
suppositories as it eliminates requirement for rate controlled cooling and prevents 
variability of polymorph formation in the final product.  
 
The Hrate on the other hand, was found to not affect the polymorphic forms produced 
in both CB and SS between 1–10 °C/min (results not shown).    
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Figure 2.7 : Thermograms of the second heating cycle of the CB. First heating was conducted to different Tmax 38, 39 and 40 °C (5 °C/min) and 
subjected to solidification at either cooling rate of 2 °C/min (a–c) or 0.5 °C/min (d–f). Smaller peaks are shown in the figure insets. Solid arrows 
denote presence of form 2; while open arrows denote form 3A. Asterisks denote form 3B.       
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Figure 2.8 : Thermograms of (i) cooling cycle and (ii) second heating thermogram after first ‘heat–cool’ cycle of SS samples. The SS samples 
were subjected to cooling rate of (a) 5 °C/min, (b) 2 °C/min, (c) 0.5 °C/min and (d) 0.2 °C/min after first heating to Tmax of 42 °C. Both first and 
second heating cycles were conducted at rate of 5 °C/min. Solid arrows denote presence of β’ form (mixture of β’1 and β’2).    
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The Crate of molten base in extemporaneously prepared suppositories was ~1 °C/min, 
projected based on the time required for molten base temperature to decrease by 10 °C 
during actual manufacturing.  
 
All extemporaneously produced suppositories from CB molten at various Tmax 
resulted in similar profiles, with the exception of molten CB at Tmax of 32 °C where an 
additional small endothermic peak at 36.5 °C (Figure 2.9a, asterisk) was a result of 
the incomplete melting of the unmanipulated (raw) CB base during manufacturing. 
This was consistent with observations in DSC simulated studies (Figures 2.4a–c). The 
main endothermic peak at 32.4 ± 0.3 °C indicated that CB suppositories existed 
mainly in the stable form 4A (Figures 2.9a-e, open arrow), with a shoulder at 25–
29 °C attributed to the presence of one or more form 3 polymorphs (Figures 2.9a-e, 
solid arrow). The proportion of form 3 polymorphs present increased with increasing 
Tmax. A small peak at 10–20 °C was observed which corresponded to very small 
amounts of form 2 polymorph (Figures 2.9a-e, inset marked with hash). 
 
This is an interesting finding since even molten which has been heated to 40 °C 
congealed to produce suppositories in the stable form 4A polymorphs (Figures 2.9a-e), 
rather than into form 2 polymorphs as observed in the DSC-simulated studies and as 
suggested by various literatures (Collett, 1990). It was deduced from these 
observations, that even when molten CB has been heated above 36 °C, it was still 
possible to manufacture suppositories in the stable form 4A as long as the molten CB 
has been allowed to congeal over longer periods of time (ie: >55 mins) at 
temperatures between 21.5–23.5 °C. If the same molten had been rapidly cooled in the 
refrigerator (simulated by the DSC cooling), it would have congealed under 
59 
 
refrigeration into form 2 polymorph which reverts to a molten once removed from the 
refrigerator, owing to its low melting point. 
 
 
Figure 2.9 : Thermograms of extemporaneously produced CB suppositories 
manufactured from molten heated to various Tmax followed by solidification at 
regulated lab conditions of 22.5 ± 1 °C; RH 63 ± 3 %. Smaller peaks are shown in the 
enlarged insets. Hashes indicate the form 2 polymorph, while solid and open arrows 
denote the presence of form 3 and form 4A polymorphs respectively. Asterisk shows 
the unmelted residual (raw) base. 
 
On the other hand, molten SS appeared white and creamy when heated up to 39 °C. 
At 40 °C, SS becomes a colourless liquid. The SS suppositories produced from 
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molten at Tmax of 40 to 50 °C consisted mainly of the stable β’1 polymorph (Figures 
2.10a-d, open arrow) with a melting point of 34.3 ± 0.1 °C, together with a small 
fraction of β’2 (Figure 2.10, solid arrow), evident as a small shoulder at 29.4 ± 0.5 °C. 
The small peak present at 40.1 °C (Figure 2.10a, asterisk) was a result of residual 
unmanipulated (raw) base due to incomplete melting.   
 
 
Figure 2.10 : Thermograms of extemporaneously produced SS suppositories 
manufactured from molten heated to various Tmax followed by solidification at 
regulated lab conditions of 22.5 C ± 1 °C; RH 63 ± 3 %. Solid arrow denotes the 
presence of small amounts of β’2 form, while open arrow denotes β’1 form. Asterisk 
shows the unmelted residual base. 
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A summary of the qualitative assessment can be found in Table 2.3. It was found that 
molten CB heated to 32 °C and below was too thick for DcNa incorporation and made 
pouring into moulds difficult. On the other hand, molten CB heated to 38 °C and 
42 °C resulted in solidification time more than 60 minutes and sedimentation of DcNa 
particles to the bottom of the suppositories was observed. Incorporation of DcNa into 
SS on the other hand, was easy in molten heated to temperatures above 36 °C. 
 
The observed differences for CB and SS between both methods (DSC-simulated 
method and extemporaneous manufacturing) were mainly due to differences in 
experimental setup. Extemporaneously compounded suppositories were manufactured 
in a lab with temperatures regulated at 22 ± 1.5 °C; RH 63 ± 3 %, while the samples 
in DSC-simulated studies were crimped into a pan and cooled at a fixed rate. 
Moreover, the molten bases in extemporaneous manufactured suppositories were 
subjected to stirring (shear) which facilitated rearrangement of the fatty acid chains 
into a more stable arrangement (Dhonsi and Stapley, 2006).  
 
The effects of temperature and shear on crystallisation and polymorphic forms 
produced has been well demonstrated by various groups (Dhonsi and Stapley, 2006; 
Macmillan and Roberts, 2002; Sato, 2001). In the presence of shearing in CB, form 
4A polymorphs were produced as a result of transformation from the precursor form 
3A (Dhonsi and Stapley, 2006; Sato, 2001). While in the absence of shearing, only the 
form 3 variants (both form 3A and 3B) were observed, with form 3A polymorph again 
acting as a precursor for the formation of more stable form 3B (Sato, 2001).  
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Table 2.3 : Qualitative assessment of CB and SS molten properties, ease of manufacturing process and visual appearance of compounded 
suppositories subjected to various Tmax, as determined by lab-scale extemporaneous manufacturing process. 
§§
 
                                                 
§§
 ‘+’ implies presence of a particular observation; ‘++’ implies presence of the observation with greater intensity; while ‘-’ implies the absence of the observation. 
Tmax (°C) 
CB SS 
30 32 34 37 40 36 40 42 50 
Molten 
properties 
Colour  Pale 
yellow 
Milky 
yellow 
Yellow 
Dark 
yellow 
Dark 
yellow 
White  Colourless Colourless Colourless 
Bubbles - - - + + - - - - 
Turbidity ++ + - - - ++ - - - 
Viscosity ++ + - - - ++ - - - 
Ease of 
manufacturing 
Drug 
incorporation 
Unable 
to mould 
Difficult 
(thick 
base) 
Easy Easy  
Difficult  
(sediment) 
Difficult  
(thick 
base) 
Easy Easy Easy 
Pouring into 
mould 
Difficult 
(viscous) 
Easy Easy Easy  
Difficult 
(viscous) 
Easy Easy Easy 
Leaking from 
mould 
- - + ++ - - - - 
Time to 
solidification 
(min) 
15 18 54 65 5 7 10 18 
Produced 
suppositories 
Colour  Yellow Yellow Yellow Yellow White White White White 
Smoothness Smooth Smooth Smooth Smooth Smooth  Smooth Smooth Smooth 
Cracks - - - - - - - - 
Airholes 
(Bubbles) 
+ - - - + + + + 
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Similarly, extemporaneously manufactured SS suppositories comprised of the higher 
melting point β’1 polymorph (33-34 °C) in the presence of shear (from stirring of 
molten) rather than the lower melting point β’2 polymorph observed in the DSC-
simulated studies.  
 
Based on both DSC-simulated and extemporaneous manufacturing of suppositories, 
Tmax of 34 and 42 °C were used in production of CB and SS suppositories respectively 
for subsequent analysis considering their practical solidification time. 
 
The DV of a compound is the weight of medicament or additive which displaces 1.0 g 
of the base in which they are to be formulated in (Allen et al., 2008). These values are 
crucial to  determine the exact quantities of excipients, active drug and bases needed 
to formulate each suppository as the moulds used during manufacturing are of a fixed 
volume (Allen et al., 2008; Babar et al., 1999; Vidras et al., 1982).   
 
DV of the same drug could be different for different bases due to difference in density, 
hence complicating the manufacturing process and resulting in inaccurate dosage 
strength. This study found that the DV of DcNa was similar among the three bases 
(CB = 1.40 ± 0.06; CE = 1.40 ± 0.02 and; SS = 1.48 ± 0.07). CE and SS may be a 
good substitute or equivalent for CB as a suppository base in existing formulations 
using CB.  
 
 Conclusion 2.5
Both the HPKS used in this study, CE and SS were found to be comparable to CB in 
terms of thermal profile, SFC, pH, viscosity and DV. 
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This chapter also found that CB has rigid processing parameters during manufacturing. 
When manufactured extemporaneously, it is crucial that the CB molten base is (1) 
maintained between 34 ± 0.5 °C during heating and (2) allowed to cool slowly to 
between 20–24 °C to produce suppositories with the desirable form 4A polymorph (3) 
molten CB should not be placed into a refrigerator before solidification is complete as 
it will result in rapid crystallisation into the form 2 polymorph. These restrictions 
however, were not relevant in HPKS where crystallisation was independent of the 
heating and cooling process during manufacturing. Stirring of molten (shear) 
promotes the formation of higher melting point polymorphic forms in both bases. 
HPKS is a suitable alternative suppository base due to its superior manufacturing 
flexibility compared to CB. 
 
Based on the findings in this chapter, the two HPKS investigated (CE and SS) appear 
to be suitable candidates as an alternative lipophilic base for the development of DcNa 
suppositories. 
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CHAPTER 3    
FORMULATION AND 
ASSESSMENT OF SUPPOSITORY 
DOSAGE FORM 
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 Introduction 3.1
 Routine analysis for manufactured suppositories 3.1.1
Analytical assessments of manufactured pharmaceutical products are routinely 
conducted to ensure quality standards are met. Following manufacture, suppositories 
are physically inspected for its appearance; examined for weight uniformity, melting 
point, viscosity, active drug content, resistance to mechanical fracture (hardness) and 
softening time (Coben and Lieberman, 1986; De Blaey and Tukker, 1996). 
 
Visual appearance of suppositories can sometimes be a good indication of the 
homogeneity of suspended ingredients as well as suitability of the manufacturing 
parameters (Allen et al., 2008; De Blaey and Tukker, 1996). Meanwhile, significant 
weight variation in a batch of suppositories could be an indication of either 
inhomogeneity of additives or the presence of a cavity which ultimately affects 
content uniformity of dosage forms. Proper standardisation of manufacturing 
parameters would minimise these variations (Mollel, 2006).  
 
Melting point of a lipophilic suppository is crucial for drug release upon insertion into 
the rectum. A depressed melting point leads to melting and damage of the 
suppositories during handling while those with melting point above body temperature 
will not melt completely. Various methods have previously been used to study melting 
point of suppositories, including the DSC (Kauss et al., 2013; Mollel, 2006; Yahagi et 
al., 1999), capillary method (Ahmad, 2001; Hammouda et al., 1993; Pugunes and 
Ugandar, 2013) and water bath method (Shegokar and Singh, 2010; Soremekun et al., 
2012). The DSC method offers a more precise measurement as it records actual phase 
changes of the base across the temperature range tested.  
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Viscosity of melted suppositories would affect spreading and release of medication in 
situ (Azechi et al., 2000). Thicker molten may hinder drug release and limit spreading 
while excessively watery molten could leak from the rectum. Suppository viscosities 
have been measured using viscometers of the Ubbelohde type (Yahagi et al., 2000), 
cone and plate type (Takatori et al., 2004) and spindle viscometer (Reanmongkol et al., 
2011; Victoria and David, 2003). 
 
Determination of the active drug (DcNa) content of suppositories is crucial to 
demonstrate dose-to-dose consistency. Method of active drug quantification ranges 
from the more conventional solvent or aqueous extraction of the drug followed by 
subsequent spectrophotometric analysis (Shegokar and Singh, 2010; Swamy et al., 
2012; Zawar and Bhandari, 2012); by way of DSC micro quantification method 
(Noordin and Chung, 2004) or by using the partial least squares treatment of the FT-
Raman spectra (Szostak and Mazurek, 2013).  
 
Additives are known to affect hardness of suppositories (Coben and Lieberman, 1986; 
Güneri et al., 2004; Kosior, 2001; Shegokar and Singh, 2010). Although there is no 
standard method to evaluate hardness of suppositories, measurements have been done 
using suppository hardness tester type SBT by Erweka (Babar et al., 1999; Ghorab et 
al., 2011; Güneri et al., 2004; Hanaee et al., 2004; Shegokar and Singh, 2010), bench 
top tablet hardness tester (El-Majri and Sharma, 2010; Kurosawa et al., 1985; Oribe et 
al., 1995), hand-held Monsanto tablet hardness tester (Noman and Kadi, 2011; Saleem 
et al., 2008; Varshney Himanshu and Tanwar, 2009), modified rheometer with tooth 
press stick B (Ramadan, 2012; Yahagi et al., 1999), and texture analyser (Gugulothu 
et al., 2010). 
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Softening time is especially important for lipophilic suppositories. A long softening 
time may result in premature expulsion from the rectum before drug absorption can 
occur, yet suppositories which soften too soon are easily damaged during handling 
prior to administration. The European Pharmacopoeia (2010) specified an apparatus in 
Section 2.9.22 which consisted of a glass tube immersed in a temperature controlled 
water bath for the measurement of time elapsed for lipophilic suppositories to soften 
permitting penetration of rod probe. Apart from that, softening time can also be 
determined using the liquefaction and softening time apparatus (Moghimipour et al., 
2009) and U-tube submerged in a water-bath (Varshney Himanshu and Tanwar, 2009).  
 
This chapter aims to manufacture bioadhesive suppositories containing DcNa (model 
drug) and four different types of bioadhesive polymers using the fusion method. The 
polymers used were the anionic polymer CBP grade 974P NF; amphiprotic polymer 
CMCTS and non-ionic polymers PVP grade K30 and HPMC grade 2910. The 
manufactured suppositories were then subjected to routine analysis in terms of 
physical inspection, weight variation, melting point, DcNa content, viscosity, hardness 
and softening time in order to ensure the quality standards are met.  
 
 Materials 3.2
The base and model drug used have been described in Section 2.2. CBP 974P NF was 
obtained as a sample from Drex-chem (M) Sdn. Bhd., Malaysia; HPMC 2910 was 
purchased from Newstar Chem Enterprise, China; PVP K30 was acquired from 
Brightchem Sdn Bhd., Malaysia; while CMCTS was procured from China Eastar Co. 
Ltd., China. Potassium dihydrogen phosphate (KH2PO4), dipotassium hydrogen 
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phosphate (K2HPO4) and potassium bromide were purchased from Nacalai Tesque 
Inc., Kyoto, Japan. Product specifications are included in Appendices 4-7. 
 
 Methods 3.3
 Manufacturing of DcNa suppositories containing bioadhesive polymers 3.3.1
Methods of suppository manufacturing have been optimised in Section 2.4. The DV 
for bioadhesive polymers were determined using methods described in Section 2.3.3.3 
for all three bases used.  
 
The actual amount of suppository base required for a specific batch of suppositories 
was calculated using Equation 3.1. The base required was accurately weighed into a 
ceramic evaporating dish using a lab analytical balance (Sartorius, Germany) and 
heated over a water bath (Julabo, Germany) to 34.0 °C for CB and 42.0 °C for both 
the HPKS (CE and SS). Accurately weighed DcNa and bioadhesive polymers were 
evenly mixed into the molten with gradual stirring before pouring into the 1.0 g steel 
suppository mould cavities. Suppositories were allowed to congeal at room 
temperature for 30 minutes before the overfilled excess was scraped-off using a heated 
spatula. The suppositories produced were stored at 3.5 ± 1.5 °C, RH 29 ± 3 %; and 
used within 2 weeks of manufacturing. Five suppository formulations were produced 
for the subsequent analyses; base-only suppositories (blank), suppositories containing 
only 50 mg DcNa (DcNa only) and suppositories containing 50 mg DcNa added with 
1, 2 or 5 %w/w bioadhesive polymers (CBP, PVP, HPMC, CMCTS). The resultant 
suppositories were 25 mm in length and 8 mm in diameter at the barrel end.  
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Equation 3.1            𝐵 = ( 𝑁 𝑥 𝐹) − [( 
𝐴1
𝐷1
) + (
𝐴2
𝐷2
)] 
 
Where,  
B = amount of base required 
N = number of suppositories to prepare 
F = fill weight of mould cavities obtained from mould calibration  
A1 = required amount of additive-1 
D1 = displacement values of additive-1 in the base used 
A2 = required amount of additive-2 
D2 = displacement values of additive-2 in the base used 
 
 Dosage form analysis 3.3.2
 Visual inspection 3.3.2.1
Physical appearances of the external surface of 10 randomly selected suppositories 
(n=10) from each formulation were examined for odour, shape integrity, colour 
uniformity, and manufacturing defects. 
 
 Weight variation 3.3.2.2
The mass of 10 randomly selected suppositories (n=10) from each formulation were 
individually weighed. Data obtained was presented as mean weight ± SD.  
 
The target weight (g) of individual suppositories for each formulation was calculated 
as a comparison to the actual weight of the suppositories produced, using the equation: 
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Equation 3.2        𝑇𝑎𝑟𝑔𝑒𝑡 𝑤𝑒𝑖𝑔ℎ𝑡  =
𝑊𝐵𝑁 + 𝑊𝐷𝑁 + 𝑊𝑃𝑁
𝑁
 
         
 
Where, 
WBN = weight of base used (CB, CE or SS) to produce one batch 
WDN = weight of active drug used (DcNa) to produce one batch 
WPN = weight of bioadhesive polymer (CBP, HPMC, PVP, CMCTS) for one batch 
N = number of suppositories to produce in one batch            
                                                  
 Melting point  3.3.2.3
The melting point of all the formulations was determined using DSC parameters 
described for determination of melting point of the bases in Section 2.3.1.1. The 
endothermic peak minimum on the DSC thermogram was identified as melting point 
of the formulation tested.  
 
 Determination of DcNa content 3.3.2.4
The suppositories were stirred in 200 mL phosphate buffer (pH 7.4) solution on a 
Variomag
®
 Telesystem magnetic stirrer plate (Thermoelectron Corp, WI, USA) 
immersed in a 37.0 °C water bath (Fisher Scientific, PA, USA) for 3 hours. The 
content of DcNa released from each suppository was quantified 
spectrophotometrically. Only formulations incorporated with 5 %w/w bioadhesive 
polymers (CBP, PVP, HPMC and CMCTS) were examined for content uniformity. 
Suppositories containing 50 mg DcNa without bioadhesive polymer was examined for 
comparison purposes.  
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 Viscosity 3.3.2.5
Viscosity measurements of the molten suppositories were carried out in the same 
manner as Section 2.3.1.5. The measurement obtained at shear rate of 50 rpm was 
used for comparison purposes between the base-only suppositories, suppositories 
containing only DcNa and suppositories containing DcNa and 1–5 %w/w bioadhesive 
polymers. The experiment was carried out in triplicates and the results were expressed 
as mean ± SD. 
 
 Hardness 3.3.2.6
Hardness of the formulated suppositories was measured using Dr. Schleuniger 8M 
Tablet Hardness Tester (Pharmatron, USA). The hardness tests were carried out at 
room temperature. Hardness measurements in units of Newton (N) were taken both at 
the cylindrical circumference (Figure 3.1a) as well as the pointed tip (Figure 3.1b) of 
the suppositories. Measurements were repeated with six independent samples (n=6) 
for each batches tested for both the forces required to break the barrel and tip of the 
suppository.  
 
 
Figure 3.1: Direction of force exerted at (a) cylindrical circumference (barrel) (b) 
pointed tip of suppository. 
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 Softening time 3.3.2.7
The softening time of suppositories were measured using a modified apparatus (Figure 
3.2) adapted from the Erweka Suppository Penetration Tester PM 30 (Erweka, 
Germany) and SPT-6 Penetration Tester (Pharmatest, USA).  
 
 
Figure 3.2 : The experimental setup of the softening point apparatus. 
 
The setup of the apparatus illustrated in Figure 3.2,  comprised of a rounded end pyrex 
test tube (inner diameter = 0.9 cm; length = 7.4 cm) (Iwaki, Japan) vertically 
immersed in a water bath maintained at 37.0 ± 0.5 °C using a test tube rack secured 
with a polystyrene holder. The polystyrene holder serves as an insulator to prevent 
heat loss as well as to secure the test tube at a 90° angle.  
 
A suppository was introduced into the test tube pointed end first and a timer was 
started simultaneously as a graduated brass probe (diameter = 0.9 cm, length = 8.9 cm, 
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weight = 51.8 g) was placed over the suppository. The rod slowly penetrated the 
suppository as it softens. The end point (softening time) was measured as the time 
elapsed for the probe to penetrate 1 cm depth of the suppository. Experiment was 
carried out in triplicates for each formulation at room temperature of 24.5 ± 2.5 °C, 
and RH of 58 ± 5 %. Results were expressed as mean time ± SD. 
 
 Statistical analysis 3.3.2.8
The results obtained from Sections 3.3.2.5, 3.3.2.6 and 3.3.2.7 were analysed using 
analysis of variance (ANOVA) (SPSS Inc., version 20, USA). Post hoc analysis using 
Tukey’s HSD test was carried out where appropriate when a statistically significant 
difference at p < 0.05 was obtained. 
 
 Results and discussion  3.4
 Physical inspection 3.4.1
The visual appearances of the suppositories were acceptable for all the formulations. 
Suppositories were intact; surface was smooth; colour was even and uniformed with 
the absence of visible defects such as those illustrated in Figure 3.3 on the external 
surface of suppositories. There was no abnormal odour from the suppositories. Only 
suppositories which have passed the visual inspection were included in subsequent 
analysis. 
 
 75 
 
Figure 3.3 : The common defects found on suppositories: (a) fissures or cracks; (b) 
pitting; (c) fat-blooming; (d) particle sedimentation; (e) chipping.  
 
 Weight variation 3.4.2
The target weight, actual weight, melting point and content uniformity of the test 
formulations were tabulated in Tables 3.1-3.3 for CB, CE and SS respectively.  
 
Suppositories produced weighed between 1.09 to 1.14 g (Tables 3.1-3.3). Mean actual 
weight of manufactured suppositories was in good agreement with the target weight, 
and deviations from respective target weights were ± 1 %. The SD value of the 
samples for each formulation was small (± 0.011 g), this was suggestive of good 
weight uniformity and that the additives were well dispersed within the suppositories. 
The British Pharmacopoeia (2015) stated that weight deviation in a batch of 
suppositories should be within the range of ± 5%. A large variation in weight could be 
due to either non-standardised mould cavity fill or non-homogeneity of molten 
mixture which would affect content uniformity of the suppositories (Mollel, 2006). 
 
All batches of suppositories produced throughout this study were assessed for 
compliance to the weight uniformity (± 5 %) before further analysis. This provides 
assurance that suppositories used in subsequent analyses were homogenous and of 
satisfactory quality. 
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 Melting point  3.4.3
Although thermal profiles of the investigated bases have been adequately 
characterised in Chapter 2, the melting point of suppositories produced may be altered 
by incorporation of additives (DcNa and bioadhesive polymers) or by the 
manufacturing process itself  (El-Majri and Sharma, 2010; Mollel, 2006; Shegokar 
and Singh, 2010; Takatori et al., 2004; Yahagi et al., 1999). This study found that 
manufactured blanks for all three bases melted between 32.5 to 34.5 °C (Tables 3.1-
3.3). Suppositories made using HPKS (CE and SS) melted at 1-2 ºC higher than the 
corresponding formulation produced using CB. The addition of DcNa did not appear 
to affect the melting point for suppositories made with all three bases (CB, CE and 
SS). 
 
The addition of 1-5 %w/w CMCTS to CB suppositories increased melting point of the 
suppositories by 1 ºC, while addition of CMCTS decreased the melting point of CE 
suppositories slightly. SS suppositories containing PVP had consistently higher 
melting points compared to SS suppositories containing other bioadhesive polymers.  
 
In general, the melting points of all suppositories containing 50 mg DcNa remained 
approximating body temperature; between 32.5 to 35.0 ºC. Yarnykh et al. (2011) 
reported that the melting point of commercial suppository bases found in the market 
ranged between 29.0 to 40.0 ºC. Suppositories produced using natural fatty bases, for 
example fat from borneo tallow seeds (Robertson, 1961) and palm oil blends (Pugunes 
and Ugandar, 2013) were found to have melting points ranging between 34.0 – 37.0 
ºC and 37.0-37.1 ºC respectively.  
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Table 3.1 : The target weight, actual weight, melting point and DcNa content of CB suppository formulations containing 50 mg DcNa and 
bioadhesive polymers. Mean ± SD. 
Polymers (%w/w) Target weight  
(g) 
Actual weight (g) 
(n=10) 
Melting point 
(°C) 
DcNa content (mg) 
(n=3) CBP HPMC PVP CMCTS 
CB  without DcNa - 1.090 ± 0.005 32.8 - 
- - - - 1.104 1.103 ± 0.005 32.7 48.51 ± 1.81 
1 - - - 1.108 1.105 ± 0.005 32.9 - 
2 - - - 1.112 1.109 ± 0.006 32.7 - 
5 - - - 1.125 1.118 ± 0.006 32.5 48.52 ± 1.07 
- 1 - - 1.108 1.112 ± 0.004 33.1 - 
- 2 - - 1.111 1.111 ± 0.004 33.0 - 
- 5 - - 1.121 1.123 ± 0.004 33.0 49.52 ± 1.08 
- - 1 - 1.104 1.100 ± 0.006 32.8 - 
- - 2 - 1.104 1.101 ± 0.005 32.6 - 
- - 5 - 1.104 1.104 ± 0.004 32.8 49.25 ± 1.01 
- - - 1 1.108 1.113 ± 0.006 33.7 - 
- - - 2 1.112 1.117 ± 0.005 33.7 - 
- - - 5 1.124 1.129 ± 0.006 33.8 49.28 ± 0.97 
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Table 3.2 : The target weight, actual weight, melting point and DcNa content of CE suppository formulations containing 50 mg DcNa and 
bioadhesive polymers. Mean ± SD. 
Polymers (%w/w) Target weight 
(g) 
Actual weight (g) 
(n=10) 
Melting Point 
(°C) 
DcNa content (mg) 
(n=3) CBP HPMC PVP CMCTS 
CE without DcNa - 1.101 ± 0.006 34.0 - 
- - - - 1.114 1.125 ± 0.006 34.4 47.97 ± 0.49 
1 - - - 1.120 1.128 ± 0.009 34.3 - 
2 - - - 1.122 1.126 ± 0.011 34.6 - 
5 - - - 1.133 1.143 ± 0.006 34.2 48.17 ± 0.32 
- 1 - - 1.118 1.118 ± 0.005 34.7 - 
- 2 - - 1.121 1.121 ± 0.005 34.9 - 
- 5 - - 1.132 1.137 ± 0.009 34.7 49.07 ± 0.50 
- - 1 - 1.114 1.119 ± 0.009 34.8 - 
- - 2 - 1.114 1.120 ± 0.009 34.3 - 
- - 5 - 1.114 1.123 ± 0.011 34.4 49.39 ± 1.14 
- - - 1 1.119 1.120 ± 0.006 33.6 - 
- - - 2 1.121 1.128 ± 0.007 33.8 - 
- - - 5 1.137 1.143 ± 0.005 33.9 49.03 ±0.24 
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Table 3.3 : The target weight, actual weight, melting point and DcNa content of SS suppository formulations containing 50 mg DcNa and 
bioadhesive polymers. Mean ± SD. 
Polymers (%w/w) Target weight  
(g) 
Actual weight (g) 
(n=10) 
Melting point 
(°C) 
DcNa content (mg) 
(n=3) CBP HPMC PVP CMCTS 
SS without DcNa - 1.098 ± 0.004 34.0 - 
- - - - 1.116 1.124 ± 0.006 34.3 48.55 ± 1.81 
1 - - - 1.120 1.126 ± 0.005 34.8 - 
2 - - - 1.124 1.131 ± 0.004 34.8 - 
5 - - - 1.136 1.142 ± 0.007 34.6 47.53 ± 0.47 
- 1 - - 1.120 1.125 ± 0.008 34.4 - 
- 2 - - 1.123 1.129 ± 0.005 34.7 - 
- 5 - - 1.134 1.136 ± 0.010 34.8 48.33 ± 1.27 
- - 1 - 1.116 1.113 ± 0.007 34.9 - 
- - 2 - 1.116 1.120 ± 0.004 34.9 - 
- - 5 - 1.116 1.124 ± 0.004 35.1 48.84 ± 0.48 
- - - 1 1.120 1.130 ± 0.005 34.7 - 
- - - 2 1.124 1.129 ± 0.011 34.6 - 
- - - 5 1.137 1.141 ± 0.005 34.5 48.68 ±0.85 
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 Determination of DcNa content 3.4.4
This is especially important when suppositories are manufactured manually, as the 
manual process is highly variable. Quantification of DcNa content in selected samples 
obtained from a large batch allows verification of the labelled content as well as the 
uniformity of DcNa content between individual suppositories produced in a particular 
batch (Allen et al., 2008). Noordin and Chung (2004) investigated both the content 
uniformity between suppositories as well as within a suppository by comparing 
between different sections of a single dosage form to address uniformity of a 
suppository in the event of dose splitting. The active drug content of suppositories 
have to be within the range of 90-110% of the stated amount (British Pharmacopoeia, 
2015). Content uniformity is achieved when not more than one suppository has drug 
content out of the 85-115 % range, and none outside the limit of 75-125% of the 
average content (British Pharmacopoeia, 2015).   
 
The results of content uniformity studies for CB, CE and SS suppositories were 
summarized in Tables 3.1-3.3 respectively. All the formulations contained more than 
95 % of the stipulated DcNa content and the SD values were ± 2 % of the average 
DcNa content. This confirmed the accuracy of DV determined in Section 2.3.3.3 
which allowed proper adjustments of the amount of base required to account for 
different densities of additives added.  
 
 Viscosity  3.4.5
The bioadhesive polymers used in this study such as CBP and HPMC are known to 
have thickening properties, thus are likely to alter the viscosities of the bases 
determined in Section 2.3.1.5. Viscosity was generally found to be highest in CB 
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suppositories followed by CE and SS (Figures 3.4a-c). This could be due to the longer 
carbon chain of the palmitic (C16) and stearic acid (C18) in CB, compared to lauric acid 
(C12) in CE and SS (Lonchampt and Hartel, 2004; Peyronel and Marangoni, 2014). 
 
(a) 
 
(b) 
 
(c) 
 
Figure 3.4 : The viscosity (cp) of suppositories made using (a) CB; (b) CE; and (c) SS; 
each suppository contained 50 mg DcNa and 1-5 %w/w of bioadhesive polymers 
(CBP, HPMC, PVP and CMCTS). Asterisks indicate formulations which are 
significantly different from blank suppositories. 
0
20
40
60
80
100
120
140
CBP HPMC PVP CMCTS
V
is
co
si
ty
 (
cp
) 
Blank
DcNa only
1 %
2 %
5 %
  * 
* 
   * 
 * 
   * 
  * 
* 
* 
*  * 
 * 
 *   * *   * * 
0
20
40
60
80
100
120
140
CBP HPMC PVP CMCTS
V
is
co
si
ty
 (
cp
) 
Blank
DcNa only
1 %
2 %
5 %
  * 
   * 
 * 
  * 
    *  *  * *  * 
  *  
 *  * 
0
20
40
60
80
100
120
140
CBP HPMC PVP CMCTS
V
is
co
si
ty
 (
cp
) 
Blank
DcNa only
1 %
2 %
5 %
 * 
   * 
  * 
  * 
  * 
     *  *  * *  * *  *  * 
82 
 
The addition of DcNa significantly increased viscosity of CB suppositories but 
conversely, reduced the viscosity of CE and SS suppositories. Suppositories 
containing DcNa and bioadhesive polymer was generally more viscous than their 
corresponding DcNa only suppositories. CB suppositories incorporated with HPMC 
(Figures 3.4a) were most viscous while CE and SS suppositories incorporated with 
CBP (Figures 3.4b-c) were most viscous compared to suppositories with other 
bioadhesive polymers. The same polymer affected the viscosity of the suppositories 
differently. While PVP and CMCTS did not alter the viscosity of CE and SS 
suppositories drastically, it resulted in a significant concentration dependent increase 
in viscosity of suppositories when formulated with CB (Figures 3.4a-c). Generally, an 
increase in viscosity was observed when concentration of polymer is increased from 1 
to 5 %w/w. Statistical comparison of the formulations using Tukey’s HSD analysis is 
tabulated in Appendices 8-10.  
 
More viscous suppositories may be beneficial to confine drug absorption within the 
lower rectum by limiting spread of the molten. However, excessively viscous 
suppositories may also impede DcNa release from the base and thus, drug release 
studies are required to determine if this increase in viscosity is unfavourable for drug 
release (Azechi et al., 2000). 
 
 Hardness 3.4.6
Hardness measurements obtained from the tip of suppositories were omitted from 
subsequent analysis as the results were less distinguishable between subsets (in 
Tukey’s HSD analysis) compared to values obtained at the suppository barrel (Figures 
3.5a-c). The values obtained depended on the crushed surface area at which the force 
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exerts on and this is made difficult by the cone-shaped pointed tip as the surface area 
varies along the length of the tip. 
 
(a) 
 
(b) 
 
(c) 
 
Figure 3.5: The hardness of suppositories produced using (a) CB; (b) CE and (c) SS; 
each suppository contained 50 mg DcNa and 1-5 %w/w of bioadhesive polymers 
(CBP, HPMC, PVP and CMCTS). Mean ± SD, n=6. Asterisks indicate formulations 
which are significantly different from blank suppositories. 
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Figures 3.5a-c showed that blank CE suppositories (82.33 ± 5.20 N) were significantly 
harder than the CB and SS suppositories (59.00 ± 2.97 N and 55.83 ± 1.60 N 
respectively). Addition of DcNa increased the hardness of all three (CB, CE, SS) 
suppositories. Statistical comparison of the formulations using Tukey’s HSD analysis 
is tabulated in Appendices 11-13.  
 
Suppositories incorporated with 1-5 %w/w of CMCTS for all three bases (CB, CE and 
SS) were hardest compared to those containing other polymers (Figures 3.5a-c). 
Addition of CBP showed an irregular hardness trend in all three bases. The presence 
of CBP significantly increased the hardness of CB suppositories; however the 
hardness of CE suppositories were not affected by addition of 1-2 %w/w CBP while 
SS suppositories were harder with 1-2 %w/w of CBP but not in the presence of 
5 %w/w CBP (Figure 3.5c). On the other hand, formulations containing PVP were 
generally harder than those containing CBP and HPMC. HPMC suppositories were 
the least hard (Figures 3.5a-c). There was however, no observable trend between 
increment in polymer content and hardness of suppositories produced.  
 
Sirisa-ard et al. (2014) found that suppositories produced using Krabok wax resulted 
in hardness of 6 N were too soft and easily broken, while Allen et al. (2008) suggested 
that suppositories should have hardness of 17-20 N. Meanwhile, studies by El-Majri 
and Sharma (2010); Oribe et al. (1995); Shegokar and Singh (2010) have reported a 
wide range of suppository hardness ranging from 10 to 60 N. These large differences 
of reported values were a result of differences in experimental methods as well as 
variability in the type of base and additives used. Although the addition of bioadhesive 
polymers have variable effects on the hardness of the bases, all the formulations in 
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this study had hardness values between 60 to 130 N, suggestive of good resistance 
towards the hazards of manufacturing and packing (Sirisa-ard et al., 2014). 
 
 Softening time 3.4.7
Figure 3.6 showed that all the formulations tested had a softening time between 3-7 
minutes. Softening time of blank suppositories was found to be shortest in CB, 
followed by SS and CE; the post hoc Tukey’s HSD test indicated that these outcomes 
were significantly different (Appendices 14-16). However, for suppositories 
containing 50 mg DcNa, the softening point of CB suppositories were increased while 
a decrease in softening time was observed for CE and SS suppositories.  
 
In all the formulations containing polymers, softening time for CB suppositories were 
always faster than the corresponding formulations for CE and SS; both of which were 
comparable (CB < SS = CE). Generally, there was an increase in softening time with 
increasing polymer concentration. CE and SS suppositories incorporated with 5 %w/w 
HPMC showed the longest softening time among all the formulations tested.  
 
The longer softening time in suppositories made using CE and SS (4-7 minutes) is an 
indication that the HPKS suppositories were slightly better at withstanding short 
exposures to heat compared to CB (3-5 minutes) suppositories. The British 
Pharmacopoeia ( 2015) has recommended that the softening time of lipophilic 
suppositories should be less than 30 minutes while studies by Janicki et al. (2001) and 
Moghimipour et al. (2009) produced suppositories with softening time which ranged 
between 4-13 minutes and 11-16 minutes respectively. Despite being harder than 
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formulations produced in similar studies (Section 4.3.6), all the formulations produced 
in this study had softening times below 7 minutes. 
 
(a) 
 
(b) 
 
(c) 
 
Figure 3.6 : The softening time of suppository formulations produced using (a) CB; 
(b) CE and (c) SS. Each suppository contained 50mg DcNa and 1-5 %w/w of 
bioadhesive polymers (CBP, HPMC, PVP and CMCTS). Mean ± SD, n=3. Asterisks 
indicate formulations which are significantly different from blank suppositories. 
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 Conclusion  3.5
Suppositories containing bioadhesive polymers (CBP, PVP, HPMC, CMCTS) were 
successfully manufactured using CB and both the HPKS (CE and SS) as suppository 
bases through the optimised manufacturing methods from Section 2.3.3. 
 
Dosage form analysis is essential for the evaluation of product quality. Suppositories 
manufactured in this study have good weight uniformity and there was minimal 
variation (± 1 %) between actual weight and the respective target weight. The melting 
point of suppositories manufactured using CE and SS were 1-2 ºC higher than CB 
suppositories but all formulations had melting points within the range of 32.5 °C to 
35.5 °C. The addition of bioadhesive polymers did not significantly alter melting point 
(less than ± 1 °C) of suppositories, maintaining a melting point close to body 
temperature which is suitable for rectal administration. All the formulations tested 
contained > 95 % of the stipulated DcNa content.  
 
In general, there was no consistent trend between hardness and increasing 
concentrations of bioadhesive polymers in the suppositories (CB, CE and SS) based 
on the post hoc Tukey’s HSD analysis (p < 0.05). Conversely, viscosity of the molten 
suppositories increased with increasing amount of bioadhesive polymers (CBP, PVP, 
HPMC, CMCTS) incorporated into the formulations. Softening times on the other 
hand, were longer in suppositories produced using the HPKS (CE and SS) than CB. 
However, the softening times for all formulations were between 3–7 minutes which 
was acceptable for rectal drug administration.  
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Physical properties of the suppositories examined in this chapter were found to be 
suitable for rectal administration. The longer softening time in HPKS suppositories 
coupled with a melting point of 34.5 ± 1 °C is an added advantage compared to CB 
suppositories. This offers more resistance to melting or damage during handling prior 
to insertion into the rectum. Although the physical properties are well characterised in 
this chapter, further studies are required to examine the impact of various additives on 
the drug release (Chapter 4) and bioadhesive properties (Chapter 5).  
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CHAPTER 4           
IN VITRO DRUG RELEASE AND 
RELEASE KINETICS 
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4.1 Introduction 
 Drug release studies 4.1.1
After suppository administration into the rectum, the base has to first melt to allow 
diffusion of drug from the base into rectal environment before absorption through 
rectal mucosa into systemic circulation (Allen et al., 2008). Previous studies have 
found that data obtained from in vitro drug release studies for suppositories were well 
correlated to plasma concentration profiles (Aiache et al., 1987; Babar et al., 1999; 
Chicco et al., 1999; Gjellan et al., 1994; Vidras et al., 1982). Therefore, these studies 
are useful for prediction of dosage form performance.  
 
Various methods exist for studying in vitro drug release from suppositories. Among 
those commonly used are the USP paddle apparatus (Ahmad, 2001; Moghimipour et 
al., 2009; Young et al., 1987), basket apparatus (Babar et al., 1999; Ermiş and Tarimci, 
1995; Gjellan et al., 1994; Swamy et al., 2012), dialysis rotating cell method (Aoyagi 
et al., 1988; Lootvoet et al., 1992; Oribe et al., 1995), Muranishi method (Ermiş and 
Tarimci, 1995; Umeda et al., 1985), and flow through cell method (Aiache et al., 
1987; Mollel, 2006; Tukker et al., 1981; Yahagi et al., 1999).  
 
Apart from type of apparatus; the type, pH and volume of dissolution medium used; 
temperature of the in vitro run as well as method of quantification of active drug has 
to be carefully selected based on the type of dosage form studied.  
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 Statistical comparison and mathematical modelling  4.1.2
The three main methods used to analyse data obtained from drug release studies are: 
(1) exploratory data analysis; (2) model–independent and; (3) model-dependent 
methods.  
 
 Exploratory data analysis 4.1.2.1
As the term suggests, exploratory data analysis is used during initial interpretation of 
raw data to provide basic understanding of how drug is released from a formulation. 
This method compares drug release both graphically and numerically.  
 
In graphical comparison, cumulative drug release against time plots were visually 
inspected for overlapping of error bars (extending two standard errors (SE) either side 
of the mean) between the drug release profiles at each time point. Non overlapping of 
error bars indicates that drug release profiles at that particular time point are 
significantly different from each other (O’Hara et al., 1998; Yuksel et al., 2000).  
 
Exploratory data analysis can also be conducted numerically by summarising data in 
the form of 95 % confidence interval for the difference in the mean drug release 
profiles at each time point. Difference at a particular time point is considered 
significant when the p> 0.05 (O’Hara et al., 1998). 
 
 Model-independent methods 4.1.2.2
This method involved computing of raw data into mathematical formulae to obtain 
single-value measurements of differences between two multiple point drug release 
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profiles. This is further differentiated into amodelistic dissolution parameters (ratio 
test) and pair-wise procedures (Costa and Sousa Lobo, 2001; O’Hara et al., 1998). 
 
Amodelistic parameters compare profiles using dissolution efficiency (DE) and mean 
dissolution time (MDT) (Costa and Sousa Lobo, 2001; Mollel, 2006; Vaghela et al., 
2011), both determined using the following equations:  
 
Equation 4.1 𝐷𝐸 =  
∫   𝑦  𝑑𝑡
𝑡2
𝑡1
𝑦100  ∗  (𝑡2− 𝑡1)
  𝑥 100% 
Where,   
y = percentage of drug released at time t2 
y100 = maximum amount of drug available for release 
 
Equation 4.2 𝑀𝐷𝑇 = ∑ ?̂?𝑖
𝑛
𝑖=1
𝑀𝑡
𝑀∞
 
Where,   
n = number of dissolution samples 
i = sample number 
?̂?𝑖 = time at midpoint between ti and ti-1 
Mt = fraction of dose released at time ti 
𝑀∞ = dose of formulation 
 
Pair-wise procedures compare profiles in terms of ‘fit factors’ and Rescigno’s indices 
(ξ). The ‘fit factors’ or ‘similarity indices’ known as ‘difference factor’ (ƒ1) and the 
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‘similarity factor’ (ƒ2), both described by Moore and Flanner using Equation 4.3 and 
Equation 4.4 (Anderson et al., 1998; Costa, 2001; Moore and Flanner, 1996). 
 
Equation 4.3 𝑓1 =  {
∑ 𝑤𝑡
𝑛
𝑡=1 |𝑅𝑡 −  𝑇𝑡|
∑ 𝑤𝑡𝑅𝑡
𝑛
𝑡=1
}  𝑥 100 
  
Equation 4.4 𝑓
2 = 50 𝑙𝑜𝑔10 {[1 +  
1
𝑛
  ∑ 𝑤𝑡 (𝑅𝑡 − 𝑇𝑡)
2]
−0.5 
𝑥 100} 
Where,  
Rt = percentage of drug release for reference sample 
Tt = percentage of drug release for test sample 
n = number of sampling points taken into account 
wt = optional weight factor which is usually kept at 1 
  
The ƒ1 represents the average percentage difference between test formulation (Tt) and 
reference formulation (Rt) across all time points analysed while the ƒ2 is a log function 
of differences between the compared profiles and can assume any value between 0 
and 100. The Food and Drug Administration (FDA) has set a standard where ƒ1 
between 0 to 15 and ƒ2 between 50 to 100 indicate similarity between two drug release 
profiles (Anderson et al., 1998; Costa and Sousa Lobo, 2001; Ministry of Health 
Malaysia, 2000).  
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 Model–dependent methods 4.1.2.3
In the model-dependent approach, data obtained from drug release studies are fitted 
into selected mathematical equations describing release kinetics. Various parameters 
are generated to determine goodness of fit of data to the selected kinetic equation. 
These parameters include release constant, linear coefficient of determination (r
2
) and 
lag time which describes the rate of release as well as the proximity of data to the 
release model tested. It was suggested that this approach requires a minimum of four 
data points excluding time point ‘zero’ up till 80 % of drug release or when asymptote 
is achieved (O’Hara et al., 1998; Yuksel et al., 2000). 
 
 First order kinetics 4.1.2.3.1
First order release kinetics describes drug release in a concentration-dependent 
manner, this was first described by Gibaldi and Feldman (1967) based on the Noyes-
Whitney equation where drug release occurs at a constant proportion to the amount 
remaining within the dosage form (Costa and Sousa Lobo, 2001). This kinetic model 
has been used to describe release of water soluble drugs from porous matrices, and 
also lipophilic suppositories (Tarimci and Ermis, 1997). First order release is 
explained by the following equation (Basak et al., 2008; Dash et al., 2010); 
 
Equation 4.5 𝑙𝑜𝑔10 𝐶𝑡 = 𝑙𝑜𝑔10 𝐶0 −
𝐾1. 𝑡
2.303
 
Where,   
Ct = amount of drug remaining to be released at time t 
C0 = initial amount of drug in the dosage form (usually 100 %) 
K1 = first order rate constant 
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 Higuchi release 4.1.2.3.2
The Higuchi model was initially developed to quantify mass transport of 
homogenously dispersed drug particles in a planar matrix into perfect sink conditions 
based on Fick’s Law (Dokoumetzidis and Macheras, 2006; Kalam et al., 2007; 
Siepmann and Peppas, 2011). This model can be described by the simplified equation 
(Costa and Sousa Lobo, 2001); 
 
Equation 4.6 𝑄𝑡 =  𝐾𝐻  . 𝑡
1/2
 
Where,   
Qt = amount of cumulative drug released at time t 
KH = Higuchi release constant 
 
This equation assumes that drug release occurs in a thin, planar geometry, where drug 
movement through the matrix (base) is a rate limiting step, provided that (1) amount 
of drug in the dosage forms greatly exceeds drug solubility to achieve pseudo-steady-
state and, (2) the base does not swell or dissolve during drug release so that distance 
of the base-medium interface remains unaltered (Siepmann and Peppas, 2011). The 
Higuchi equation is only valid for analysis of the first 60 % of drug release. 
 
Previous studies on drug release from lipophilic suppositories have suggested that the 
release were in agreement with Higuchi equation (Nakajima et al., 1990; Takatori et 
al., 2004). This equation could be useful to describe drug release from suppositories as 
the suppositories melt and form a thin layer of molten base matrix containing 
suspended drug particles, similar to that observed in the ointment-skin interface from 
which the Higuchi equation stems from. 
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 Korsmeyer – Peppas model  4.1.2.3.3
This mathematical model was initially developed by (Korsmeyer et al., 1983) to 
explain diffusion-controlled drug release mechanisms from polymeric systems, and 
subsequent studies lead to characterisation of the type of diffusional release based on 
the release exponent ‘n’, taking into account variable geometries and swelling 
capacities of dosage forms. A number of lipophilic suppositories demonstrated release 
patterns with good fit to the Korsmeyers-Peppas model (Güneri et al., 2004; Mollel, 
2006; Uzunkaya and Bergişadi, 2003). The release kinetics can be described as,   
 
Equation 4.7 log
𝑀𝑡
𝑀∞
= n. log 𝑡 +  log 𝑘𝑚      
Where,   
Mt/ M∞ = fraction of drug released at time t 
Km = release constant 
n = release exponent 
 
In suppositories (non-swellable cylindrical dosage forms); the ‘n’ value limits of n = 
0.45 for Fickian diffusion; 0.45 < n < 1.0 non- Fickian or anomalous diffusion; n ≥ 1 
for case-2 transport (zero order release) were adopted.  
 
 Weibull model  4.1.2.3.4
The Weibull model has been used empirically to describe drug release from Euclidian 
and fractal matrices; despite criticism of the lack of kinetic basis and non-dissolution 
specific nature of its parameters (Costa et al., 2003). Use of Weibull function in drug 
release stemmed from the concept where a concentration gradient is present at the 
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releasing boundaries of dosage forms, which are either described as a Euclidian matrix 
or fractal geometry (Kosmidis et al., 2003). The Weibull model is described by the 
following equation;  
 
Equation 4.8 
 
𝑚 = 1 − exp(
−(𝑡 − 𝑇𝑙𝑎𝑔)
𝛽
𝛼
 
Where,  
m = amount of drug released 
α = scale parameter (rate constant) 
β = shape parameter 
Tlag = lag time 
 
Description of drug release using the Weibull model is through the scale parameter (α) 
and shape parameter (β) which represents the apparent rate of release and shape of the 
curve respectively. When β=1, the curve corresponds exactly to a homogeneous model 
similar to that of first order kinetics; while β>1 indicates a sigmoidal curve with an 
inflexion point; and β<1 indicates a steeper initial slope than exponential curves 
(Cupera, 2009; Dash et al., 2010). 
 
 Bi-exponential first-order kinetic model 4.1.2.3.5
This model had been used to describe drug release from fenbufen suppositories made 
using lipophilic, hydrophilic and ampiphilic bases as well as in sustained release 
indomethacin tablets and capsules (Laakso et al., 1984; Young et al., 1987). The 
equation defining bi-exponential first-order kinetics is as the following; 
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Equation 4.9 𝑤 = 𝐴𝑒−𝑘1𝑡 + 𝐵𝑒−𝑘2𝑡 
Where,   
w = drug remaining to be released at time t 
k1 = release rate constant for initial phase   
k2 = release rate constant for terminal phase 
A = amount of drug released in initial phase 
B = amount of drug released in terminal phase 
 
The plot of remaining drug against time would generate a biphasic curve. Parameters 
generated from linear regression would yield release constants, k1 and k2 which 
reflects rate of release at each phase and their respective coefficient of determination 
(r
2
) which indicates closeness of fit to the equation while the y-axis intercept 
corresponds to lag time. A good fit to the equation is represented by r
2
 approximating 
to 1 and small, reasonable lag times (Laakso et al., 1984). 
 
 Selection of the best fit model 4.1.3
To determine the best fit model, previous studies employed coefficient of 
determination (r
2
) or adjusted coefficient of determination (r
2
 adjusted) (Ladani et al., 
2011), sum of squares residues (SSR) (Thakkar et al., 2009), mean square error (MSE), 
Akaike Information Criterion (AIC) (Ozkan et al., 2000) and more recently the ratio 
of SSR/r
2
 (Costa and Sousa Lobo, 2001; Singh et al., 2011). The r
2
 measures 
proportion of variation between observed data and the mean generated through linear 
regression model. The greater approximation of r
2
 to 1, the closer the fit of data to a 
particular model (Ladani et al., 2011). The AIC, on the other hand, shows the quality 
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of fit by comparing models using the same weighting scheme. The model which 
produces the smallest AIC value is regarded to provide the best fit out of a set of 
models tested (Costa, 2001). 
 
Within the context of this research project, in vitro drug release studies of DcNa from 
the HPKS bases (CE and SS) were essential as the suppository bases used were non-
conventional. There were no reported data on drug release characteristics from these 
bases and how they fared compared to CB. Furthermore, the inclusion of a 
bioadhesive component in the form of polymers could alter drug release profiles. Thus, 
this chapter aims to quantify DcNa release from the formulation prototypes developed 
in Chapter 3 using suitable dissolution study methods, followed by comparison of 
DcNa release kinetics from the formulations using exploratory data analysis methods, 
model independent methods and mathematical models. This chapter will also assess 
the effects of bioadhesive polymers (CBP, HPMC, PVP and CMCTS) on drug release 
kinetics. 
 
 Materials and methods 4.2
 Dissolution setup and evaluation of formulations 4.2.1
 Experimental setup 4.2.1.1
The in vitro release of DcNa from suppositories was studied using the 8-vessel Distek 
dissolution system 2100c (Distek Inc., New Jersey, USA) fitted with thermocirculator 
TCS 0200 (Distek Inc., New Jersey, USA). The system is connected to Distek 
Evolution 4300 syringe pump dissolution sampler (Distek Inc., New Jersey, USA).  
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Suppositories were enclosed in helix-shaped sinkers made using steel wires with 
dimensions (length 2.8 cm x diameter 1.0 cm; interloop distance of 0.5 cm) to ensure 
retention of suppositories at the bottom of the vessel. Dissolution of a blank 
suppository made with only the base (CB, CE and SS) was used as experimental blank. 
The parameters employed during dissolution studies were summarized in Table 4.1. 
Samples were then analysed using a single cell UV-Visible spectrophotometer (Libra, 
S12) at a wavelength of 276 nm as determined in Chapter 2. 
 
Table 4.1 : Summary of parameters used for in vitro drug release studies. 
Experimental Parameters Settings 
Dissolution tester USP Apparatus II – Paddle 
Dissolution media Distilled water  
Volume of media  900 mL 
Temperature 37.0 ± 0.5 °C 
Paddle rotation speed 50.0 ± 0.2 rpm 
Filter pore size 0.45 μm 
Replicates 6 suppositories per experiment 
Sampling time (min) 2, 6, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360  
Sampling volume (mL) 5 mL, reconstituted 
 
 Evaluation of formulations 4.2.1.2
 The effects of drug loading on DcNa release 4.2.1.2.1
The effects of drug loading on DcNa release was evaluated using suppositories made 
from all three bases (CB, CE, SS) containing 25, 50 and 75 mg DcNa using 
procedures mentioned in Section 4.2.1.1. Data obtained was analysed using 
exploratory data analysis method.  
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 The effects of bioadhesive polymers on DcNa release 4.2.1.2.2
DcNa release from the formulations containing bioadhesive polymers (CBP, HPMC, 
PVP, CMCTS) at concentrations of 1-5 %w/w were studied using methods described 
in Section 4.2.1.1. A suppository containing the corresponding amount of bioadhesive 
polymers without DcNa was used as experimental blank. Comparisons were carried 
out via model-independent methods and model dependent methods. 
 
 Statistical and mathematical analysis of data 4.2.2
 Exploratory data analysis 4.2.2.1
Graphical comparison was employed to analyse DcNa release from suppositories (CB, 
CE and SS) incorporated with 25, 50 and 75 mg of DcNa. Percentage cumulative drug 
release was plotted against time with error bars indicative of two SE at both sides of 
the error bar (95 % confidence interval) at each time point (Mollel, 2006; O’Hara et 
al., 1998). The graph is then visually inspected for overlapping of error bars. 
 
 Model-independent method 4.2.2.2
The fit-factors (ƒ1 and ƒ2) were used to identify dissimilar drug release profiles by 
comparing the Tt formulations containing bioadhesive polymers (CBP, HPMC, PVP, 
CMCTS) and their corresponding Rt (suppositories containing only base and DcNa). 
Meanwhile, other model-independent parameters such as DE and MDT were used to 
describe the rate and extent of DcNa release from both Rt and Tt suppositories. 
 
 Model dependent method 4.2.2.3
Drug release data from all formulations were fitted into first order, Higuchi’s release, 
Korsmeyer–Peppas model, Weibull’s equation and biphasic first-order release 
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equations using KinetDS
®
 software version 3.0 (Aleksander Mendyk, Kraków, 
Poland.). Goodness of fit for the various models were investigated and compared in 
terms of r
2
 and AIC values.  
 
 Results and discussion  4.3
 Method development 4.3.1
While the United States Pharmacopeia and National Formulary, (2008) and European 
Pharmacopoeia, (2010) specified the use of paddle dissolution apparatus and flow 
through cell apparatus respectively to study drug release from suppositories; various 
alternatives have been attempted (Gjellan and Graffner, 1994; Nair and Bhargava, 
1999; Palmieri, 1981; Webster et al., 1998). Palmieri (1981) however, reported erratic 
and irreproducible results using the basket apparatus due to clogging of basket mesh 
by melted base; while Gjellan and Graffner (1994) found that the flow through cell 
resulted in more rapid drug release with a larger variance in data compared to basket 
and paddle apparatus.  
 
The rectal environment is simulated by the receptor medium during in vitro drug 
release studies. Although it should mimic physiological environment closely, it is 
impractical to carry out drug release studies under stringent rectal physiological 
parameters especially when only 2-3 mL of mucus is present in the rectum. The use of 
2-3 mL receptor media will not be able to provide ‘sink’ conditions for drug release 
which should be at least 3 times the solubility of the drug tested (Brown et al., 2011; 
Lee et al., 2008; Vaghela et al., 2011).  
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Meanwhile the rectal pH also affects ionisation of drug and its partitioning out of the 
base which could alter drug release. pH of the rectum varies with age and has been 
reported to be within the range of 6.29–6.45 in neonates; 6.68–7.12 in infants older 
than 28 days while rectal pH in children aged between 1 to 14 years ranged between 
7.2-12.1 (Jantzen et al., 1989; Turner et al., 2012). Adult rectal pH on the other hand 
is approximately 7.2, but varies according to colonic content (Desai, 2007). Since the 
rectum is void of buffering capacity; use of a buffered medium would not reflect 
actual drug release conditions within the rectum, especially when aqueous solubility 
of DcNa is pH dependant (Chuasuwan et al., 2009). 
 
After careful considerations of the factors mentioned above, this research employed 
the USP II paddle dissolution apparatus with the use of sinkers due to considerations 
that lipophilic bases and bioadhesive polymers used are likely to clog the basket 
apparatus mesh. Distilled water maintained at 37.0 ± 0.5 °C was selected as the 
receptor medium for drug release studies to reflect lack of buffering capacity and 
temperature within the rectum (Allen et al., 2008; Bottger et al., 1989; Grayson, 1951).  
 
 Exploratory data analysis 4.3.2
 The effects of drug loading on DcNa release 4.3.2.1
Drug release profiles of suppositories incorporated with 25, 50 and 75 mg of DcNa 
were superimposable upon visual inspection for all the three bases (CB, CE and SS) 
investigated (Figures 4.1a-c). However, the exploratory analysis method produced 
inconclusive results as there was overlapping of error bars at certain time points (no 
significant difference) while others were significantly different.  
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 (a)  
 
 
(b) 
 
(c) 
 
Figure 4.1 : Cumulative percentage release of DcNa in (a) CB; (b) CE; (c) SS 
suppositories containing 25, 50 and 75 mg of DcNa. Mean ± 2 SE, n=6. 
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Further ANOVA analysis followed by post hoc Tukey’s test showed that extent of 
DcNa release from bases was not affected by initial amount of DcNa incorporated. 
Figure 4.1a showed that although CB suppositories with 25 mg DcNa had 
significantly lower initial rate of release from 10 to 60 minutes compared to those with 
50 and 75 mg DcNa (p< 0.05), the extent of DcNa release was indifferent at 180 
minutes (p = 0.155).  
 
CE and SS suppositories containing 25 mg DcNa on the other hand, had significantly 
lower release between 6 to 15 minutes (p< 0.05) and  15 to 60 minutes (p< 0.05) 
respectively compared to the corresponding formulations containing 50 and 75 mg of 
DcNa (Figures 4.1b-c). The extent of DcNa released at 180 minutes was not 
significantly different between the three CE formulations (p= 0.977) and the three SS 
formulations (p= 0.06). This indicated that while drug load did not affect the extent of 
DcNa release; the initial rate of release was increased when drug loading is doubled 
from 25 mg to 50 mg, but this effect was not significant when drug loading was 
further increased to 75 mg.  
 
This was further supported by the plot of actual DcNa released (Appendix 17) as each 
time point interval showed that there was rapid release of DcNa during the first 45 
minutes for all the suppositories. The actual amount released at each time interval 
increased with increasing amount of DcNa incorporated (p< 0.05). This suggested that 
initial release of DcNa did not occur at a fixed rate (zero order). The anomalous 
increase in actual amount of DcNa released at time point interval of 30 minutes could 
be a result of change in surface area for DcNa release due to melting and molten 
accumulation at the dissolution media-air interface in the dissolution vessel. Further 
106 
 
investigation on kinetics of DcNa release was conducted using mathematical models 
(Section 4.3.4).  
 
Comparing DcNa release from suppositories containing 50 mg DcNa (Figure 4.2), 
release profiles between CB and SS were not significantly different up to 240 minutes 
while the profiles for CE were significantly different from CB and SS up to 120 
minutes (p< 0.05). The release plateaued after 120 minutes in both CB and SS while it 
was only achieved after 180 minutes in CE suppositories.  
 
 
Figure 4.2 : DcNa release profiles from suppositories made with different bases, each 
containing 50 mg of DcNa. Mean ± 2 SE, n=6. 
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first 60 minutes of dissolution. CB, CE and SS suppositories were found to provide 
fast release of DcNa upon dissolution. 
 
The ANOVA analysis with post hoc Tukey’s test used in this section was used to 
provide descriptions for the observations via exploratory method of data interpretation. 
However, this method was found to be tedious and generated large quantities of data 
based on point-to-point comparisons between two profiles. The method did not 
consider drug release process as a whole but provided only comparison at a specific 
time point which limits its practicality when more than two time points or release 
profiles are being compared.   
 
 Model- independent method 4.3.3
Due to difficulties in simultaneous interpretation of multiple drug release profiles 
using methods in Section 4.3.2, fit factors (f1 and f2) were used to compare 
dissimilarities between dissolution profiles in the course of this study. Subsequently, 
DE and MDT were calculated for evaluation of the extent and rate of DcNa release of 
each formulation. The corresponding drug release profiles were attached in 
Appendices 18-21 for reference.  
 
 Effects of bioadhesive polymers on DcNa release 4.3.3.1
 Fit factors (ƒ1 and ƒ2) 4.3.3.1.1
This method had been endorsed by both FDA and Malaysian Ministry of Health for 
model-independent comparison of drug release profiles (Ministry of Health, 2000; US 
Department of Health and Human Services & CDER, 1997).  
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Comparisons using fit factors (Table 4.2) were made between the Rt which contains 
only 50 mg DcNa, against Tt which are incorporated with 1-5 %w/w bioadhesive 
polymer. Table 4.2 showed that drug release profiles between CB-SS suppositories 
and CE-SS suppositories appear more similar than CB-CE. The addition of CBP 
increasingly altered drug release profiles with increasing polymer concentrations, 
resulting in ƒ1 > 15 and ƒ2 < 50 for suppositories made with all three bases.  
Generally, incorporation of 1-5 %w/w HPMC, PVP and CMCTS to CE and SS did 
not alter drug release profiles compared to their respective Rt. In CB suppositories, the 
addition of 1-2 %w/w HPMC, PVP and CMCTS did not alter dissolution profiles; but 
when concentration of polymer was increased to 5 %w/w, DcNa release for all three 
formulations were significantly different from Rt  (ƒ1 > 15 and ƒ2 < 50). 
 
Although fit factors were effective in describing the similarities and dissimilarities 
between profiles, it was unable to reflect the reason of dissimilarities in terms of rate 
and extent (maximum amount) of drug release or kinetics of drug release. In order to 
understand DcNa release from these suppositories, it is thus essential to assess the DE 
(Section 4.3.3.1.2) and MDT (Section 4.3.3.1.3) for evaluation of the extent and rate 
of DcNa release from each formulation. 
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Table 4.2 : Statistical comparison of formulations containing DcNa only (Rt) and 
formulations with DcNa and bioadhesive polymers (Tt). Dissolution profiles are 
considered similar when; 0 < ƒ1 < 15 and 50 < ƒ2 < 100. The highlighted ƒ1 and ƒ2 
values indicate similar dissolution profiles between Rt and Tt.  
Formulation 
Parameters Rt  Tt 
Base 
Polymer amount (%w/w) 
CBP HPMC PVP CMCTS ƒ1 ƒ2 
CB CE 0 0 0 0 17.389 47.450 
CB SS 0 0 0 0 3.729 78.410 
CE SS 0 0 0 0 14.652 52.490 
CB CB 1 - - - 36.418 29.433 
CB CB 2 - - - 49.455 23.911 
CB CB 5 - - - 88.266 1.867 
CB CB - 1 - - 9.861 55.968 
CB CB - 2 - - 7.395 61.663 
CB CB - 5 - - 28.995 34.874 
CB CB - - 1 - 14.161 48.072 
CB CB - - 2 - 19.774 41.019 
CB CB - - 5 - 25.740 35.515 
CB  CB - - - 1 10.914 55.759 
CB CB - - - 2 9.693 57.316 
CB CB - - - 5 22.288 38.843 
CE CE 1 - - - 32.530 35.763 
CE CE 2 - - - 66.797 21.675 
CE CE 5 - - - 83.739 16.724 
CE CE - 1 - - 12.553 55.443 
CE CE - 2 - - 8.311 64.993 
CE CE - 5 - - 7.086 65.839 
 
 
110 
 
“Table 4.2 : Continued…” 
Formulation 
Parameters  Rt Tt 
Base 
Polymer amount (% w/w) 
CBP HPMC PVP CMCTS ƒ1 ƒ2 
CE CE - - 1 - 4.438 75.840 
CE CE - - 2 - 4.318 74.878 
CE CE - - 5 - 3.883 80.308 
CE CE - - - 1 5.691 71.193 
CE CE - - - 2 13.039 54.323 
CE CE - - - 5 2.362 83.401 
SS SS 1 - - - 38.049 29.091 
SS SS 2 - - - 71.912 15.819 
SS SS 5 - - - 89.125 11.003 
SS SS - 1 - - 3.873 76.739 
SS SS - 2 - - 3.269 79.135 
SS SS - 5 - - 5.233 70.184 
SS SS - - 1 - 5.967 67.582 
SS SS - - 2 - 5.956 66.663 
SS SS - - 5 - 6.636 65.966 
SS SS - - - 1 10.454 57.512 
SS SS - - - 2 6.524 68.781 
SS SS - - - 5 3.937 78.985 
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 Dissolution efficiency (DE)  4.3.3.1.2
The DE (Figure 4.3) provided an insight on the amount of DcNa released over a time 
period, reflecting the extent of drug release from the formulations examined. Among 
DcNa only formulations, CE showed a significantly lower DE compared to both CB 
and SS; this correlated well to the observations from Figure 4.2 where DcNa release 
rates were lower in CE. Statistical comparison of the formulations using Tukey’s HSD 
analysis is tabulated in Appendices 22-24.  
 
In general, the addition of CBP reduced extent of DcNa release in a concentration 
dependent manner in all three bases (Figures 4.3a–c). The DE of suppositories 
containing 5 %w/w CBP was decreased by 60 % in CB and 80 % in both CE and SS 
suppositories.  
 
On the other hand, addition of 5 %w/w PVP resulted in a slight but significantly lower 
DE in CB, CE and SS suppositories. While the incorporation of 1-5 %w/w HPMC did 
not significantly alter the DE of CB suppositories; it resulted in a slight decrease in 
DE for both CE and SS suppositories. CB suppositories incorporated with 1-5 %w/w 
CMCTS had a significantly lower DE while CE suppositories containing 2-5 %w/w 
CMCTS resulted in a higher DE. The DE of CB suppositories containing 1-5 % w/w 
HPMC and SS suppositories containing 1-5 %w/w CMCTS remained unchanged 
compared to DcNa only suppositories. There were however, no consistent trends on 
the effects of HPMC, PVP and CMCTS on DE of all formulations.  
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(a) 
 
(b) 
 
(c) 
 
Figure 4.3 : The DE of suppository formulations containing 50 mg DcNa and 1-
5%w/w bioadhesive polymers (CBP, HPMC, PVP, CMCTS) in (a) CB; (b) CE; and 
(c) SS. Asterisks indicate formulations which are significantly different from 
formulations without polymer (DcNa only). Mean ± SD, n=6. 
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the comparison of MDT generated for each formulation. Tukey’s HSD post hoc test at 
95 % confidence interval is tabulated in Appendices 25-27.  
 
(a) 
 
(b) 
 
(c) 
 
Figure 4.4 : The MDT of suppository formulations containing 50 mg DcNa and 
1-5 %w/w bioadhesive polymers (CBP, HPMC, PVP, CMCTS) made from (a) 
CB; (b) CE; and (c) SS. Asterisks indicate formulations which are significantly 
different from formulations without polymer (DcNa only). Mean ± SD, n=6. 
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Figures 4.4a-c showed that formulations containing 1-5 %w/w CBP had significantly 
longer MDT compared to DcNa only formulations. This increase in MDT caused by 
incorporation of CBP was concentration dependent and was consistent in all three 
bases. The higher the CBP content, the slower the rate of DcNa release (reflected by 
longer MDT, Figures 4.4a-c) accompanied by a lowering in the maximum percentage 
of DcNa released at the end of 6 hours (reflected by DE, Figures 4.3a-c). This 
observation was similar to the report of impaired ramosetron release from 
suppositories containing 2-10 %w/w of Carbopol 934P, where the authors 
hypothesised the formation of a viscous CBP gel that suppressed drug release (Yahagi 
et al., 2000). 
 
Decrease in DcNa release with increasing CBP content could also be due to reduction 
in DcNa solubility as a result of decreased receptor medium pH brought about by 
dispersion of CBP. CBP is acidic and produces a solution with pH 2.7–3.5 at 
0.5 %w/v (Lubrizol Advanced Materials, 2009). Kincl et al. (2004) reported that 
solubility of DcNa at pH 5.8 can be reduced by up to 86 folds compared to at pH 8.0.  
 
In general, the addition of HPMC, PVP and CMCTS at 1 %w/w did not significantly 
alter MDT of formulations in comparison to DcNa only formulations, while 2-
5 %w/w of polymers resulted in small but significant changes in MDT (Figures 4.4a-
c). There was however, no clear trend of concentration-dependent alteration of MDT 
by HPMC, PVP and CMCTS formulations.  
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 Mathematical modelling  4.3.4
Although fit factors were effective in showing dissimilarities between profiles while 
DE and MDT allowed direct comparison of the rate and extent of DcNa release 
between profiles; release kinetics can only be explained by substituting drug release 
data into mathematical equations.  
 
Release parameters for the selected mathematical model (first order, Higuchi’s, 
Korsmeyer-Peppas and Weibull’s mathematical models) after empirical fitting of each 
formulation were tabulated in Tables 4.3-4.5. Higuchi’s equation and Korsmeyer-
Peppas model were fitted with up to 60 % of the drug dissolution data in conjunction 
with the assumption that these two models are valid for description of cumulative drug 
release of 60 % (Korsmeyer et al., 1983). Meanwhile, both the first order and 
Weibull’s model were fitted with data up to the first time point at plateau (maximum 
dissolution). 
      
 1
1
6
 
Table 4.3 : The goodness of fit parameters obtained from equation fitting of drug release data from all CB formulations.   
Amount of Polymer (%w/w) First order Higuchi Korsmeyer- Peppas Weibull model 
CBP HPMC PVP CMCTS r
2 AIC r2 AIC r2 AIC r2 AIC 
0 0 0 0 0.241 118.946 0.797 28.180 0.953 26.289 0.924 43.695 
1 0 0 0 0.272 84.845 -1.739 100.043 0.647 79.800 0.988 50.021 
2 0 0 0 0.309 126.062 -0.8502 105.469 0.720 83.61 0.938 81.581 
5 0 0 0 0.3 150.781 0.728 109.206 0.892 119.661 0.872 109.000 
0 1 0 0 0.49 71.925 0.876 33.536 0.943 35.357 0.870 22.522 
0 2 0 0 0.532 74.000 0.779 35.813 0.956 34.117 0.862 10.463 
0 5 0 0 0.621 72.642 0.842 32.951 0.985 26.452 0.792 24.267 
0 0 1 0 0.51 71.557 0.875 33.067 0.946 34.616 0.870 22.428 
0 0 2 0 0.611 68.686 0.908 28.720 0.952 30.523 0.841 34.969 
0 0 5 0 0.558 73.484 0.799 34.870 0.967 31.623 0.851 12.567 
0 0 0 1 0.393 82.570 0.674 29.759 0.977 24.096 0.927 41.995 
0 0 0 2 0.418 82.956 0.745 28.414 0.978 22.881 0.901 33.132 
0 0 0 5 0.523 76.730 0.681 38.436 0.960 35.066 0.923 48.734 
 1
1
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Table 4.4 : The goodness of fit parameters obtained from equation fitting of drug release data from all CE formulations.  
Amount of Polymer (%w/w) First order Higuchi Korsmeyer- Peppas Weibull model 
CBP HPMC PVP CMCTS r
2 AIC r2 AIC r2 AIC r2 AIC 
0 0 0 0 0.306 118.806 0.765 27.229 0.966 23.620 0.946 54.683 
1 0 0 0 0.212 144.910 -0.886 108.831 0.675 94.124 0.983 91.430 
2 0 0 0 0.226 137.598 -1.003 151.483 0.692 133.769 0.937 104.763 
5 0 0 0 0.319 142.782 0.827 112.236 0.824 134.667 0.859 111.005 
0 1 0 0 0.438 76.189 0.522 39.593 0.915 40.066 0.948 39.330 
0 2 0 0 0.411 74.169 0.731 37.803 0.903 40.125 0.947 34.930 
0 5 0 0 0.494 72.340 0.775 35.636 0.943 35.743 0.908 33.777 
0 0 1 0 0.476 80.340 0.883 32.101 0.950 33.517 0.890 35.355 
0 0 2 0 0.369 83.874 0.731 37.803 0.957 40.125 0.950 42.744 
0 0 5 0 0.382 82.377 0.757 36.793 0.903 39.416 0.953 41.415 
0 0 0 1 0.377 84.159 0.687 38.283 0.957 40.693 0.954 37.455 
0 0 0 2 0.430 74.676 0.590 30.996 0.970 26.301 0.899 35.078 
0 0 0 5 0.417 81.403 0.777 35.864 0.910 38.400 0.935 39.156 
 1
1
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Table 4.5 : The goodness of fit parameters obtained from equation fitting of drug release data from all SS formulations.  
Amount of Polymer (%w/w) First order Higuchi Korsmeyer- Peppas Weibull model 
CBP HPMC PVP CMCTS r
2
 AIC r
2
 AIC r
2
 AIC r
2
 AIC 
0 0 0 0 0.229 119.01 0.729 29.433 0.952 27.754 0.938 61.568 
1 0 0 0 0.213 143.137 -6.839 183.66 0.643 133.642 0.986 87.630 
2 0 0 0 0.183 132.781 -1.748 150.488 0.616 131.717 0.932 110.567 
5 0 0 0 0.291 125.585 0.554 110.627 0.798 117.730 0.926 91.910 
0 1 0 0 0.439 67.757 0.834 26.59 0.934 26.488 0.922 36.212 
0 2 0 0 0.401 68.72 0.786 28.116 0.926 27.885 0.948 35.007 
0 5 0 0 0.459 69.178 0.810 26.985 0.958 24.801 0.919 29.679 
0 0 1 0 0.421 75.566 0.857 25.833 0.923 26.627 0.895 47.908 
0 0 2 0 0.408 75.584 0.851 25.974 0.916 26.955 0.925 41.593 
0 0 5 0 0.409 75.025 0.868 25.225 0.924 26.167 0.945 33.686 
0 0 0 1 0.345 71.832 0.763 29.905 0.966 26.243 0.953 44.333 
0 0 0 2 0.377 70.348 0.815 28.102 0.962 25.600 0.952 38.441 
0 0 0 5 0.374 70.717 0.771 28.900 0.949 27.092 0.962 33.666 
119 
 
The formulations containing only DcNa (no bioadhesive polymers) displayed the best 
‘goodness of fit’ to the Korsmeyer-Peppas model (r2> 0.95), supported by the AIC 
values. The order of increasing possibilities of fit to the kinetic equations based on 
AIC values were first order (lowest), Weibull’s model, Higuchi’s equation, 
Korsmeyer-Peppas (highest). 
 
The n-values obtained through fitting of data into the Korsmeyer-Peppas equation 
(Table 4.6) were within the range of 0.45–1.00, which was indicative of non-Fickian 
diffusion of DcNa from the suppositories.  
 
In general, the incorporation of HPMC, PVP and CMCTS did not affect the release 
mechanism of DcNa from the suppositories. The DcNa release was predominantly via 
non-Fickian diffusional methods as the Korsmeyer-Peppas release exponent (n), 
ranged between 0.580–0.980 (Table 4.6). DcNa release from the suppositories were 
therefore diffusion and erosion-controlled. These polymers (HPMC, PVP and 
CMCTS) dissolve upon contact with dissolution media to form gaps which facilitates 
erosion of the suppository matrix while DcNa simultaneously diffuse out of the DcNa-
drug matrix.  
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Table 4.6 : The release constant (km) and release exponent (n) of formulations fitted to 
Korsmeyer- Peppas model. 
Formulation Korsmeyer –Peppas 
parameters Base Amount of Polymer (%w/w) 
CB HPMC PVP CMCTS km n 
0 0 0 7.945 0.878 
1 0 0 7.772 0.756 
2 0 0 4.382 0.896 
5 0 0 5.157 0.795 
0 1 0 7.285 0.759 
0 2 0 8.096 0.584 
0 5 0 6.569 0.662 
0 0 1 4.489 0.949 
0 0 2 5.649 0.953 
0 0 5 3.228 0.980 
CE 0 0 0 5.539 0.931 
1 0 0 7.109 0.802 
2 0 0 7.704 0.642 
5 0 0 4.366 0.898 
0 1 0 7.080 0.747 
0 2 0 4.370 0.957 
0 5 0 4.770 0.915 
0 0 1 3.589 0.913 
0 0 2 3.460 0.916 
0 0 5 4.992 0.882 
SS 0 0 0 6.221 0.972 
1 0 0 9.442 0.792 
2 0 0 8.287 0.860 
5 0 0 7.390 0.862 
0 1 0 7.668 0.895 
0 2 0 8.073 0.878 
0 5 0 8.179 0.862 
0 0 1 7.644 0.934 
0 0 2 8.714 0.856 
0 0 5 7.405 0.914 
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Meanwhile, addition of 1-5 %w/w CBP resulted in a change of DcNa release 
mechanism in CB, CE and SS where poor fit of the data to Korsmeyers–Peppas model 
(r
2
 < 0.9) was observed (Tables 4.3-4.5). Instead, these data was better fitted to the 
Weibull’s model (Table 4.7) which describes release of matrix-like drugs (higher R2 
and smaller AIC). This could be due to the higher viscosity of molten suppository 
mixture (in the presence of DcNa and CBP) coupled with gelling properties of CBP 
upon contact with water which subsequently lead to trapping of DcNa within a base-
DcNa matrix.  
 
Based on the Weibull’s model, Table 4.7 showed that as the concentration of CBP 
increased, the scale factor (α) which corresponded to apparent rate constant decreased. 
This was in good agreement with the findings in Sections 4.3.3.1.2 and 4.3.3.1.3 that 
showed prolonged MDT and lowered DE as the concentration of CBP increased.  
 
On the other hand, the shape dependence factor (β) were within the range of 0.3–0.7 
(<1), which described the shape of drug release curves as having a steeper initial slope 
than exponential release curves. The β value of the formulations containing 1-5 %w/w 
CBP in this study reflected drug release in accordance to Fickian’s diffusion (β < 
0.75), as quoted by Papadopoulou et al. (2006). As the suppository melts and CBP 
starts to gel in contact with dissolution medium, it traps DcNa within the matrix. As 
gelling continues, the gel layer forms a barrier which impedes DcNa release, similar to 
that observed in drug release for devices with fractal geometry (Kosmidis et al., 2003). 
DcNa release from the dosage form is therefore expected to be proportionate to the 
fraction of particles that are sufficiently close to the barrier surface to diffuse from the 
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dosage form, down its concentration gradient (Kosmidis et al., 2003; Papadopoulou et 
al., 2006).  
 
Table 4.7 : The release parameters of formulations containing CBP fitted with Weibull 
equation. 
Formulation Weibull model parameters 
Base 
CBP  
(%w/w) 
α 
(time dependence factor) 
β 
(shape dependence factor) 
CB 
1 15.216 0.297 
2 10.702 0.334 
5 0.417 0.754 
CE 
1 10.321 0.370 
2 3.779 0.404 
5 0.795 0.620 
SS 
1 16.605 0.239 
2 3.636 0.391 
5 0.916 0.534 
 
Despite a generally better fit of formulations containing CBP to the Weibull model 
(smaller AIC), the goodness of fit in terms (r
2
) of the formulations at higher 
concentrations of CBP were still < 0.95 (Tables 4.3-4.5). Thus, further investigation 
using a biphasic release model (bi-exponential first-order kinetic model) was 
attempted. Parameters obtained from fitting into bi-exponential first-order kinetic 
equation were described in Table 4.8. 
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Table 4.8 : The release parameters of formulations containing 1-5 %w/w CBP fitted 
with bi-exponential first-order kinetic equation. All the r
2
 values for initial and 
terminal phases were > 0.95 when goodness of fit of the data was reviewed by linear 
regression. 
Formulation Bi-exponential first-order kinetics parameters 
Base 
CBP 
(%w/w) 
A 
k1 
(min
-1
) 
B 
k2 
(min
-1
) 
Lag time 
(min) 
CB 
1 49.422 0.282 54.495 0.002 0.290 
2 42.423 0.200 61.271 0.001 0.451 
5 28.968 0.026 74.344 0.001 4.185 
CE 
1 52.305 0.217 56.821 0.002 0.870 
2 27.975 0.102 75.384 0.001 1.205 
5 21.313 0.057 82.914 0.001 3.701 
SS 
1 49.979 0.247 58.096 0.004 0.699 
2 28.011 0.108 74.911 0.001 1.000 
5 11.642 0.062 89.407 0.001 1.427 
 
The CBP formulations showed good linearity and reasonable lag times with bi-
exponential first-order kinetic equation. The results suggested that DcNa was released 
from suppositories via a rapid initial phase (k1) followed by a slow terminal phase 
drug release (k2). The addition of CBP increased lag times and decreased k1 in a 
concentration dependent manner.  
 
The bi-exponential first-order kinetic fitting was initially modelled to characterise 
rapid intravenous injections. Over time, it has been used to describe the release of 
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drugs from solid dosage forms such as tablets and capsules (Laakso et al., 1984). In 
tablets, the rapid initial release was described as a result of increasing surface area for 
dissolution following tablet disintegration while the slower phase describes diffusion 
of drug from the dosage form.  
 
This concept can be adapted to explain DcNa release form CBP suppositories. During 
dissolution, the suppository undergoes initial melting followed by formation of fatty 
globules (containing molten base, DcNa and CBP). At this stage, DcNa release is via 
both diffusion from the molten base as well as erosion or deformation of the dosage 
form during the melting process (k1). But as CBP comes in contact with the 
dissolution medium, it starts to gel and eventually form a barrier between the matrix 
(base with DcNa) and dissolution medium, whereby DcNa can now only be released 
via a slow diffusion process across the barrier (k2). Weibull’s equation provided 
information on possible mechanism of DcNa release from CBP suppositories while 
the bi-exponential first-order equation described the release rate and kinetics during 
the biphasic release process; thus both models were used concomitantly to describe 
the release of DcNa from CBP suppositories. 
 
 Conclusion  4.4
The HPKS bases were comparable to CB in terms of drug release capacity and could 
be good lipophilic base candidates for fast-acting DcNa suppository formulations.  
 
Although convenient, the exploratory data analysis methods were unable to compare 
between large number of drug release profiles and offered no explanations to drug 
release mechanisms. The fit factors allowed quick detection of dissimilar profiles yet 
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does not identify cause of the differences between profiles. DE and MDT were useful 
for comparing differences between rate and extent of drug release but only 
mathematical modelling enabled the prediction of DcNa release mechanism. However, 
none of these methods were sufficient as a standalone analysis and thus, they should 
be used concomitantly to provide a complete picture of drug release profiles. 
 
Generally, the model independent methods (fit factors, DE, MDT) provided strong 
indication that DcNa release from formulations containing 1-5 %w/w CBP was 
markedly different (statistically significant at 95 % confidence interval) from their 
respective reference formulations (DcNa only suppositories). Although the fit factors 
found that 5 %w/w PVP, HPMC and CMCTS made in CB were significantly different 
from reference formulations (containing only DcNa), this difference was mainly 
reflected in terms of DE rather than due to a change in mechanism of drug release.   
 
Mathematical modelling of data found that suppositories containing only DcNa 
released the drug via non-Fickian diffusion kinetics. Addition of 1-5 %w/w HPMC, 
PVP and CMCTS to the formulations did not alter mechanism of DcNa release. They 
are therefore suitable candidates of bioadhesive polymers for development of DcNa 
suppositories.  
 
However, the addition of CBP lead to considerable change in morphology of molten 
suppository during dissolution via gelling, which resulted in biphasic DcNa release 
process involving a rapid initial diffusion and erosion process followed by slow 
diffusion process across the CBP gel layer. Furthermore, as CBP gels in the 
dissolution medium, it decreases the environment pH which leads to decreased DcNa 
126 
 
solubility, thus further retarding the release of DcNa from suppositories. The 
concentration dependent impedance of DcNa release from CBP suppositories indicate 
that CBP should only be used at the lowest possible concentration to confer 
bioadhesivity as concentrations of 1-5 %w/w had evidently suppressed drug release.  
 
The drug release studies using distilled water were only preliminary in nature. Drug 
release studies using buffered solutions at rectal pH of 7.2 should be considered after 
further investigation on bioadhesive properties and enhancement on formulation 
prototypes.  
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CHAPTER 5       
BIOADHESION STUDIES 
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 Introduction 5.1
 Methods to study bioadhesion  5.1.1
Bioadhesion studies can be performed via in vitro, in vivo and ex vivo experimental 
setups. In vitro bioadhesion studies are by far most commonly adopted due to ease of 
experimental setup. This method involves the use of a suitable excised mucosal 
membrane or synthetic membrane surface as the site of attachment under simulated 
conditions.   
 
To date, various methods have been developed and applied to study bioadhesive 
properties of pharmaceutical formulations. Among the techniques employed were (a) 
florescence probe technique (Park and Robinson, 1984) which measures change in 
fluorescence upon binding of polymer to epithelial cells labelled with pyrene and 
fluorescein, (b) detachment stress methods including Wilhelmy plate method (Sam et 
al., 1992; Santos et al., 1999), tensile stress method (Smart, 1991; Thirawong et al., 
2007; Tobyn et al., 1995; Wong et al., 1999a) and shear stress method (Jiménez-
Castellanos et al., 1993; Leung and Robinson, 1988; Mortazavi and Smart, 1995; 
Wang and Tang, 2008); (c) the wash-off method (Lehr and Bouwstra, 1992) which 
quantifies amount of particulate remaining on the test surface after bouts of agitation; 
and (d) mucin-particulate method (Takeuchi et al., 2005) which measures change in 
zeta potential of mucin brought about by mucin-polymer interaction. The Biacore
®
 
method to study bioadhesion was subsequently developed as an extension of this 
concept, where the change in surface plasmon resonance brought about by interaction 
between polymer and mucin reacted onto chitosan-immobilised sensor chips were 
measured arbitrarily (Thongborisute and Takeuchi, 2008). Of these, the detachment 
methods were most commonly used on solid and semi-solid dosage forms.  
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 Detachment methods  5.1.2
 Tensile stress 5.1.2.1
(a) 
 
 
(b) 
 
Figure 5.1 : Experimental setup for testing tensile stress of bioadhesion using texture 
analyser; (a) without temperature control (Thirawong et al., 2007; Tobyn et al., 1995; 
Wong et al., 1999a) and; (b) with temperature control (Thirawong et al., 2007). 
 
The tensile setup measures force required to fracture bioadhesion bond at right angles 
to the plane of contact between test sample and mucosa surface. Wilhelmy plate 
method (Smart et al., 1984) measures the tensile stress generated upon detaching a 
glass plate coated with polymer vertically immersed in mucin using a microforce 
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balance. This concept was subsequently modified to measure tensile stress generated 
upon the detachment between a tablet and mucosa surface using the tensiometer 
(Leung and Robinson, 1988; Ponchel et al., 1987) and texture analyser (Thirawong et 
al., 2007; Tobyn et al., 1995; Wong et al., 1999a). Figures 5.1a-b shows some of the 
experimental setup developed by other researchers to measure tensile stress of force 
required to detach dosage form from the mucosa.  
 
 Shear stress 5.1.2.2
Figure 5.2 shows some of the experimental setups developed to measure tangential 
shear stress. Shear setup measures the sliding force parallel to the plane of contact 
required to dislodge a sample disc from mucosa surface. 
 
Most studies measure the degree of bioadhesion in terms of tensile stress or tensile 
strength, although in actual fact, dosage forms administered into the GIT or vagina or 
buccal regions are most likely to undergo frictional and shear stress which occurs 
parallel to the adhesive joint. This might be due to the difficulties in measuring shear 
stress as well as the inadequacy of current methods to distinguish between actual force 
from the bond joint fracture and the force contributed by the friction of both surfaces 
(Jiménez-Castellanos et al., 1993; Leung and Robinson, 1988; Mortazavi and Smart, 
1995). While Leung and Robinson (1988) reported good results with their 
experimental setup (Figure 5.2b), Mortazavi and Smart (1995) were unable to yield 
comprehendible shear stress readings using the setup in Figure 5.2a because the 
readings were affected by friction and the occurrence of re-adhesion after joint 
fracture under the influence of gravity. 
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(a) 
 
(b) 
 
(c) 
 
Figure 5.2 : Experimental setups used to investigate the shear stress of the bioadhesion 
joint between bioadhesive material and membrane; (a) modified Dia-Stron rheometer 
equipped with pulley system (Mortazavi and Smart, 1995); (b) dual modified 
tensiometer method (Leung and Robinson, 1988) and; (c) vertical rod coupled to 
tensiometer (Jiménez-Castellanos et al., 1993). 
 
 Experimental design considerations 5.1.3
Methods to measure stress of detachment vary greatly in terms of experimental setup, 
choice of mucosa membrane and test medium used, in order to simulate in vivo 
conditions at which bioadhesion is expected to take place.  
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Experimental setup designed for testing bioadhesion in the GIT involved complete 
immersion of tissue and dosage form samples in a suitable test medium (Figure 5.1b 
and Figures 5.2a-b); usually simulated gastric which served as both a hydration 
medium and water bath to maintain the tissue at physiological temperature 
(Thirawong et al., 2007; Tobyn et al., 1995). This however, may not be applicable for 
the testing of bioadhesive suppositories as the rectum contains only 2–3 mL of inert 
mucus over a surface area of 200–400 cm2 (Allen et al., 2008). Conversely, some 
studies excluded immersion of tissue in test medium, but at the expense of 
physiological temperature control (Figure 5.1a and Figure 5.2c) (Jiménez-Castellanos 
et al., 1993; Ponchel et al., 1987; Wong et al., 1999a). Temperature control was 
particularly important for current work as suppositories would soften and melt at 
human body temperature, yet immersion of samples in test medium does not reflect 
physiological rectal conditions.  
 
Bioadhesive polymers were incorporated into rectal suppositories in this research as 
an attempt to circumvent the pre-systemic first-pass metabolism. It is hoped that the 
bioadhesive polymers would enable adherence of suppositories to the rectal mucosa, 
thus preventing its movement towards the upper rectum where capillaries drain into 
the hepatic portal system which is responsible for a substantial degree of pre-systemic 
drug inactivation. Previous studies by Yahagi et al. (2000) and Ramadan (2012) have 
incorporated CBP into suppositories, however, bioadhesive properties of the 
formulations were not tested.  
 
Therefore, this chapter aims to develop and optimise methods for in vitro assessment 
of bioadhesivity of suppositories using the texture analyser for measurement of tensile 
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and shear stresses required to disrupt bioadhesion. Measurements were made in terms 
of peak force of detachment (Fmax) and work of adhesion (Wad). This is followed by 
evaluation of bioadhesive properties of the suppository formulations developed in 
Chapter 3. Finally, as efforts to diversify experimental setup, synthetic cellulose 
membrane was investigated as a potential alternative to biological membranes in 
bioadhesion studies. 
 
 Materials and methods 5.2
 Materials 5.2.1
Type III mucin from porcine stomach was purchased from Sigma Aldrich, Missouri, 
USA. The regenerated cellulose membrane (nominal MW 12,000–14,000; thickness 
33 mm) was purchased from Fisher Scientific. Other materials used have been 
described in Sections 2.2 and 3.2. All reagents were analytical grade. The materials 
were used as received. 
 
 Methods 5.2.2
 Preparation of sample discs 5.2.2.1
Cylindrical sample discs with a radius of 1.3 cm and thickness of 0.5 cm were 
prepared via fusion moulding. Method of manufacturing was similar to that of 
suppositories (Section 3.3.1) with the exception of acrylate disc moulds in place of 
suppository moulds. Bioadhesive polymers (CBP, HPMC, PVP and CMCTS) were 
added to the molten base at concentrations of 1, 2 and 5 %w/w alongside 50 mg of 
DcNa per disc.  
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 Preparation of large intestinal tissue 5.2.2.2
Freshly excised porcine large intestines were obtained from a local slaughterhouse and 
processed within 24 hours. The large intestines were split lengthwise and luminal 
contents were removed by careful rinsing with distilled water. The serosa, tunica 
muscularis and the submucosa layer were removed and the large intestines were 
separated into three sections - the crown, rectum and colon (Figures 5.3a-b).  
 
(a) 
 
(b) 
 
Figure 5.3: Different segments of freshly excised porcine large intestinal tissues used 
in this study, (a) intact large intestines with serosa, tunica muscularis and submucosa 
layer; (b) split large intestines, with mucosa facing upwards.    
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The crown was discarded and rectum region was harvested 3 cm after the dentate 
while 10-15 cm of the mucosa between rectum and colon were discarded to omit 
‘transitional regions’. The rectum and colon were carefully examined to ensure the 
membrane is intact before cutting into 6 cm x 6 cm membrane segments. The 
membranes were immersed in 0.9 %w/v sodium chloride and kept frozen until use, 
within 1 week from the day of processing. The yield of sample membranes from the 
intestines was tabulated. 
 
 Preparation of simulated rectal mucus 5.2.2.3
Simulated rectal mucus (SRM) was prepared by stirring 5 %w/w type III mucin in pH 
7.4 simulated colonic fluid (SCF) for 3 hours. The SCF was prepared based on the 
formula for SCF by Marques et al. (2011). SRM was stored refrigerated at 4 °C and 
used within 72 hours from time of preparation.  
 
 Experimental setup 5.2.2.4
Bioadhesion measurement was conducted using a Ta.XT plus Texture Analyser 
(Stable Microsystems, Surrey, UK) equipped with a 5 kg load cell. All measurements 
were conducted at 29 ± 1 °C with RH of 55–65 %. All studies were carried out in 5–6 
replicates. Fresh tissue and sample disc was used for each replicate. 
 
 Tensile measurement  5.2.2.4.1
The method used in the current study was modified from Thirawong et al. (2007) and 
Wong et al. (1999) to allow temperature control of the membrane without immersion 
of the setup in a water bath. The setup comprised of a probe affixed to the texture 
analyser arm with a flat round surface and a copper membrane stage heated using a 
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ceramic top stirring hotplate (Fisher Scientific, Pittsburg, USA). The entire assembly 
is as depicted in Figure 5.4.  
 
 
Figure 5.4 : The tensile bioadhesion study experimental setup using texture analyser 
with heated copper membrane stage. 
 
Sample discs were securely mounted onto the flat surface of the cylindrical probe 
using double sided tape. The tissue prepared using methods describe in Section 5.2.2.2 
were allowed to thaw to room temperature and immersed in SCF for 30 minutes 
before clamping on the copper stage using binder clips, luminal surface facing 
upwards. The copper stage was then positioned below the texture analyser arm and 
aligned to ensure the sample disc comes into direct contact with membrane surface 
when probe is lowered. A fixed volume of SRM was dispensed onto the mucosa 
surface and spread out evenly before lowering the sample disc to 5 cm above the 
membrane. The membrane temperature was measured using an infrared thermometer 
and allowed to equilibrate to 37.0 ± 0.5 °C on the copper stage before commencement 
of experiments. The probe was lowered at a speed of 1 mm/s until contact was made 
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between the sample disc and the membrane (Figure 5.4, Step I). This contact was 
maintained for a specific time (contact time) under a fixed contact force (Figure 5.4, 
Step II). At the end of contact time, the probe was withdrawn at a predetermined 
speed (probe withdrawal speed) to a 10 mm distance (Figure 5.4, Step III).  
 
 Shear measurement  5.2.2.4.2
The method used in the current study was modified from Chary et al. (1999) and 
Wang and Tang (2008) to allow direct measurement of shear force required to disrupt 
bioadhesion between sample disc and the membrane under temperature control. The 
entire assembly is as depicted in Figure 5.5. 
 
 
Figure 5.5 : The shear bioadhesion study experimental setup using texture analyser 
with heated copper membrane stage.  
 
The setup comprised of three components: a sample holder; a copper stage connected 
to an acrylate stage affixed with a pulley wheel and; a texture analyser probe fitted 
with a hook. Sample discs were securely mounted onto the flat surface of the sample 
holder using double sided tape while the mucosa was attached to the copper stage 
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using binder clips (luminal surface upwards). The entire copper stage was maintained 
at 37 °C using a ceramic top stirring hotplate (Fisher Scientific, Pittsburg, USA). A 
fixed length of nylon string was attached from the sample holder to the hook on the 
probe through a pulley at right angles. The position of the probe was adjusted to 
ensure there is no slack along the length of the string. The membrane temperature was 
allowed to equilibrate to 37.0 ± 0.5 °C on the copper stage and dispensed with a fixed 
volume of SRM before commencement of experiments. Weights (contact force) were 
placed on the sample holder for a predetermined duration of time (contact time) to 
facilitate bioadhesion between sample disc and membrane (Figure 5.5, Step I). At the 
end of the contact time, the probe was withdrawn at a predetermined speed (probe 
withdrawal speed) to dislodge sample disc from membrane surface (Figure 5.5, Step 
II).  
 
 Effects of instrument and test variables on the bioadhesive test 5.2.2.5
Fmax of the sample discs from the porcine large intestinal mucosa under different test 
conditions was measured. Three instrumental variables were studied; the contact time, 
probe withdrawal speed and contact force; while the two test variables studied were 
the volume of mucin used and the type of large intestinal mucosa used (rectum or 
colon). Studies on the instrument variables were conducted using the porcine colon 
mucosa with 150 μL of SRM evenly spread over the surface. All studies were carried 
out in 5–6 replicates.  
 
 Tensile measurement  5.2.2.5.1
Sample discs containing 50 mg DcNa and 5 %w/w CBP were used to optimise the 
instrument and test variables used in tensile measurements. Four different contact 
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times, five probe withdrawal speed, five contact forces, five volumes of SRM and two 
types of mucosa. The parameters are tabulated in Table 5.1. 
 
 Shear measurement 5.2.2.5.2
Sample discs containing 50 mg DcNa and 5 %w/w PVP were used to optimise the 
instrument and test variables used in shear measurements. Four different contact times, 
four probe withdrawal speed, four contact forces, four volumes of SRM and two types 
of mucosa. The parameters are tabulated in Table 5.2.  
  
 Evaluation of the bioadhesive strengths in suppository formulations 5.2.2.6
using biological membranes 
The instrumental and experimental parameters used to evaluate bioadhesive strength 
of suppository sample disc were obtained from studies in Section 5.2.2.5.1 and 
5.2.2.5.2.  All measurements were carried out in 5-6 replicates.  
 
 Evaluation of synthetic regenerated cellulose membrane as an 5.2.2.7
alternative to biological membrane  
Evaluation was carried out using settings and parameters used in Section 5.2.2.6 with 
the substitution of synthetic regenerated cellulose membrane for porcine colon mucosa. 
The regenerated cellulose membrane was cut to 6 cm x 6 cm squares and immersed in 
SCF for 1 hour prior to use. All measurements were carried out in 5-6 replicates. 
 1
4
0
 
Table 5.1 : The fixed and variable parameters used for tensile force optimisation using sample discs containing 50 mg DcNa and 5 %w/w CBP. 
Fixed parameter 
Variable parameter 
Contact time Probe withdrawal speed Contact force Volume of SRM Type of mucosa 
Contact times 5, 10, 20, 30 s 20 s 20 s 20 s 20 s 
Probe withdrawal speed 10 mm/s 1, 2, 5, 10, 20 mm/s 10 mm/s 10 mm/s 10 mm/s 
Contact force 2 N 2 N 0.5, 1, 1.5, 2, 3 N 2 N 2 N 
Volumes of SRM 150 μL 150 μL 150 μL 0, 50, 100, 150, 300 μL 150 μL 
Type of mucosa colon colon colon colon colon, rectum 
 
 
 
 
 1
4
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Table 5.2 : The fixed and variable parameters used for shear force optimisation using sample discs containing 50 mg DcNa and 5 %w/w PVP. 
Fixed parameter 
Variable parameter 
Contact time Probe withdrawal speed Contact force Volume of SRM Type of mucosa 
Contact times 20, 40, 60, 90 s 60 s 60 s 60 s 60 s 
Probe withdrawal speed 30 mm/s 5, 10, 20, 30 mm/s 30 mm/s 30 mm/s 30 mm/s 
Contact force 2 N 2 N 1, 2, 3, 4 N 2 N 2 N 
Volumes of SRM 150 μL 150 μL 150 μL 0, 100, 150, 300 μL 150 μL 
Type of mucosa colon colon colon colon colon, rectum 
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 Data analysis 5.2.2.8
Figure 5.6 showed the typical plot of force versus distance data obtained through 
tensile measurement. The maximum force required for separation of sample disc from 
the membrane or Fmax was obtained directly from the force–distance curve while the 
work of adhesion (Wad) was calculated using area under the force–distance curve 
using the Texture Exponent 32 software. Bioadhesive properties of the different 
formulations were evaluated and compared based on these two parameters. ANOVA 
followed by a post hoc Tukey’s HSD test was performed to examine both effects of 
instrument and experimental variables on bioadhesion as well as bioadhesive strength 
of various formulations. The statistical analyses were conducted using SPSS version 
20 (SPSS Inc., USA). A statistically significant difference was observed when p <0.05.  
 
 
 
Figure 5.6: A typical plot of force versus distance data for suppository sample disc 
(CB + 50 mg DcNa + 1 %w/w PVP) tested with colon mucosa using the tensile setup.  
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 Results and discussion 5.3
The design of both experimental setup for tensile and shear measurement were 
targeted at mimicking the internal environment of the rectum. The disc surface area 
was designed to reflect total surface area for bioadhesion in an actual torpedo shaped 
suppository with height of 2.5 cm and radius of 0.4 cm (at its barrel end). The 
intestinal mucosa and SRM (pH 7.4) was used to reproduce rectal environment.  
 
 Preparation of large intestinal tissue 5.3.1
The yield of both rectum and colon samples were tabulated in Table 5.3. The yield of 
colon membrane samples were usually 2-3 times more than the amount of rectum 
mucosa obtained per intestine. 
 
Table 5.3 : The yield of biological membrane mucosa. 
Intestine 
Rectum Colon 
Length 
(cm) 
Yield 
(6 cm x 6 cm) 
Length 
(cm) 
Yield 
(6 cm x 6 cm) 
A 25 12 122 34 
B 25 7 116 19 
C 25 8 95 26 
D 19 8 90 22 
E 22 7 100 25 
F 30 8 127 20 
 
 Effects of instrument and test variables on the bioadhesive test 5.3.2
 Tensile measurement 5.3.2.1
Figure 5.7 showed that Fmax and Wad increased as contact time was increased until 20 
s, where a further 10 s of contact time did not significantly increase Fmax.  
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(a) 
 
(b) 
 
Figure 5.7: Effect of contact time on (a) Fmax and (b) Wad of SS discs containing 50 
mg DcNa and 5 %w/w CBP against porcine colon mucosa using the tensile setup. 
Mean ± SD, n=5-6.   
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Initial increase in contact time may have allowed interdiffusion and chain 
entanglement between CBP and mucin in the SRM; however as the contact time was 
increased, a higher fraction of the sample disc melted, resulting in an oily, slippery 
layer between the sample disc and the tissue mucosa. Therefore, 20 s was selected as 
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The effect of increasing probe withdrawal speed on both the Fmax and Wad (Figure 5.8) 
were similar to findings by Wong et al. (1999), and Thirawong et al. (2007). 
Increasing probe withdrawal speed from 1 mm/s to 10 and 20 mm/s resulted in 
statistically significant increase in Fmax and Wad, but there were no differences 
between 10 and 20 mm/s. Higher probe speeds produced larger Fmax and Wad which 
afforded higher sensitivities in measuring bioadhesion while the lower speeds resulted 
in bigger standard deviations. Therefore, an intermediate probe speed of 10 mm/s was 
selected for subsequent bioadhesion studies.  
 
(a) 
 
(b) 
 
Figure 5.8: Effect of probe withdrawal speed on (a) Fmax and (b) Wad of SS discs 
containing 50 mg DcNa and 5 %w/w CBP against porcine colon mucosa using tensile 
setup. Mean ± SD, n=5-6.   
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A significant increase in Fmax and Wad was observed only after contact force was 
increased from 0.5 to 2 N (Figure 5.9). The observed trend was similar to that by 
Thirawong et al. (2007) although the latter study investigated contact force at the 
range of 0.05 to 0.5 N. Various studies have shown that basal rectal pressure is at the 
range of 5–25 cmH2O (Farouk, 2003) and 20–25 mmHg (Rao et al., 1988) while anal 
pressure is approximately 26–75 cmH2O (Hancock, 1976). Therefore, 2 N which 
translated to 0.049–0.74 N/cm2 (equivalent to 5-75.5 cmH2O) was selected as contact 
force for future studies, derived from contact surface area of sample disc (5.1 cm
2
). 
 
(a) 
 
(b) 
 
Figure 5.9 : Effect of contact force on (a) Fmax and (b) Wad of SS discs containing 50 
mg DcNa and 5 %w/w CBP against porcine colon mucosa using tensile setup. Mean 
± SD, n=5-6.   
 
0
2
4
6
0 0.5 1 1.5 2 2.5 3 3.5P
e
ak
 f
o
rc
e
 o
f 
d
e
ta
ch
m
e
n
t 
(N
) 
Contact force (N) 
0
2
4
6
0 0.5 1 1.5 2 2.5 3 3.5W
o
rk
 o
f 
ad
h
e
si
o
n
 (
N
.m
m
) 
Contact force (N) 
147 
 
The effect of different SRM volumes ranging from 0–300 μL on the Fmax and Wad 
were investigated to select the suitable volume which simulates rectal conditions yet 
produced reasonable measurements of Fmax and Wad. Figure 5.10 showed that different 
volumes of SRM did not significantly affect the Fmax and Wad generated, although it 
was suggested that adhesive forces weakens as mucus content increases (Mortazavi 
and Smart, 1995). However, 150 μL was selected for subsequent studies as it is the 
average volume of rectal conditions based on the surface area of the tissue used.   
 
(a) 
 
(b) 
 
Figure 5.10 : Effect of volume of SRM on (a) Fmax and (b) Wad of SS discs containing 
50 mg DcNa and 5 %w/w CBP against the porcine colon mucosa using the tensile 
setup. Mean ± SD, n=5-6.   
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This study also investigated suitability and consistency of various segments of the 
large intestine (rectum and colon) as model mucosa for bioadhesion studies. Generally, 
formulations containing either CMCTS or CBP exhibited higher Fmax and Wad values 
than those without polymer (Figure 5.11). Bioadhesive properties of CBP were 
greater than CMCTS and increased in a concentration dependant manner.  
 
(a) 
 
(b) 
 
Figure 5.11 : Effect of different segments (rectum and colon) of the porcine large 
intestines on (a) Fmax and (b) Wad of SS discs containing 50 mg DcNa and 2–5 %w/w 
of CMCTS or CBP using the tensile setup. Values expressed as mean ± SD, n=5-6.   
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tensile setup. Due to the low yield of rectum membranes (Table 5.3), the colon 
mucosa was used in subsequent evaluative studies in Section 5.3.3.   
 
 Shear measurement 5.3.2.2
Figure 5.12 showed that Fmax and Wad increased as contact time was increased until 90 
s, followed by a decrease in bioadhesion at 120 s. Shojaei et al. (2000) reported that 
bioadhesion strength plateaued when contact time was increased beyond 120 s, and 
attributed it to excessive water sorption. In this study, it is likely that a slippery 
surface was produced as the disc melts, resulting in a decrease in bioadhesion forces 
with longer contact times; thus 60 s was selected for subsequent studies.  
 
(a) 
 
(b) 
 
 Figure 5.12 : Effect of contact time on (a) Fmax and (b) Wad of SS discs containing 50 
mg DcNa and 5 %w/w PVP against the porcine colon mucosa using the shear setup. 
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Mean ± SD, n=5-6.   
 
The effects of increasing probe withdrawal speed on both the Fmax and Wad (Figure 
5.13) were similar to findings from the tensile setup. Increment in probe withdrawal 
speed from 5 mm/s to 10, 20 and 30 mm/s resulted in statistically significant increase 
in Fmax and Wad. Therefore, probe speed of 30 mm/s was selected for subsequent 
bioadhesion studies using the shear setup. 
 
(a) 
 
(b) 
 
Figure 5.13 : Effect of probe withdrawal speed on (a) Fmax and (b) Wad of SS discs 
containing 50 mg DcNa and 5 %w/w PVP against porcine colon mucosa using the 
shear setup. Mean ± SD, n=5-6.   
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A significant increase in Fmax and Wad was observed when contact force was increase 
from 1 to 2, 3 and 4 N (Figure 5.14). There was a ceiling effect for the increment in 
Fmax and Wad brought about by increasing contact force, as no significant difference in 
Fmax and Wad between contact force of 2, 3 and 4 N. This was in agreement with 
Wong et al. (1999) where the authors suggested that excessive contact force may lead 
to mucosal damage without any improvements on bioadhesion. Contact force of 2 N 
was used in subsequent studies. 
 
(a) 
 
(b) 
 
Figure 5.14 : Effect of contact force on (a) Fmax and (b) Wad of SS discs containing 
50 mg DcNa and 5 %w/w PVP against the porcine colon mucosa using the shear 
setup. Mean ± SD, n=5-6.   
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Figure 5.15 showed that the different volumes of SRM used in this study did not 
significantly affect the Fmax and Wad generated. SRM volume of 150 μL was selected 
for the subsequent studies.  
(a) 
 
(b) 
 
Figure 5.15 : Effect of volume of SRM on (a) Fmax and (b) Wad of SS discs 
containing 50 mg DcNa and 5 %w/w PVP against the porcine colon mucosa using 
the shear setup. Mean ± SD, n=5-6.   
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in section 5.3.2.1, the colon mucosa was a suitable replacement of the rectum. 
Generally, formulations containing either CBP or PVP exhibited higher Fmax and Wad 
values than those without polymer, and the bioadhesion conferred by PVP was greater 
than CBP and increased in a concentration dependant manner.  
 
(a) 
 
(b) 
 
Figure 5.16 : Effect of different segments (rectum and colon) of the porcine large 
intestines on (a) Fmax and (b) Wad of SS discs containing 50 mg DcNa and 2–5 %w/w 
of CBP or PVP using the shear setup. Mean ± SD, n=5-6.   
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 Evaluation of bioadhesive strength in suppository formulations using 5.3.3
biological and synthetic membranes 
 Tensile measurement  5.3.3.1
A contact time of 20 s under a contact force of 2 N, followed by a probe withdrawal 
speed of 10 mm/s was used in this segment of studies. Porcine colon mucosa spread 
with 150 μL of SRM was used as a model mucosa. The Fmax of various bioadhesive 
suppository formulations are shown in Figure 5.17.  
 
For CB and CE suppositories, only 5 %w/w CBP, 5 %w/w CMCTS and 5 %w/w PVP 
showed significantly higher Fmax compared to blank formulations. Although there 
were small increases in Fmax for formulations containing 1–2 %w/w of bioadhesive 
polymers, none of these were statistically significant.  
 
Meanwhile, SS suppositories containing 2–5 %w/w of CBP and PVP and 5 %w/w of 
CMCTS resulted in a significantly higher Fmax compared to suppositories without 
polymers. Formulations with higher amounts of polymer generally exhibited greater 
bioadhesive properties. The strength of bioadhesion conferred by the polymers was in 
the ascending rank order of: HPMC < CMCTS < CBP < PVP. Formulations 
containing HPMC at concentrations of up to 5 %w/w exhibited the weakest 
bioadhesion (lowest Fmax) compared to other polymers. Outcomes of the statistical 
analysis are included in the Appendices 28-30. 
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(a) 
 
(b) 
 
(c) 
 
Figure 5.17 : The Fmax of (a) CB; (b) CE and (c) SS formulations containing 50 mg 
DcNa and 1–5 %w/w of bioadhesive polymer (CBP, HPMC, PVP, CMCTS) using 
tensile setup. Asterisks indicate Fmax values which are significantly different from 
formulations without bioadhesive polymers. Mean ± SD, n=5–6. 
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 Shear measurement 5.3.3.2
A contact time of 60 s under a contact force of 2 N, followed by a probe withdrawal 
speed of 30 mm/s was used in this segment of studies. Porcine colon mucosa spread 
with 150 μL of SRM was used as a model mucosa.  
 
Figure 5.18 showed the Fmax and Wad measured using the shear setup. In general, 
bioadhesion measured using the shear setup was observed to increase in the following 
order: CBP = HPMC < CMCTS < PVP; with formulations containing PVP exhibiting 
the highest bioadhesive properties. Although all formulations containing 5 %w/w of 
polymer had significantly higher Fmax, HPMC exhibited limited bioadhesive 
properties. This was observed in both the tensile and shear measurements and strongly 
suggests the limited benefit of using HPMC in the formulation of bioadhesive 
suppositories. Outcomes of the statistical analysis are included in the Appendices 31-
33.  
 
Similar to the tensile setup, formulations containing 5 %w/w PVP was found to 
generate the highest Fmax, which indicated the superior bioadhesivity conferred by this 
particular polymer when incorporated in lipophilic suppositories. The shear forces 
required to detach sample discs increased with increasing amounts of PVP 
incorporated into the sample disc. A similar albeit less obvious trend was observed in 
formulations containing other polymers.  
 
Formulations containing CBP exhibited poor bioadhesive properties when tested 
using the shear setup; contrary to results obtained using the tensile setup in Section 
5.3.3.1. 
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(a) 
 
(b) 
 
(c) 
 
Figure 5.18 : The Fmax of (a) CB; (b) CE and (c) SS formulations containing 50 mg 
DcNa and 1–5 %w/w of bioadhesive polymer (CBP, HPMC, PVP, CMCTS) using 
shear setup. Asterisks indicate Fmax values which are significantly different from 
formulations without bioadhesive polymers. Mean ± SD, n=5-6. 
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The bioadhesion properties of CBP, an anionic polymer is attributed to presence of 
carboxylic acid (-COOH) groups which facilitates the formation of hydrogen bonds. 
Lehr and Bouwstra (1992) found that bioadhesion of anionic polycarbophil decreased 
as the pH of the test medium increased. Furthermore, CBP is known to gel at higher 
pH. Upon mixing with molten suppository base and simulated rectal fluid (pH 7.4), 
CBP could have resulted in slippery mucilage which facilitates sliding between the 
sample disc and mucosa surface; resulting in poor shear Fmax. Apart from that, this 
observation could also be a result of the smooth and fine texture of CBP compared to 
the grainier PVP, CMCTS and HPMC.   
 
Previous studies had inconsistent findings on bioadhesive properties of PVP; Wong et 
al. (1999) found that PVP K30 produced Fmax comparable to that of CBP 974P. 
Conversely, Ivarsson and Wahlgren (2012) reported that PVP had limited 
bioadhesivity via ellipsometry, tensile strength and rheology methods while Smart et 
al. (1984) reported poor bioadhesivity in PVP using the Wilhelmy plate method. 
Current study found that PVP exhibited similar bioadhesive performance compared to 
CBP in tensile stress measurements and displayed superior bioadhesivity compared to 
CBP in the shear measurements. PVP, although lack hydrophilic groups, possess 
cyclic amide groups which could serve as potential sites for hydrogen bonding.  
 
The secondary amine of CMCTS (structure depicted in Figure 1.2c) is protonated to 
form a positive charge at lower pH while the carboxylic acid groups ionise to form 
carboxylate groups as the pH increased. At the pH of SRM (pH 7.4), both the amine 
and carboxylic acid groups would be protonated and could result in formation of 
temporary bonds between the polymer chains, reducing polymer–mucin interaction 
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(Hombach and Bernkop-Schnurch, 2010). However, this work found that CMCTS has 
more promising bioadhesivity compared to CBP when both the tensile and shear 
measurements were considered collectively.  
 
The poorest bioadhesion was observed in the formulations with HPMC, a linear, 
nonionic polymer derived from etherified anhydro-glucose rings substituted with a 
28–30 % hydrophobic methyl groups. Most of the previous studies which reported of 
good bioadhesion properties in HPMC formulations employed the lesser methyl 
substituted HPMC grade 2208 rather than 2910 used in this study (Akbari et al., 2010; 
Mortazavi and Smart, 1995; Wong et al., 1999). This further affirms the importance of 
potential hydrogen bonding groups in conferring bioadhesive properties. 
 
 Evaluation of synthetic regenerated cellulose membrane as an 5.3.4
alternative to biological membrane  
Due to variability in mucosa surface properties and difficulties in obtaining biological 
samples, a synthetic regenerated cellulose membrane was investigated as potential 
substitute for biological mucosa used during in vitro measurement of bioadhesion. 
 
 Tensile measurement 5.3.4.1
Figure 5.19 showed that Fmax generated for the same formulations using synthetic 
(regenerated cellulose) membrane were much higher than those generated using 
biological (colon) membranes. However, both were similar in terms of rank order of 
bioadhesion. The bioadhesivity in ascending manner was found to be: HPMC < 
CMCTS < CBP < PVP. Formulations tested using the synthetic membranes resulted 
in smaller SD but were less sensitive compared to the biological membrane, as 
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observed by the higher Fmax produced by blank samples. An outcome of the statistical 
analysis is included in the Appendix 34. 
 
(a) 
 
(b) 
 
Figure 5.19 : The Fmax of the SS formulations containing 50 mg DcNa and 0-5 %w/w 
of bioadhesive polymer (CBP, HPMC, PVP, CMCTS) tested with (a) colon mucosa 
as biological membrane and (b) synthetic membrane using the tensile experimental 
setup.  Mean ± SD, n=5-6. 
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correlation, the usage of synthetic regenerated cellulose as an alternative membrane to 
colon samples may only be feasible for qualitative comparison (rank order of 
bioadhesion), as the Fmax values obtained using synthetic membranes were 
approximately 3-4 times higher than those obtained using the rectum and colon 
membranes. 
     
 Shear measurement 5.3.4.2
Contrary to the findings from tensile measurements (Section 5.3.4.1); both Fmax 
generated using biological and synthetic membranes were comparable and of the same 
rank order (Figure 5.20). An outcome of the statistical analysis is included in 
Appendix 35. 
 
The correlation coefficient of Fmax between the colon and synthetic regenerated 
cellulose was found to be 0.959. Synthetic regenerated cellulose appeared to be a 
suitable alternative to biological membrane in in vitro bioadhesion studies using the 
shear setup as there were no marked differences between the results obtained from 
colonic mucosa and synthetic regenerated cellulose. However, caution has to be 
exercised while interpreting results in both situations as synthetic membranes have a 
flat and even surface which is a stark contrast to biological mucosal surfaces.  
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(a) 
 
(b) 
 
Figure 5.20 : The Fmax of the SS formulations containing 50 mg DcNa and 0-5 %w/w 
of bioadhesive polymer (CBP, HPMC, PVP, CMCTS) tested with (a) colon mucosa 
as biological membrane and (b) synthetic membrane using the shear experimental 
setup. Mean ± SD, n=5-6. 
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the other polymers when subjected to both tensile and shear forces of detachment. 
This finding was promising for the development of bioadhesive suppositories. 
Conversely, HPMC exhibited poor bioadhesive properties in both tests and has 
limited role in the development of bioadhesive suppositories. In addition to evaluation 
of the bioadhesivity of the formulations, this study also investigated synthetic 
regenerated cellulose membrane as a practical alternative to biological membranes as 
mucosa surface for in vitro bioadhesion studies. Synthetic regenerated cellulose 
membranes were generally found to be a good substitute for colon mucosa for 
qualitative assessment of bioadhesion strengths in both the tensile and shear 
measurements. 
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CHAPTER 6         
STABILITY STUDIES 
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 Introduction 6.1
 Stability studies in suppositories 6.1.1
Suppository formulations are susceptible to both chemical and physical instability 
when inappropriately stored (Coben and Lordi, 1980; Tukker et al., 1984). Storage 
temperature and storage duration are common factors causing ageing which leads to 
altered stability in suppositories (Hosny et al., 1990; Sah and Saini, 2008; Yoshida et 
al., 1991; Yoshino et al., 1981). 
 
Stability studies fundamentally involve testing both physical and chemical aspects of 
a particular formulation to determine its shelf life and preferential storage conditions. 
Physical analysis comprises visual inspection of the physical appearance, mechanical 
strength (hardness), melting point and softening time, while analysis of active drug 
compound as well drug release studies make up the crucial aspects of chemical testing.  
 
 Chemical testing  6.1.2
Certain drugs are susceptible to chemical degradation or may interact with 
suppository base after prolonged exposure to warm temperatures (Tukker et al., 1984; 
Whitworth et al., 1973). When drug degrades, the formulation may no longer be 
clinically effective and in some cases, the degraded product may even be toxic.  
 
Yoshida et al. (1991) observed that indomethacin suppositories aged by storage at 
room temperature for one month resulted in slower drug release compared to those 
stored refrigerated for the same duration of time. A separate study also found that 
aminophylline suppositories made with CB kept at 30 ºC for 8 weeks resulted in 
retarded in vitro drug release compared to freshly prepared suppositories (Tukker et 
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al., 1984). Although the authors attributed the slow and incomplete drug release to 
degradation of aminophylline to theophylline, they also noted that shape of the 
suppositories remained intact (not melted) for 30 minutes during drug release studies, 
which could also imply changes in physical properties of the dosage form leading to 
difficulty in melting or softening. 
 
 Physical testing  6.1.3
Lipophilic suppository base in particular, are at risk of a multitude of physical 
instabilities as they are made up of a mixture of TAG with various polymorphic forms. 
Visible signs of physical instability include deformation, separation of incorporated 
additives and active drug from the base as well as the presence of blooming (Khan 
and Craig, 2004). Bloom occurs as a dull grey surface haze which may sometimes 
cause the surface of the suppository to feel grainy or crumbly to touch (Allen et al., 
2008).   
 
Oleaginous suppositories also undergo transitions into forms exhibiting higher 
melting points during storage, and these effects appear to be less pronounced when 
stored at lower temperatures (Hosny et al., 1990; Liversidge et al., 1982; Webster et 
al., 1998; Yoshino et al., 1981). When its melting point is elevated beyond 37 ºC, a 
suppository may not melt completely upon administration into the rectum or result in 
molten with a higher viscosity at body temperature, both occurrences impede drug 
release (Tukker et al., 1984). Hardening or prolonged softening time of suppositories 
leads to incomplete melting upon administration into the rectum and may cause local 
irritation or trigger the defecatory reflex, resulting in expulsion of suppository (Coben 
and Lordi, 1980). 
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The effects of ageing in suppositories were highly variable depending on the type of 
drug and excipients used to formulate the suppositories (Hosny et al., 1990; Yoshino 
et al., 1982). Furthermore, effects of DcNa and bioadhesive polymers (CBP, HPMC, 
PVP and CMCTS) towards ageing of suppositories were unknown.  
 
Among formulations developed and tested in the previous chapters, suppositories (CB, 
CE and SS) containing bioadhesive polymers PVP and CMCTS appear to be 
promising candidates for fast release DcNa suppositories with bioadhesive properties. 
Thus, this chapter aims to assess stability of these suppositories as a function of 
storage duration and storage condition. The suppositories were evaluated and 
compared in terms of visual appearance, thermal profile, hardness, softening time and 
DcNa release to ascertain consequences of ageing and the preferred storage conditions 
in these formulations.  
 
 Materials and methods 6.2
 Materials 6.2.1
The materials used to manufacture suppository samples used in this chapter have been 
previously described in Sections 2.1 and 3.2. All other chemicals used have been 
described in Sections 3.2 and 4.2.  
 
 Methods 6.2.2
Suppositories were prepared using methods previously described in Section 3.3.1. 
Prepared suppositories were either stored refrigerated (3.5 ± 1.5 °C; RH of 29 ± 3%) 
or kept at room temperature (24.5 ± 2.5 °C; RH 58 ± 5%). The samples were analysed 
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at three time points; freshly prepared, 100 ± 10 days and 200 ± 10 days on storage 
until analysis. 
 
 Physical appearance 6.2.2.1
The samples were inspected in terms of changes in colour, surface texture or presence 
of bloom compared to freshly manufactured suppositories. Changes to the 
suppositories in terms of colour, surface glossiness and smoothness (tactile) after 
storage for 100 and 200 days were evaluated both visually and by touch.  
 
 Thermal profile 6.2.2.2
Thermal analyses of the suppositories were conducted using the DSC system 
mentioned in Section 2.3.1.1.2. The samples were prepared according to methods 
described and heated from -10 ºC to 60 ºC. Thermograms were analysed to: (a) 
determine melting point of the formulations (endothermic peak minimum on 
thermogram); (b) identify presence of new endothermic peaks; and (c) quantify SFC 
of the formulations (continuous integration of the thermogram). 
 
 Hardness 6.2.2.3
Hardness of suppositories was examined using method described in Section 3.3.2.6. 
Measurements were repeated with 6 independent samples (n=6) for each of the 
formulation tested. 
 
 Softening time 6.2.2.4
The softening time of suppositories was determined using method described in 
Section 3.3.2.7. Experiment was carried out in triplicates (n=3) for each formulation. 
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 DcNa release 6.2.2.5
The release of DcNa from aged suppository samples was investigated using method 
described in Section 4.2.1. Drug release studies (n=3) were carried out for 180 
minutes.  
 
 Statistical analysis of data 6.2.2.6
The results from hardness (Section 6.2.2.3) and softening time (Section 6.2.2.4) were 
subjected to analysis of variance (ANOVA) followed by post hoc Tukey’s HSD test 
to detect presence of significant differences between the formulations (freshly 
prepared samples; samples stored refrigerated for 100 and 200 days; and samples 
stored at room temperature for 100 and 200 days). The results from DcNa release 
(Section 6.2.2.5) on the other hand, were analysed via visual comparison of the DcNa 
release curves alongside DE and MDT.  
 
 Results and discussion 6.3
 Physical appearance 6.3.1
The physical appearance of PVP and CMCTS suppositories made using CB, CE and 
SS bases were examined (Table 6.1). There was a general trend of decreasing surface 
glossiness and increasing graininess of the suppositories stored at room temperature 
over a period of 200 days. This effect was more predominant in suppositories 
containing 5 %w/w PVP. Suppositories which were kept refrigerated have less 
detectable physical changes compared to freshly made samples.  
 1
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Table 6.1: The physical appearance of PVP and CMCTS suppositories containing 50 mg DcNa after storage at various conditions up to 200 days. 
Formulations 
Freshly prepared 
100 days 200 days 
Refrigerated Room temp Refrigerated Room temp 
Surface Texture Surface Texture Surface Texture Surface Texture Surface Texture 
CB 
No polymer +++ *** +++ *** ++ ** +++ *** ++ ** 
5%w/w PVP +++ *** +++ *** ++ * +++ *** + * 
5%w/w CMCTS +++ *** +++ *** ++ ** +++ *** + ** 
CE 
No polymer +++ *** +++ *** ++ *** +++ *** + ** 
5%w/w PVP +++ *** +++ *** ++ ** +++ *** + * 
5%w/w CMCTS +++ *** +++ *** ++ *** +++ *** + ** 
SS 
No polymer +++ *** +++ *** ++ *** +++ *** + ** 
5%w/w PVP +++ *** +++ *** ++ ** +++ *** + * 
5%w/w CMCTS +++ *** +++ *** ++ *** +++ *** + ** 
‘+’ denotes glossiness of the suppository surface, with ‘+++’ glossy and ‘+’ dull; while ‘*’ denotes smoothness of the suppository to touch, with 
‘***’ smooth and ‘*’ grainy.           
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 Thermal profile 6.3.2
Due to the natural composition of fats, their polymorphic transitions often involve 
multiple TAG which by themselves exists in an array of polymorphs. Changes in 
properties of fats have been mainly attributed to polymorphic transitions and 
segregation of components within complex lipids. 
 
Figures 6.1(ii-iii) showed that the CB suppositories containing  DcNa and 5 %w/w PVP 
which were kept refrigerated (3.5 ± 1.5 ºC) for up to 200 days did not result in a change 
in melting point (endothermic peak). However, the onset of melting for these 
suppositories shifted to a lower temperature, as demonstrated by the widening of the 
endothermic peak (Figure 6.1, arrow). A similar observation was demonstrated in CB 
suppositories containing DcNa and 5 %w/w CMCTS in Figure 6.2. This a potential 
cause of concern as excessively low onset of melting could result in suppositories 
liquefying during handling prior to insertion into the rectum. 
 
On the other hand, melting point of CB suppositories kept at room temperature 
increased throughout storage (Figures 6.1(iv-v) and Figures 6.2(iv-v)). This increase in 
melting point was observed as early as 100 days of storage at room temperature. The 
melting point was 34.5 and 35.1 ºC for suppositories stored at room temperature for 100 
and 200 days respectively; compared to freshly prepared suppositories which melted at 
32.9 ºC. This was believed to be due to gradual transformation of polymorphic forms 
3B and 4A to the stable 4B (nomenclature as described in Table 2.1), which was a 
commonly observed polymorphic transition in poorly stored chocolates (Lonchampt 
and Hartel, 2004). Increment in melting point of suppositories stored at room 
temperature was reflected as a rightward shift in the SFC curve in Figure 6.3. 
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Figure 6.1 : The DSC thermogram of CB suppositories containing 50 mg DcNa and 5 %w/w PVP. Individual thermograms show the melting 
endotherm of suppositories which were (i) freshly prepared; stored refrigerated at for (ii) 100 days and (iii) 200 days; stored at room 
temperature for (iv) 100 days and (v) 200 days. Inset shows enlarged portions of the thermogram.  
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Figure 6.2 :  The DSC thermogram of CB suppositories containing 50 mg DcNa and 5 %w/w CMCTS. Individual thermograms show the 
melting endotherm of suppositories which were (i) freshly prepared; stored refrigerated at for (ii) 100 days and (iii) 200 days; stored at room 
temperature for (iv) 100 days and (v) 200 days. Inset shows enlarged portions of the thermogram. 
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(a) 
 
(b) 
 
Figure 6.3 : The SFC of CB suppositories containing 50 mg DcNa and (a) 5 %w/w 
PVP and (b) 5 %w/w CMCTS. 
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A faint shoulder at approximately 42 ºC (Figures 6.1-6.2, Section A inset) was 
observed in all freshly prepared, refrigerated and room temperature samples. This is 
likely to be due to the presence of small amounts of the β form of the stearic acid-oleic 
acid-stearic acid (SOS) TAG which were already present in the CB stock used to 
manufacture suppositories. The melting points of CB TAG and their polymorphic 
forms are tabulated in Table 6.2. 
 
Table 6.2 : The melting points of various polymorphic forms of CB TAG. (Fatty acid 
nomenclature under TAG column as follows: P = palmitic acid; O = oleic acid; S = 
stearic acid) 
TAG 
Composition in 
CB (%) 
(Lonchampt and 
Hartel, 2004) 
Melting Points of Polymorphic forms (°C)  
(Arishima et al., 1991; McClements, 1999; Sato, 2001; 
Smith, 2009; Susumu and Konishi, 2011)  
α γ δ 
β’ β 
β2’ β1’ β2 β1 
POS  46.9 19.5  28.3 31.6 35.5 
SOS 29.8 23.5 35.4  36.5 41.0 43.0 
POP  12.6 15.2 27.0 29.2 30.3 33.5 35.1 36.7 
POO 11.0 -4.0  18.2 – 19.0 
SOO 1.8 24 
 
Furthermore, a small endotherm was observed at 50 ºC (Figures 6.1-6.2, Sections B 
and C; insets iv-v). This endotherm is believed to be due to increased fraction of 
saturated TAG as a result of subsequent storage of CB suppositories at room 
temperature. Loisel et al. (1998) observed that lipid segregation occurred in CB during 
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storage at 30 ºC which resulted in crystallisation of a saturated TAG, in addition to the 
usual form V polymorph (Forms 4A and 4B as per nomenclature in Table 2.1). The 
melting point of polymorphic forms observed in various saturated TAG was tabulated 
in Table 6.3.  
 
Table 6.3: The melting points of various polymorphic forms of saturated TAG. 
TAG 
Melting point of polymorphic forms (ºC) 
(Belitz et al., 2009; Da Silva et al., 2009; Sato and Kuroda, 1987) 
α β’ β 
Trilaurin 15.2 34 46.5 
Trimyristin 32.8 45 58.5 
Tripalmitin 44.7 56.5 66.4 
Tristearin 54 65 72.5 
 
Figures 6.4-6.7 showed the thermal profile of 5 %w/w PVP and CMCTS suppositories 
made using HPKS (CE and SS). The progression of thermal changes in both CE and 
SS were similar and findings from Figures 6.4-6.7 will be discussed using CE 
suppositories containing DcNa and 5 %w/w PVP as reference (Figure 6.4).  
 
CE suppositories containing 5 %w/w of PVP (Figure 6.4) which were kept 
refrigerated for 100 and 200 days (melting point= 34.0 ºC on both occasions) did not 
show any significant changes in melting point compared to freshly prepared samples 
(melting point=33.9 ºC). The melting points were similar and there were no additional 
endothermic or exothermic events even up to 200 days of refrigeration (3.5 ± 1.5 °C; 
RH 29 ± 3 %).  
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Figure 6.4 : The DSC thermogram of suppositories made using CE as suppository base containing 5 %w/w PVP. Individual thermograms 
show the melting endotherm of suppositories which were (i) freshly prepared; stored refrigerated at for (ii) 100 days and (iii) 200 days; stored 
at room temperature for (iv) 100 days and (v) 200 days. Inset shows enlarged portions of the thermogram. 
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Figure 6.5 : The DSC thermogram of CE suppositories containing 50 mg DcNa and 5 %w/w CMCTS. Individual thermograms show the 
melting endotherm of suppositories which were (i) freshly prepared; stored refrigerated at for (ii) 100 days and (iii) 200 days; stored at room 
temperature for (iv) 100 days and (v) 200 days. Inset shows enlarged portions of the thermogram. 
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Figure 6.6 : The DSC thermogram of SS suppositories containing 50 mg DcNa and 5 %w/w PVP. Individual thermograms show the melting 
endotherm of suppositories which were (i) freshly prepared; stored refrigerated for (ii) 100 days and (iii) 200 days; stored at room temperature 
for (iv) 100 days and (v) 200 days. Inset shows enlarged portions of the thermogram.  
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Figure 6.7 : The DSC thermogram of SS suppositories containing 50 mg DcNa and 5 %w/w CMCTS. Individual thermograms show the 
melting endotherm of suppositories which were (i) freshly prepared; stored refrigerated for (ii) 100 days and (iii) 200 days; stored at room 
temperature for (iv) 100 days and (v) 200 days. Inset shows enlarged portions of the thermogram. 
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Conversely, an additional peak was observed at 27.3 and 29.4 ºC in suppositories 
stored at room temperature for 100 and 200 days respectively (Figures 6.4(iv-v), 
arrow). These peaks were likely due to separation of lower melting point TAG 
from the complex multicomponent mixture which makes up HPKS. Furthermore, 
another shoulder peak was observed at approximately 38 ºC in suppositories kept 
at room temperature (Figures 6.4(iv-v); Section A). This could be a result of 
gradual β stabilisation of trilaurin (C36) which is present as 26–29 % of HPKS 
content (Chin et al., 2003; Smith et al., 2004; Siew, 2001).  
 
An endothermic event was observed at 50 ºC (Figure 6.4, insets B and C) but at a 
bigger magnitude compared to CB. This is probably due to the melting of 
trisaturated TAG. CB contains approximately 3 % of trisaturated TAG while 
HPKS contains approximately 7 % these high melting trisaturated TAG (Smith et 
al., 2004). The amount of TAG component which melts at 50 ºC in samples stored 
at room temperature increased from 100 days (Figure 6.4, inset B) to 200 days 
(Figure 6.4, inset C) of storage. This was consistent in all the HPKS formulations, 
suggesting that storage at room temperature resulted in an increased formation of 
this TAG species.  
 
The SFC curves of CE and SS suppositories (Figures 6.8-6.9) stored under 
refrigeration and at room temperature were similar up to 35 °C; after which the 
curve for suppositories stored at room temperature shift rightward, indicating the 
presence of TAG with a higher melting point. This was different from CB 
suppositories where the entire SFC curve shifted to a higher temperature (Figure 
6.3).
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(a) 
 
(b) 
 
Figure 6.8 : The SFC of CE suppositories containing 50 mg DcNa and (a) 5 %w/w 
PVP and (b) 5 %w/w CMCTS. 
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(a) 
 
(b) 
 
Figure 6.9 : The SFC of SS suppositories containing 50 mg DcNa and (a) 5 %w/w 
PVP and (b) 5 %w/w CMCTS. 
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 Hardness 6.3.3
Figures 6.10a-c showed changes in hardness of suppositories stored under different 
storage conditions for different durations.  
 
(a) 
 
(b) 
 
(c) 
 
Figure 6.10 : The hardness of suppositories made using (a) CB; (b) CE and (c) SS 
containing 50 mg DcNa and 5 %w/w PVP and 5 %w/w CMCTS after various storage 
conditions up to 200 days. Asterisks indicate a significant difference in hardness from 
‘freshly prepared’ suppositories. Mean ± SD, n=6. 
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Refrigerated suppositories containing 5 %w/w PVP demonstrated statistically 
significant increase in hardness at both 100 and 200 days (p <0.05). In general, 
refrigerated 5 %w/w PVP suppositories were harder than suppositories kept at room 
temperature for the same period.  
 
Meanwhile, suppositories with 5 %w/w CMCTS showed very minimal differences in 
hardness even when stored for 200 days both refrigerated and at room temperature. A 
significant increase in hardness was only observed in CB and SS suppositories 
containing 5 %w/w CMCTS after refrigeration for 200 days. Statistical comparison of 
the formulations using Tukey’s HSD analysis is tabulated in Appendix 36.  
 
Sah and Saini (2008) found that lipophilic indomethacin suppositories made using 
Mayol W45 and Hydrokote AP5 became harder after being subjected to freeze-thaw 
cycles or accelerated stability test at 30 ºC. The current work however, did not find a 
clear trend of changes in hardness of the suppositories containing 5 %w/w of PVP and 
CMCTS against storage time and storage conditions. 
 
 Softening time 6.3.4
Figure 6.11 showed that suppositories stored at room temperature have longer 
softening times. This was consistent for suppositories containing both PVP and 
CMCTS. All the formulations stored at room temperature for 100 and 200 days 
(except SS suppositories containing 5 %w/w PVP at room temperature for 100 days) 
had significantly prolonged softening times compared to freshly prepared 
suppositories.  
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(a) 
 
(b) 
 
(c) 
 
Figure 6.11 : The softening time of suppositories made using (a) CB; (b) CE and (c) 
SS containing 50 mg DcNa and 5 %w/w PVP and 5 %w/w CMCTS under different 
storage conditions. Asterisks indicate a significant difference in softening time 
compared to ‘freshly prepared’ suppositories. Mean ± SD, n=6. 
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With the exception of CB suppositories containing 5 %w/w PVP (Figure 6.11a), all 
other refrigerated formulations have shorter softening times compared to freshly 
prepared samples. This observation however, was only statistically significant in CE 
suppositories containing 5 %w/w PVP and SS suppositories containing 5 %w/w 
CMCTS after refrigeration for 100 days. Statistical comparison of the formulations 
using Tukey’s HSD analysis is tabulated in Appendix 37. 
 
Moes and Jaminet (1976) observed marked increase in liquefaction time of 
suppositories measured at 37 ºC after prolonged storage at 30 ºC. However, the same 
authors also found that increment in liquefaction time may or may not affect rectal 
absorption of drugs. Other factors such as change in viscosity and melting point as a 
result of ageing could have brought about a cumulative synergistic or contradictory 
effect on rectal absorption.  
 
 DcNa release 6.3.5
Both Figures 6.12-6.13 showed that refrigeration of suppositories up to 200 days did 
not alter DcNa release from all the formulations tested, with the exception of CB 
suppositories containing 5 %w/w CMCTS (Figure 6.13a). Refrigerated CB 
suppositories containing 5 %w/w CMCTS showed a slight and gradual decrease in 
rate of DcNa released over time (from freshly prepared to 100 and 200 days). Another 
study reported reduction in ampicillin release from suppositories stored at 4 °C over a 
period of 240 days and the degree of reduction was dependent on type of base used as 
well as the medicament used (Hosny et al., 1990). 
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(a) 
 
(b) 
 
(c) 
 
Figure 6.12: The cumulative DcNa release from (a) CB; (b) CE and (c) SS 
suppositories containing 50 mg DcNa and 5 %w/w PVP under different storage 
conditions and duration. Mean ± 2 SE, n=3. 
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(a) 
 
(b) 
 
(c) 
 
Figure 6.13: The cumulative DcNa release from (a) CB; (b) CE and (c) SS 
suppositories containing 50 mg DcNa and 5 %w/w CMCTS under different storage 
conditions and duration.  Mean ± 2 SE, n=3. 
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Conversely, suppositories stored at room temperature for 100 and 200 days generally 
had lower rates as well as lesser extent of DcNa release at 180 minutes. This 
observation was independent of type of suppository base (CB, CE and SS) and type of 
bioadhesive polymer incorporated (PVP, CMCTS). A study by De Blaey and Rutten-
Kingma (1977) reported a drastic decrease (50-60 %) in aminophylline release from 
CB suppositories as early as 4 weeks storage at 22 °C and 6 days at 30 °C. 
 
The parameters of drug release were numerically presented as the DE and MDT 
values in Tables 6.4-6.5 respectively for easier comparison. Suppositories stored at 
room temperature had significantly lower DE and higher MDT compared to freshly 
prepared samples and the refrigerated samples. Among the suppositories stored at 
room temperature, formulations containing 5 %w/w CMCTS have lower DE and 
longer MDT compared to those containing 5 %w/w PVP. This suggests that 
suppositories containing PVP have better resistance towards accelerated ageing 
conditions although a definite reason for this observation is not known.  
 
The decreased DcNa release could be explained via findings of the DSC thermogram 
and SFC curves in Section 6.3.2. Storage of CB suppositories at room temperature 
resulted in a 2–3 ºC rightward shift of the endothermic peak (higher melting points); 
while a new endothermic shoulder peak was observed at approximately 38 ºC in 
HPKS suppositories. Both these observations lead to an increase in SFC at 37 ºC; thus 
preventing complete melting of the base which in turn hinders DcNa release from the 
base. Suppositories stored at room temperature also had lower initial rates of DcNa 
release, consistent with the longer softening times observed in these samples in 
Section 6.3.4.   
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Table 6.4 : The DE (%) of suppositories made using CB, CE and SS containing 50 mg DcNa and 5 %w/w bioadhesive polymer (PVP, CMCTS). 
Asterisks indicate a significant difference in DE compared to ‘freshly prepared’ suppositories. Mean ± SD, n=3. 
Formulation 
DE (%) 
Freshly prepared 
Refrigerated Room temperature 
Base Polymer 100 days 200 days 100 days 200 days 
CB PVP 90.951 ± 0.641 92.337 ± 0.957 89.299 ± 1.410 88.925 ± 0.642 * 80.546 ± 0.630 * 
CE PVP 85.829 ± 0.665 85.244 ± 1.406 87.656 ± 4.106 51.840 ± 0.651 * 56.099 ± 2.383 * 
SS PVP 86.270 ± 1.382 87.557 ± 0.862 89.823 ± 2.104 * 75.081 ± 1.344 * 79.269 ± 0.421 * 
CB CMCTS 91.673 ± 1.099 91.984 ± 1.861 85.497 ± 1.132 * 82.913 ± 0.774 * 51.139 ± 3.250 * 
CE CMCTS 92.039 ± 1.021 90.238 ± 2.207 90.379 ± 0.134 59.904 ± 4.085 * 36.582 ± 0.697 * 
SS CMCTS 91.638 ± 1.551 93.089 ± 0.236 93.620 ± 0.663 74.913 ± 1.386 * 67.064 ± 1.118 * 
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Table 6.5 : The MDT (minutes) of suppositories made using CB, CE and SS containing 50 mg DcNa and 5 %w/w bioadhesive polymer (PVP, 
CMCTS). Asterisks indicate a significant difference in MDT compared to ‘freshly prepared’ suppositories. Mean ± SD, n=3. 
Formulation 
MDT (min) 
Freshly prepared 
Refrigerated Room temperature 
Base Polymer 100 days 200 days 100 days 200 days 
CB PVP 24.740 ± 2.285 14.199 ± 0.835 * 28.009 ± 3.507 27.639 ± 1.839 39.763 ± 5.428 * 
CE PVP 21.478 ±1.932 18.757 ± 1.437 24.159 ± 0.955 106.426 ± 16.754 * 93.973 ± 7.685 * 
SS PVP 17.531 ± 0.511 17.369 ± 2.012 15.405 ± 2.577 42.026 ± 5.608 * 32.946 ± 3.310 * 
CB CMCTS 20.001 ± 2.660 26.794 ± 3.816 39.124 ± 2.632 * 52.453 ± 2.684 * 112.75 ± 6.897 * 
CE CMCTS 24.616 ± 3.082 27.098 ± 2.320 25.317 ± 0.424 86.192 ± 4.466 * 92.735 ± 8.642 * 
SS CMCTS 18.082 ± 3.263 16.896 ± 1.398 19.175 ± 1.055 52.315 ± 6.651 * 75.695 ± 15.255 * 
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 Conclusion 6.4
In general, suppositories which were stored at room temperature for up to 200 days 
(accelerated ageing conditions) resulted in: (1) compromised aesthetic values in terms 
of loss of glossiness and increasing graininess; (2) increased melting point; (3) 
possible TAG separation suggested by the presence of new endothermic peaks; (4) 
higher solid fat content at 37 °C; (5) prolonged softening times; and (6) decreased rate 
and amount of DcNa release. Such changes to the tested formulations were 
unfavourable and could potentially lead to treatment failure in patients. Based on 
stability studies conducted in this chapter, the suppositories tested were better suited 
for storage in the refrigerator rather than at room temperature. There were no 
conclusive finding of superior stability at room temperature among HPKS and CB 
formulations tested as both exhibited notable changes in terms of thermal profiles and 
drug release after subjection to the accelerated ageing process. However, SS 
suppositories appear to release DcNa more efficiently than CE suppositories after 
being exposed to the same accelerated ageing process.   
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CHAPTER 7         
GENERAL CONCLUSION AND 
FUTURE WORK 
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 General conclusion 7.1
There has been substantial interest in utilising alternative fat sources as suppository 
bases due to the occurrence of up to six polymorphic forms in CB, one of the oldest 
lipophilic bases used in manufacturing of suppositories (Loisel et al., 1998; 
Marangoni and McGauley, 2003). The presence of various polymorphic forms and 
rigid processing requirements were a hindrance to stability and storage as well as 
industrial scale up. The HPKS, which have long been used in the chocolate and 
confectionary industry as CB substitutes in the coating of candies, caramel 
centrefilling and manufacturing of chocolate bars were evaluated as a potential 
alternative to CB for the manufacturing of suppositories. 
 
The model drug DcNa, a nonsteroidal anti-inflammatory drug (NSAID) has been 
marketed for well over 30 years as oral tablets, suppositories, injectables and topical 
creams. Although not as popular as oral administration, suppositories may prove 
valuable in conditions where patients are unable to swallow their medication or are 
inaccessible to a qualified caregiver for parenteral administration. In fact, a recent 
study by van der Marel et al. (2004) found that DcNa suppositories administered in 
children undergoing tonsilectomy had higher relative bioavailability and needed a 
shorter time to achieve maximum plasma concentration compared to oral enteric 
coated tablets of equivalent doses. 
 
This drug however, has been reported to undergo substantial first pass metabolism, 
resulting in oral bioavailability of approximately 55 % (Willis et al., 1979). Drugs 
administered rectally may avoid the presystemic circulation if absorbed in the lower 
rectum which drains into the inferior and middle hemorrhoidal veins flowing directly 
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into the systemic circulation, bypassing presystemic metabolism pathways (Allen et 
al., 2008; Kokate et al., 2006).  
 
Therefore, this research sought to (1) evaluate HPKS as an alternative lipophilic base 
and (2) characterise DcNa bioadhesive suppositories produced by incorporation of 
bioadhesive polymers (CBP, PVP, HPMC, CMCTS) to produce suppositories which 
preferentially be retained at the lower rectum, thus bypassing presystemic metabolism 
pathways.  
 
The two HPKS used in this study (CE and SS) were found to be suitable lipophilic 
suppository bases. They were comparable to CB in terms of thermal profile, SFC, pH, 
viscosity and DV but with added benefits of lesser polymorphic forms and less rigid 
manufacturing requirements. This study concluded that to manufacture CB 
suppositories extemporaneously, the molten base should be maintained between 34 ± 
0.5 °C during heating and allowed to cool slowly to between 20–24 °C to produce 
suppositories with the desirable form 4A polymorph. Molten CB should not be placed 
into a refrigerator before solidification is complete as it will result in rapid 
crystallisation into the form 2 polymorph. These rigid processing restrictions however, 
were not relevant in HPKS. The HPKS allowed more manufacturing flexibility 
compared to CB. 
 
Furthermore, the finished products (HPKS bioadhesive suppositories) were deemed 
suitable for rectal administration as melting points were within the range of 32.5-
35.5 °C. The addition of bioadhesive polymers did not significantly alter melting 
point (less than ±1 °C) of the suppositories and all formulations tested contained 
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>95 % of the stipulated DcNa content. Softening times recorded for all the 
formulations were between 3–7 minutes which were acceptable for rectal drug release. 
Viscosity of the molten suppositories were enhanced with increasing amount of 
bioadhesive polymers (CBP, PVP, HPMC, CMCTS) incorporated into the 
formulation and this may be beneficial for retention of suppositories within the lower 
rectum by limiting its spread.  
 
Apart from physical evaluation, the HPKS bases appeared to be comparable to CB in 
terms of drug release capacity and could be good lipophilic base candidates for fast-
acting DcNa suppository formulations. Mathematical modelling of the data found that 
DcNa release in suppositories without polymer was via non-Fickian diffusion kinetics 
(Korsmeyer-Peppas model). Addition of 1-5 %w/w HPMC, PVP and CMCTS to the 
suppositories did not alter the mechanism of DcNa release, and these were decent 
candidates of polymers for development of bioadhesive suppositories. However, 
formulations added with 1-5 %w/w CBP significantly suppressed DcNa release 
compared to their respective blanks (DcNa only suppositories). The addition of CBP 
lead to considerable change in morphology of molten suppository during dissolution 
via gelling, resulting in a biphasic DcNa release process involving a rapid initial 
diffusion and erosion process followed by a slow diffusion process across the CBP gel 
layer. Furthermore, as CBP gels in the dissolution medium, it decreases the 
environment pH which lowers DcNa solubility, thus further retarding the release of 
DcNa from the suppositories.  
 
Evaluation of bioadhesive properties of suppository formulations using the two 
fabricated in vitro methods in current research found that formulations containing 
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PVP exhibited superior bioadhesion compared to the other polymers when subjected 
to both the tensile and shear forces of detachment. This finding was promising for the 
development of bioadhesive suppositories. CBP displayed good bioadhesive 
properties only via tensile stress measurement while CMCTS showed appreciable 
shear stress of bioadhesion. Conversely, HPMC exhibited poor bioadhesivity in both 
tests and has limited role in the development of bioadhesive suppositories. Although 
both methods used were temperature controlled to simulate in vivo conditions, 
evaluation of shear stress of bioadhesion is more likely to reflect actual attachment 
and detachment of a suppository in the human rectum. Meanwhile, colon mucosa and 
regenerated cellulose membranes were also found to be good substitutes for rectal 
membranes in qualitative evaluation of bioadhesion in suppositories.  
 
Only suppositories (CB, CE and SS) containing 5 %w/w PVP and 5 %w/w CMCTS 
were subjected to stability assessment, while suppositories containing 1-5 %w/w of 
CBP and 1-5 %w/w HPMC were omitted from further development due to their 
limited benefit in the formulation of bioadhesive suppositories. The concentration 
dependent suppression of DcNa release from CBP suppositories indicate that CBP 
should only be used at the lowest possible concentration but lower concentrations of 
CBP (1 %w/w) exhibited poor bioadhesive properties. HPMC suppositories on the 
other hand demonstrated poor bioadhesive properties at all concentrations tested (1-
5 %w/w).  
 
In general, suppositories stored at room temperature for up to 200 days (accelerated 
ageing conditions) resulted in: (1) compromised aesthetic values in terms of loss of 
glossiness and increasing graininess; (2) increase in melting point; (3) possible TAG 
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separation suggested by the presence of new endothermic peaks; (4) higher SFC at 
37 °C; (5) prolonged softening times; and (6) decreased rate and amount of DcNa 
release. Such changes to the tested formulations were unfavourable and could 
potential lead to treatment failure in patients. Based on the stability studies conducted 
in this study, the suppositories tested were better suited for storage in refrigerator 
rather than at room temperature. There were no conclusive findings of formulations 
with superior stability at room temperature among the HPKS and CB formulations 
tested as both exhibited notable changes in terms of thermal profiles and drug release 
after subjection to the accelerated aging process. However, SS suppositories appeared 
to release DcNa more efficiently than CE suppositories after being exposed to the 
same accelerated ageing process.  
 
Among all the formulations developed and tested, SS suppositories containing 
5 %w/w PVP appeared to be the most suitable candidate for future development of 
bioadhesive DcNa suppositories because (1) it has less rigid manufacturing 
requirements compared to CB; (2) melts rapidly at human body temperature; (3) did 
not cause retardation of DcNa release and (4) exhibits good bioadhesive properties. 
However, additional work is required for in vivo studies to evaluate the retention 
capacity of the suppositories within the lower rectum as well as the actual 
bioavailability of these bioadhesive suppositories.  
 
 Future work 7.2
The work described in this thesis has been concerned with characterisation of two 
HPKS as an alternative suppository base to CB, as well as to develop bioadhesive 
suppositories by incorporating bioadhesive polymers into the two HPKS bases. A 
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number of problems and challenges were encountered during the course of this work 
which suggests research directions to be pursued for further development of a 
bioadhesive suppository system.  
 
 Evaluation of bioadhesive suppository migration in the rectum 7.2.1
The bulk of this work has been focused on the development of methods to study 
bioadhesion as well as evaluation of bioadhesive properties of suppository 
formulations. However, further studies should be designed to investigate the 
migration and disposition of these bioadhesive suppositories in the rectum compared 
to conventional suppositories. One of the methods would be to administer 
suppositories stained with brilliant blue to fasted Wistar rats. The rat rectums were 
then excised and length of the coloured regions reflected distance travelled by 
suppositories (Yahagi et al., 1999). An alternative method which avoids sacrificial of 
test subjects is by using gamma-scintigraphy. Administration of suppositories 
radiolabelled with technetium hydroxymethyldiphosphonate (
99m 
Tc) into volunteers 
would allow continuous observation of suppository migration along the human rectum 
via external scintigraphy (Jay et al., 1985; Sugito et al., 1988). 
 
 Incorporation of DcNa-polymer granules 7.2.2
Incorporation of bioadhesive polymers in this study has been via a direct solid 
dispersion in the semi-solid base. This was done to increase viscosity as well as to 
adhere the base matrix to the lower rectum. An alternative for further investigation 
would be to prepare bioadhesive granules containing drug and bioadhesive polymer 
(PVP and CMCTS) for incorporation into the base. These bioadhesive granules can be 
prepared using wet granulation methods similar to that in manufacturing of tablets 
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(Attama et al., 2000). This approach could improve adhesion of DcNa to the rectal 
mucosa by concentrating the polymers around the DcNa granules 
 
 Introduction of synthetic cellulose membrane as alternative to 7.2.3
biological membranes 
Current work has found that synthetic cellulose membranes were well correlated to 
porcine colon and rectum membranes and could be a possible alternative to biological 
membranes using the newly devised experimental setup for measurement of the shear 
forces of bioadhesion. Further investigations should be conducted using other 
biological and synthetic membranes to evaluate and validate this proposed correlation 
between biological and synthetic membranes at different experimental parameters.  
 
 In vivo bioavailability studies 7.2.4
This work has evaluated in vitro release of DcNa from the suppositories 
comprehensively; however, further in vivo evaluation using animal models or human 
test subjects would provide a better depiction of the systemic bioavailability of DcNa 
from bioadhesive suppositories. The pharmacokinetics and metabolism of DcNa in 
Yucatan miniature pigs (Oberle et al., 1994) and rats (Reiss et al., 1978) were similar 
to man. While avoidance of first pass metabolism via the rectal route was 
demonstrated in rabbits (Kurosawa et al., 1998) and rats (De Leede et al., 1983), 
where bioavailability of drugs increased as the site of absorption was closer to the 
anus. These observations were similar to that observed in man. Therefore, rats would 
be a reasonable model for in vivo studies. Aoyagi et al. (1988) studied bioavailability 
of indomethacin suppository in rabbits and pigs by administering the suppository to 
the fasted test subjects and plasma samples were withdrawn for analysis at specific 
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intervals. Comparison of DcNa bioavailability between bioadhesive and conventional 
suppositories would provide an indication of effectiveness in avoidance of first pass 
metabolism provided by the addition of bioadhesive polymers. 
 
There is clearly much work to be done in the development of a bioadhesive 
suppository system. Perhaps, the most direct extension to this work is the evaluation 
of bioadhesive suppository migration in the rectum post administration. Comparison 
of shortlisted formulations from this work against conventional suppositories would 
elucidate feasibility and practicality of a bioadhesive suppository.  
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Appendix 1: Certificate of analysis of cocoa butter (CB). 
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Appendix 2 : Certificate of analysis for Chocexa (CE). 
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Appendix 3 : Certificate of analysis for Supersocolate Special
TM
 (SS). 
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Appendix 4 : Certificate of analysis for diclofenac sodium (DcNa). 
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Appendix 5 : Certificate of analysis for Carbopol 974P NF (CBP). 
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Appendix 6 : Certificate of analysis of hydroxypropyl methylcellulose 2910 (HPMC). 
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Appendix 7 : Certificate of analysis for carboxymethyl chitosan (CMCTS). 
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Appendix 8 : The viscosity (cp) of CB suppositories measured at 50 rpm shear rate. Outcomes were a result of ANOVA and post hoc Tukey’s 
HSD analysis.  Mean ± SD, n=3. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
Blank (A) 54.6 ± 4.14 54.6 ± 4.14 54.6 ± 4.14 54.6 ± 4.14 
DcNa only (B) 82.8 ± 1.29 82.8 ± 1.29 82.8 ± 1.29 82.8 ± 1.29 
1 %w/w polymer (C) 78.43 ± 0.95 90.03 ± 2.95 84.83 ± 2.53 94.23 ± 2.58 
2 %w/w polymer (D) 76.03 ± 0.76 104.8 ± 3.33 92.30 ± 0.40 98.73 ± 4.65 
5 %w/w polymer (E) 87.87 ± 6.27 122.3 ± 1.06 97.67 ± 2.27 106.6 ± 0.92 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 9 : The viscosity (cp) of CE suppositories measured at 50 rpm shear rate. Outcomes were a result of ANOVA and post hoc Tukey’s 
HSD analysis.  Mean ± SD, n=3. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
Blank (A) 53.43 ± 4.74 53.43 ± 4.74 53.43 ± 4.74 53.43 ± 4.74 
DcNa only (B) 42.00 ± 0.96 42.00 ± 0.96 42.00 ± 0.96 42.00 ± 0.96 
1 %w/w polymer (C) 68.10 ± 2.08 46.20 ± 1.79 43.70 ± 2.02 41.70 ± 1.87 
2 %w/w polymer (D) 79.33 ± 1.15 56.10 ± 1.06  44.17 ± 1.27 49.93 ± 2.12 
5 %w/w polymer (E) 102.60 ± 6.52 67.77 ± 3.10 56.40 ± 4.06 52.47 ± 5.24 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 10 : The viscosity (cp) of SS suppositories measured at 50 rpm shear rate. Outcomes were a result of ANOVA and post hoc Tukey’s 
HSD analysis.  Mean ± SD, n=3. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
Blank (A) 49.03 ± 1.46 49.03 ± 1.46 49.03 ± 1.46 49.03 ± 1.46 
DcNa only (B) 37.73 ± 1.06 37.73 ± 1.06 37.73 ± 1.06 37.73 ± 1.06 
1 %w/w polymer (C) 44.33 ± 1.89 41.40 ± 0.53 39.00 ± 1.52 40.73 ± 0.45 
2 %w/w polymer (D) 55.87 ± 1.70 48.83 ± 0.80 44.93 ± 1.00 41.30 ± 0.91 
5 %w/w polymer (E) 81.8 ± 4.78 67.77 ± 3.10 56.50 ± 2.23 46.15 ± 1.91 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 11 : The hardness (N) of CB suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis. Mean ± SD, n=6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
Blank (A) 59.00 ± 2.97 59.00 ± 2.97 59.00 ± 2.97 59.00 ± 2.97 
DcNa only (B) 73.33 ± 2.07 73.33 ± 2.07 73.33 ± 2.07 73.33 ± 2.07 
1 %w/w polymer (C) 100.67 ± 4.27 101.00 ± 4.56 89.00 ± 1.90 121.50 ± 2.43 
2 %w/w polymer (D) 91.67 ± 5.28 92.50 ± 1.76 103.00 ± 1.41 116.67 ± 2.16 
5 %w/w polymer (E) 100.67 ± 3.01 80.83 ± 4.36 99.83 ± 1.47  131.17 ± 2.32 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 12 : The hardness (N) of CE suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis. Mean ± SD, n=6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
Blank (A) 82.33 ± 5.20 82.33 ± 5.20 82.33 ± 5.20 82.33 ± 5.20 
DcNa only (B) 88.33 ± 2.34 88.33 ± 2.34 88.33 ± 2.34 88.33 ± 2.34 
1 %w/w polymer (C) 89.00 ± 3.41 2.64 ± 2.64 99.33 ± 5.09 104.83 ± 7.57 
2 %w/w polymer (D) 84.17 ± 5.85 83.83 ± 4.17 94.17± 2.79 122.00 ± 6.99 
5 %w/w polymer (E) 103.50 ± 2.35 87.83 ± 4.22 91.33 ± 3.93 106.67 ± 8.09 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 13 : The hardness (N) of SS suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis. Mean ± SD, n=6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
Blank (A) 55.83 ± 1.60 55.83 ± 1.60 55.83 ± 1.60 55.83 ± 1.60 
DcNa only (B) 70.17 ± 1.72 70.17 ± 1.72  70.17 ± 1.72 70.17 ± 1.72 
1 %w/w polymer (C) 103.50 ± 2.88 83.00 ± 4.20 91.17 ± 2.48 100.00 ± 5.18 
2 %w/w polymer (D) 98.33 ± 4.50 70.33 ± 5.85 96.00 ± 1.55  102.50 ± 5.32 
5 %w/w polymer (E) 74.67 ± 4.97 69.83 ± 2.76 90.50 ± 1.87 101.50 ± 5.65 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 14 : The softening time (min) of CB suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis. Mean ± 
SD, n=3. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
Blank (A) 3.03 ± 0.01 3.03 ± 0.01 3.03 ± 0.01 3.03 ± 0.01 
DcNa only (B) 3.79 ± 0.11 3.79 ± 0.11 3.79 ± 0.11 3.79 ± 0.11 
1 %w/w polymer (C) 4.06 ± 0.03 3.82 ± 0.126 3.83 ± 0.106 3.68 ± 0.202 
2 %w/w polymer (D) 3.68 ± 0.09 4.08 ± 0.051 4.26 ± 0.025 3.77 ± 0.035  
5 %w/w polymer (E) 4.16 ± 0.04 4.31 ± 0.054 4.03 ± 0.017 4.20 ± 0.033 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 15 : The softening time (min) of CE suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis. Mean ± 
SD, n=3. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
Blank (A) 6.16 ± 0.17 6.16 ± 0.17 6.16 ± 0.17 6.16 ± 0.17 
DcNa only (B) 4.36 ± 0.07 4.36 ± 0.07 4.36 ± 0.07 4.36 ± 0.07 
1 %w/w polymer (C) 4.60 ± 0.09 4.79 ± 0.03 4.66 ± 0.06 4.92 ± 0.09 
2 %w/w polymer (D) 5.68 ± 0.09 5.07 ± 0.04 5.07 ± 0.05 4.99 ± 0.13 
5 %w/w polymer (E) 5.34 ± 0.08 6.84 ± 0.08 5.58 ± 0.08 4.92 ± 0.08 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 16 : The softening time (min) of SS suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis. Mean ± 
SD, n=3. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
Blank (A) 5.66 ± 0.10 5.66 ± 0.10 5.66 ± 0.10 5.66 ± 0.10 
DcNa only (B) 4.36 ± 0.13 4.36 ± 0.13 4.36 ± 0.13 4.36 ± 0.13 
1 %w/w polymer (C) 4.48 ± 0.13 4.81 ± 0.08 4.56 ± 0.06 4.93 ± 0.03 
2 %w/w polymer (D) 4.72 ± 0.05  5.16 ± 0.05 4.76 ± 0.04 4.76 ± 0.09 
5 %w/w polymer (E) 5.43 ± 0.04 6.14 ± 0.04 5.13 ± 0.04 5.29 ± 0.04 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 17: Amount of DcNa (mg) released at each time interval in (a) CB; (b) CE; 
and (c) SS suppositories containing 25, 50, 75 mg of DcNa. Mean ± 2 SE, n=6. 
 
     
0
5
10
15
20
25
30
0 60 120 180 240A
m
o
u
n
t 
o
f 
D
cN
a 
re
le
as
e
 (
m
g)
 
Time (min) 
25 mg
50 mg
75 mg
0
5
10
15
20
25
30
0 60 120 180 240A
m
o
u
n
t 
o
f 
D
cN
a 
re
le
as
e
 (
m
g)
 
Time (min) 
25 mg
50 mg
75 mg
0
5
10
15
20
25
30
0 60 120 180 240A
m
o
u
n
t 
o
f 
D
cN
a 
re
le
as
e
 (
m
g)
 
Time (min) 
25 mg
50 mg
75 mg
242 
 
a) 
 
b) 
 
c) 
 
Appendix 18: Cumulative percentage DcNa release in a) CB; b) CE; c) SS 
suppositories incorporated with 1-5 %w/w of CBP. Mean ± 2 SE, n=6. 
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Appendix 19 : Cumulative percentage of DcNa release in a) CB; b) CE; c) SS 
suppositories incorporated with 1-5 %w/w of HPMC. Mean ± 2 SE, n= 6. 
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Appendix 20 : Cumulative percentage of DcNa release in a) CB; b) CE; c) SS 
suppositories incorporated with 1-5%w/w PVP. Mean ± 2 SE, n=6. 
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Appendix 21 : Cumulative percentage of DcNa release in a) CB; b) CE; c) SS 
suppositories incorporated with 1-5%w/w CMCTS. Mean ± 2 SE, n=6. 
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Appendix 22 : The dissolution efficiency (DE) of CB suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis.  
Mean ± SD, n=6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
0 %w/w polymer (A) 93.79 ± 1.52 93.79 ± 1.52 93.79 ± 1.52 93.79 ± 1.52 
1 %w/w polymer (B) 59.65 ± 1.74 94.27 ± 1.18 92.56 ± 0.76 89.52 ± 0.95 
2 %w/w polymer (C) 51.78 ± 1.34 92.87 ± 0.88 88.83 ± 1.22 90.97 ± 2.19 
5 %w/w polymer (D) 36.80 ± 1.14 92.68 ± 0.83 90.95 ± 0.64 91.67 ± 1.10 
ANOVA P < 0.05 P > 0.05 (0.078) P < 0.05 P < 0.05 
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Appendix 23 : The dissolution efficiency (DE) of CE suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis.  
Mean ± SD, n=6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
0 %w/w polymer (A) 88.73 ± 2.12 88.73 ± 2.12 88.73 ± 2.12 88.73 ± 2.12 
1 %w/w polymer (B) 58.47 ± 1.56 83.55 ± 2.32 86.55 ± 0.60 87.62 ± 0.65 
2 %w/w polymer (C) 33.20 ± 1.81 87.58 ± 1.03 87.91 ± 0.51 91.74 ± 1.14 
5 %w/w polymer (D) 22.59 ± 1.37 85.52 ± 0.64  85.83 ± 0.67 92.04 ± 1.02 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 24 : The dissolution efficiency (DE) of SS suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis.  
Mean ± SD, n=6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
0 %w/w polymer (A) 91.93 ± 1.04 91.93 ± 1.04 91.93 ± 1.04 91.93 ± 1.04 
1 %w/w polymer (B) 59.29 ± 1.71 90.76 ± 0.37 88.13 ± 0.37 92.04 ± 1.02 
2 %w/w polymer (C) 29.91 ± 1.91  90.78 ± 1.17 87.62 ± 0.67 91.60 ± 0.95 
5 %w/w polymer (D) 16.49 ± 2.56 89.70 ± 0.53 86.27 ± 1.38 91.64 ± 1.55 
ANOVA P < 0.05 P < 0.05  P < 0.05 P > 0.05 (0.892) 
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Appendix 25 : The min dissolution time (MDT) of CB suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis.  
Mean ± SD, n=6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
0 %w/w polymer (A) 14.73 ± 2.47 14.73 ± 2.47 14.73 ± 2.47 14.73 ± 2.47 
1 %w/w polymer (B) 60.72 ± 2.09 19.04 ± 2.28 18.21 ± 1.60 18.89 ± 0.98 
2 %w/w polymer (C) 69.24 ± 2.09 24.08 ± 1.78 27.98 ± 3.85 18.47 ± 2.14 
5 %w/w polymer (D) 114.03 ± 4.42 26.25 ± 2.80 24.74 ± 2.28 20.03 ± 2.66 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 26 : The min dissolution time (MDT) of CE suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis.  
Mean ± SD, n=6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
0 %w/w polymer (A) 26.44 ± 3.32 26.44 ± 3.32 26.44 ± 3.32 26.44 ± 3.32 
1 %w/w polymer (B) 36.36 ± 1.73 26.07 ± 2.12 23.17 ± 1.28 20.81 ± 1.91 
2 %w/w polymer (C) 43.04 ± 3.13 19.85 ± 1.48 19.01 ± 1.08 17.34 ± 1.91 
5 %w/w polymer (D) 74.15 ± 6.14 25.04 ± 0.95 21.48 ± 1.93 24.62 ± 3.08 
ANOVA P < 0.05 P < 0.05  P < 0.05 P < 0.05 
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Appendix 27 : The min dissolution time (MDT) of SS suppositories. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis.  
Mean ± SD, n=6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
0 %w/w polymer (A) 15.60 ± 1.07 15.60 ± 1.07 15.60 ± 1.07 15.60 ± 1.07 
1 %w/w polymer (B) 30.63 ± 2.89 16.77 ± 0.50 18.49 ± 0.19 14.82 ± 3.00 
2 %w/w polymer (C) 42.18 ± 7.35 17.15 ± 0.81 17.03 ± 1.28 17.43 ± 2.44 
5 %w/w polymer (D) 83.01 ± 10.39 17.92 ± 0.52 17.53 ± 0.51 18.08 ± 3.26 
ANOVA P < 0.05 P < 0.05  P < 0.05 P > 0.05 (0.134) 
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Appendix 28 : The peak force of detachment (Fmax) of CB suppositories measured using tensile setup against colon mucosa. Outcomes were a 
result of ANOVA and post hoc Tukey’s HSD analysis.  Mean ± SD,  n=5-6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
DcNa only (A) 2.17 ± 0.43 2.17 ± 0.43  2.17 ± 0.43 2.17 ± 0.43 
1 %w/w polymer (B) 2.48 ± 0.43  2.19 ± 0.47  2.74 ± 0.55  2.51 ± 0.32  
2 %w/w polymer (C) 3.04 ± 0.46  2.65 ± 0.40  3.07 ± 0.48  2.93 ± 0.44  
5 %w/w polymer (D) 4.17 ± 0.74  2.74 ± 0.70  3.89 ± 0.38  3.52 ± 0.47  
ANOVA P < 0.05 P > 0.05 (0.40) P < 0.05 P < 0.05 
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Appendix 29 : The peak force of detachment (Fmax) of CE suppositories measured using tensile setup against colon mucosa. Outcomes were a 
result of ANOVA and post hoc Tukey’s HSD analysis.  Mean ± SD, n=5-6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
DcNa only (A) 2.12 ± 0.30 2.12 ± 0.30 2.12 ± 0.30 2.12 ± 0.30 
1 %w/w polymer (B) 3.28 ± 0.41 2.18 ± 0.46 2.81 ± 0.54 3.00 ± 0.40 
2 %w/w polymer (C) 3.08 ± 0.40 2.39 ± 0.30 3.22 ± 0.91 2.70 ± 0.49 
5 %w/w polymer (D) 4.20 ± 0.73 2.68 ± 0.62 4.27 ± 0.83 3.78 ± 0.70 
ANOVA P < 0.05 P > 0.05 (0.18) P < 0.05 P < 0.05 
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Appendix 30 : The peak force of detachment (Fmax) of SS suppositories measured using tensile setup against colon mucosa. Outcomes were a 
result of ANOVA and post hoc Tukey’s HSD analysis.  Mean ± SD, n=5-6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
DcNa only (A) 1.82 ± 0.13 1.82 ± 0.13 1.82 ± 0.13 1.82 ± 0.13 
1 %w/w polymer (B) 2.68 ± 0.51 1.90 ± 0.49 2.91 ± 0.64 2.24 ± 0.25 
2 %w/w polymer (C) 3.80 ± 0.17 2.27 ± 0.50 3.53 ± 0.45 2.79 ± 0.33 
5 %w/w polymer (D) 4.57 ± 0.29 2.86 ± 0.50 4.94 ± 0.65 3.56 ± 0.22 
ANOVA P < 0.05 P > 0.05 (0.07) P < 0.05 P < 0.05 
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Appendix 31 : The peak force of detachment (Fmax) of CB suppositories measured using shear setup against colon mucosa. Outcomes were a 
result of ANOVA and post hoc Tukey’s HSD analysis.  Mean ± SD, n=5-6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
DcNa only (A) 0.33 ± 0.04 0.33 ± 0.04 0.33 ± 0.04 0.33 ± 0.04 
1 %w/w polymer (B) 0.37 ± 0.02 0.43 ± 0.07 0.51 ± 0.03 0.57 ± 0.02 
2 %w/w polymer (C) 0.41 ± 0.07 0.55 ± 0.03 0.55 ± 0.06 0.58 ± 0.03 
5 %w/w polymer (D) 0.57 ± 0.05 0.63 ± 0.05 0.85 ± 0.01 0.71 ± 0.02 
ANOVA P < 0.05 P < 0.05 P < 0.05 P < 0.05 
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Appendix 32 : The peak force of detachment (Fmax) of CE suppositories measured using shear setup against colon mucosa. Outcomes were a 
result of ANOVA and post hoc Tukey’s HSD analysis.  Mean ± SD, n=5-6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
DcNa only (A) 0.46 ± 0.02 0.46 ± 0.02 0.46 ± 0.02 0.46 ± 0.02 
1 %w/w polymer (B) 0.49 ± 0.04 0.56 ± 0.05 0.52 ± 0.05 0.56 ± 0.04 
2 %w/w polymer (C) 0.49 ± 0.01 0.56 ± 0.01 0.69 ± 0.06 0.63 ± 0.02 
5 %w/w polymer (D) 0.53 ± 0.04 0.56 ± 0.03 0.81 ± 0.07 0.65 ± 0.02 
ANOVA P < 0.05 P < 0.05 P < 0.05 P < 0.05 
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Appendix 33 : The peak force of detachment (Fmax) of SS suppositories measured using shear setup against colon mucosa. Outcomes were a 
result of ANOVA and post hoc Tukey’s HSD analysis.  Mean ± SD, n=5-6. 
 FORMULATION 
 CBP HPMC PVP CMCTS 
DcNa only (A) 0.41 ± 0.03 0.41 ± 0.03 0.41 ± 0.03 0.41 ± 0.03 
1 %w/w polymer (B) 0.40 ± 0.05 0.46 ± 0.04 0.45 ± 0.07 0.48 ± 0.05 
2 %w/w polymer (C) 0.49 ± 0.05 0.49 ± 0.04 0.65 ± 0.04 0.53 ± 0.04 
5 %w/w polymer (D) 0.59 ± 0.03 0.55 ± 0.04 0.78 ± 0.05 0.61 ± 0.04 
ANOVA P < 0.05 P < 0.05 P < 0.05 P < 0.05 
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Appendix 34 : The peak force of detachment (Fmax) of SS suppositories measured using tensile setup against colon mucosa and synthetic 
regenerated cellulose. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis.  Mean ± SD, n=5-6. 
 FORMULATION 
 Colon mucosa Synthetic membrane 
 CBP HPMC PVP CMCTS CBP HPMC PVP CMCTS 
DcNa only (A) 1.82 ± 0.13 1.82 ± 0.13 1.82 ± 0.13 1.82 ± 0.13 9.89 ± 0.86 9.89 ± 0.86 9.89 ± 0.86 9.89 ± 0.86 
2 %w/w polymer (B) 3.80 ± 0.17 2.27 ± 0.50 3.53 ± 0.45 2.79 ± 0.33 12.00 ± 1.19 11.92 ± 0.85 13.13 ± 1.41 12.98 ± 0.73 
5 %w/w polymer (C) 4.57 ± 0.29 2.86 ± 0.50 4.94 ± 0.65 3.56 ± 0.22 13.71 ± 0.48 12.60 ± 1.27 14.60 ± 0.48 13.69 ± 0.42 
ANOVA P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 
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Appendix 35 : The peak force of detachment (Fmax) of SS suppositories measured using shear setup against colon mucosa and synthetic 
regenerated cellulose. Outcomes were a result of ANOVA and post hoc Tukey’s HSD analysis.  Mean ± SD, n=5-6. 
 FORMULATION 
 Colon mucosa Synthetic membrane 
 CBP HPMC PVP CMCTS CBP HPMC PVP CMCTS 
DcNa only (A) 0.41 ± 0.03 0.41 ± 0.03 0.41 ± 0.03 0.41 ± 0.03 0.40 ± 0.07 0.40 ± 0.07 0.40 ± 0.07 0.40 ± 0.07 
2 %w/w polymer (B) 0.49 ± 0.05 0.49 ± 0.04 0.65 ± 0.04 0.53 ± 0.04 0.47 ± 0.06 0.47 ± 0.04 0.54 ± 0.05 0.53 ± 0.02 
5 %w/w polymer (C) 0.59 ± 0.03 0.55 ± 0.04 0.78 ± 0.05 0.61 ± 0.04 0.53 ± 0.04 0.53 ± 0.05 0.70 ± 0.07 0.62 ± 0.07 
ANOVA P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 
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Appendix 36 : Hardness values (N) of suppositories subjected to various storage condition and duration. Outcomes were a result of ANOVA and 
post hoc Tukey’s HSD analysis.  Mean ± SD, n=6. 
 FORMULATION 
 
CB + DcNa + 
5 % PVP 
CB + DcNa + 
5 % CMCTS 
CE + DcNa + 
5 % PVP 
CE + DcNa + 
5 % CMCTS 
SS + DcNa + 
5 % PVP 
SS + DcNa + 
5 % CMCTS 
Fresh samples (A) 99.83 ± 2.32 131.17 ± 2.32 91.33 ± 3.94 106.67 ± 8.09 91.33 ± 3.93 106.67 ± 8.09 
Refrigerated for 100 
days (B) 
133.83 ± 5.64 114.50 ± 2.80 118.67 ± 5.05 106.50 ± 4.09 108.67 ± 5.05 106.50 ± 4.09 
Refrigerated for 200 
days (C) 
128.33 ± 3.51 138.33 ± 5.32 127.67 ± 4.27 116.67 ± 8.71 100.83 ± 8.35 114.17 ± 2.93 
Room temperature 
for 100 days (D) 
116.17 ± 1.60 127.67 ± 4.27 98.17 ± 6.55 111.17 ± 7.83 82.83 ± 6.05 111.17 ± 7.83 
Room temperature 
for 200 days (E) 
123.50 ± 5.05 131.17 ± 3.87 112.67 ± 6.44 102.83 ± 7.78 86.83 ± 5.23 106.17 ± 2.79 
ANOVA P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 
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Appendix 37 : Softening time (min) of suppositories subjected to various storage condition and duration. Outcomes were a result of ANOVA 
and post hoc Tukey’s HSD analysis.  Mean ± SD, n=3. 
 FORMULATION 
 
CB + DcNa + 
5 % PVP 
CB + DcNa + 
5 % CMCTS 
CE + DcNa + 
5 % PVP 
CE + DcNa + 
5 % CMCTS 
SS + DcNa + 
5 % PVP 
SS + DcNa + 
5 % CMCTS 
Fresh samples (A) 4.03 ± 0.02 4.20 ± 0.03 5.58 ± 0.08 4.92 ± 0.09 5.13 ± 0.05 5.29 ± 0.04 
Refrigerated for 100 
days (B) 
4.63 ± 0.08 3.99 ± 0.14 4.54 ± 0.04 4.45 ± 0.55 4.77 ± 0.06 4.20 ± 0.64 
Refrigerated for 200 
days (C) 
4.27 ± 0.09 4.03 ± 0.06 5.44 ± 0.08 5.04 ± 0.04 5.14 ± 0.60 4.99 ± 0.06 
Room temperature 
for 100 days (D) 
6.38 ± 0.04 6.18 ± 0.13 6.06 ± 0.09 6.24 ± 0.26 5.57 ± 0.05 6.06 ± 0.23 
Room temperature 
for 200 days (E) 
6.87 ± 0.09 5.99 ± 0.07 7.08 ± 0.41 7.54 ± 0.06 6.5 ± 0.08 6.33 ± 0.08 
ANOVA P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 
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